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The Canadian Network for Mood and Anxiety Treatments published
guidelines for the management of bipolar disorder in 2005, with
updates in 2007 and 2009. This third update, in conjunction with the
International Society for Bipolar Disorders, reviews new evidence and
is designed to be used in conjunction with the previous publications.
The recommendations for the management of acute mania remain
largely unchanged. Lithium, valproate, and several atypical
antipsychotic agents continue to be ﬁrst-line treatments for acute
mania. Monotherapy with asenapine, paliperidone extended release
(ER), and divalproex ER, as well as adjunctive asenapine, have been
added as ﬁrst-line options.
For the management of bipolar depression, lithium, lamotrigine, and
quetiapine monotherapy, as well as olanzapine plus selective serotonin
reuptake inhibitor (SSRI), and lithium or divalproex plus
SSRI ⁄bupropion remain ﬁrst-line options. Lurasidone monotherapy
and the combination of lurasidone or lamotrigine plus lithium or
divalproex have been added as a second-line options. Ziprasidone alone
or as adjunctive therapy, and adjunctive levetiracetam have been added
as not-recommended options for the treatment of bipolar depression.
Lithium, lamotrigine, valproate, olanzapine, quetiapine,
aripiprazole, risperidone long-acting injection, and adjunctive
ziprasidone continue to be ﬁrst-line options for maintenance treatment
of bipolar disorder. Asenapine alone or as adjunctive therapy have been
added as third-line options.
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In 2005, the Canadian Network for Mood and
Anxiety Treatments (CANMAT) published guide-
lines for the management of bipolar disorder (BD)
(1), followed by updates in early 2007 (2) and in
2009 [in collaboration with the International
Society for Bipolar Disorders (ISBD)] (3). This
update includes data published in 2009 through
early 2012, and is designed to be used in conjunc-
tion with the 2005 CANMAT guidelines and
previous updates (1–3).
The purpose of this update is to add previously
unpublished material to the guidelines. This update
is designed to be used with the previous iterations of
the guidelines. As in the previous updates, the guide-
lines are divided into eight sections (Table 1.0) and
the same numbering system has been used for the
sections and tables in order to facilitate ease of use.
New evidence is incorporated into the management
recommendations, and changes to the recommen-
dation tables have been clearly denoted with bold
italics and a footnote, and have been described
in the text. The objective is to ensure that the
CANMAT guidelines for treatment of BD remain
current and useful for the practicing clinician.
Central to this update are the tables showing
ﬁrst-line, second-line, third-line, and not-recom-
mended treatment options. These tables may assist
in the selection of treatment, while the text of this
update and the previous guideline iterations
provide the details of the evidence that was used
to make the recommendations. Similarly, the
treatment algorithms condense key management
information into a decision-tree ﬂow-chart; the
clinician should begin by positioning the patient in
the decision tree, and then follow the arrows for
subsequent management suggestions.
Search strategies and methods to assess evidence
were as described in the original guidelines (1).
Evidence available only in abstract form was also
considered in order to ensure that the recommen-
dations are as up to date as possible. The criteria
for rating strength of evidence and making a
clinical recommendation are shown in Tables 1.1
and 1.2.
We caution the readers that the evidence-based
guidelines are limited by the data that are avail-
able. For instance, drugs that have patents are
likely to have been more widely studied and their
design was likely inﬂuenced by the goals of the
sponsor to obtain approval. Generic drugs,
although may be useful, may not have been widely
studied because of lack of sponsorship, thus
aﬀecting their placement in the treatment algo-
rithm. Finally, it is important to understand that
the lack of evidence for a particular drug does not
imply ineﬃcacy or eﬃcacy. Clinicians must exercise
caution and choose treatments based on a careful
risk–beneﬁt analysis for each situation.
Section 2. Foundations of management
Epidemiology
Prevalence. The World Mental Health Survey
Initiative, involving 61392 people in nine countries
in North and South America, Europe, and Asia,
reported lifetime (and 12-month) prevalence esti-
mates of 0.6% (0.4%) for BD I, 0.4% (0.3%) for
BD II, and 1.4% (0.8%) for subthreshold BD (4).
However, there were large cross-national diﬀer-
ences in rates, with the lifetime rates ranging from
0 to 1% for BD I, 0 to 1.1% for BD II, and 0.1 to
2.4% for subthreshold BD.
In the Canadian Community Health Survey–
Mental Health and Well-Being (CCHS 1.2), the
prevalence of BD was signiﬁcantly lower among
Table 1.0. Overview of guideline sections
Section 1. Introduction
Section 2. Foundations of management
Section 3. Acute management of bipolar mania
Section 4. Acute management of bipolar depression
Section 5. Maintenance therapy for bipolar disorder
Section 6. Special populations
Section 7. Acute and maintenance management of bipolar II
disorder




Table 1.1. Evidence criteria
1 Meta-analysis or replicated double-blind (DB), randomized
controlled trial (RCT) that includes a placebo condition
2 At least one DB-RCT with placebo or active comparison
condition
3 Prospective uncontrolled trial with at least ten or more
subjects
4 Anecdotal reports or expert opinion
Table 1.2. Treatment recommendation
First line Level 1 or level 2 evidence plus clinical
support for efficacy and safety
Second line Level 3 evidence or higher plus clinical
support for efficacy and safety
Third line Level 4 evidence or higher plus clinical
support for efficacy and safety




immigrant, compared to non-immigrant, subjects,
but immigrants with BD were signiﬁcantly less
likely to report contact with mental health profes-
sionals (5).
Impact. A meta-analysis of 15 studies identiﬁed a
high prevalence of lifetime suicide attempts both in
patients with BD I (36.3%) and in those with BD II
(32.4%) (6). In the Systematic Treatment Enhance-
ment Program for Bipolar Disorder (STEP-BD)
(n = 4360), the completed suicide rate was 0.014
per 100 person-years (7). A large cohort study
found that among men, the absolute risk of suicide
was highest with BD (7.8%) compared to any
other psychiatric condition, and among women,
BD was associated with the second highest risk, at
4.8%, just below schizophrenia at 4.9% (8). Claims
database data demonstrate the signiﬁcant eco-
nomic impact of suicide attempts, with one-year
healthcare costs in the period post-attempt being
more than double those in the year prior to an
attempt (9).
The large, two-year, prospective, observational
European Mania in Bipolar disorder Longitudi-
nal Evaluation of Medication (EMBLEM) study
(n = 2289) found high work impairment in 69%
of patients at baseline and 41% at two years
(10). Rapid cycling, high baseline work impair-
ment, lower levels of education, recent admis-
sions, mania symptom severity, and overall
severity all predicted higher work impairment,
while living in a relationship and independent
housing predicted lower work impairment at
follow-up. Similarly, the Understanding Patients
Needs, Interactions, Treatment, and Expectations
(UNITE) global survey (n = 1300) revealed that
only one-third of patients with BD were em-
ployed full-time (11). In the UNITE survey,
treatment of depression, weight gain, and quality
of life were identiﬁed by patients with BD as
aspects of care most in need of improvement
(11).
A meta-analysis of data from 12 trials
(n = 1838) found that the self-esteem of patients
with remitted BD was signiﬁcantly lower than that
of controls but signiﬁcantly higher than that of
patients with remitted major depressive disorder
(MDD) (12). In addition, self-esteem may follow a
ﬂuctuating course during remission of BD.
In a health claims database, risk of arrest was
associated with substance use, poor reﬁll compli-
ance, and prior arrest (13). Among patients treated
with an atypical antipsychotic agent, there was a
lower risk of arrest in those who had frequent
outpatient visits (approximately monthly) com-
pared to those who did not.
Course. In a sub-analysis of 771 patients in the
two-year EMBLEM study, approximately one in
three presented with a mixed episode, which was
associated with a lower likelihood of recovery and
greater use of antidepressant therapy compared to
a pure manic state during follow-up (14). The
Systematic Treatment Optimization Program for
Early Mania (STOP-EM) project followed 53
patients presenting with a ﬁrst episode of mania,
and found that more than half experienced recur-
rence of a mood episode during the one-year
follow-up, with a mean time to event of
7.9 months (15). The mean duration of mood
episodes in BD I, in a longitudinal analysis of 219
patients followed for up to 25 years, was found to
be 13 weeks (16).
Diagnostic assessment
The proposed ﬁfth edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5) is
scheduled to be completed by mid-2013. Revisions
suggested by the International Society for Bipolar
Disorders Diagnostic Guidelines Task Force (17)
were summarized in the previous update to these
guidelines (3). DSM-5 will have separate chapters
for bipolar and related conditions, and depressive
disorders. The condition BD not otherwise spec-
iﬁed (NOS) has been replaced with bipolar
conditions not elsewhere classiﬁed. Substance-
induced BD and BD associated with a general
medical condition have been added.
In the criteria for a manic episode, abnormally
and persistently increased activity or energy has
been added to criterion A, which previously
referred only to a distinct period of abnormally
and persistently elevated, expansive, or irritable
mood. A manic episode emerging during antide-
pressant treatment can qualify as a manic episode
of BD, provided that the symptoms persisted
beyond the physiological eﬀects of treatment. The
mixed episode diagnosis has been replaced with a
mixed features speciﬁer, requiring three symptoms
of the opposite pole, which would apply to manic,
hypomanic, and depressive episodes (18). In addi-
tion, dimensional speciﬁers for anxiety and suicide
risk have also been proposed.
Chronic disease management
BD is a chronic illness and patients require long-
term multi-disciplinary management as described
in the 2005 guidelines (1). A small, cluster-ran-
domized controlled trial (RCT) examined the eﬀect
of community mental health teams (n = 23) who
received enhanced training in relapse prevention
CANMAT guidelines for bipolar disorder
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versus treatment-as-usual (TAU) in 96 patients
with BD (19). The median survival time of patients
treated by the trained teams was prolonged by
8.5 weeks compared to those receiving TAU
(42 weeks versus 33.5 weeks). A collaborative care
model including clinician support through the use
of simpliﬁed guidelines was found to result in
signiﬁcantly greater guideline-concordant therapy
over a three-year follow-up period compared to
TAU in patients with BD (n = 306) (20).
Data suggest that use of a symptom checklist can
substantially increase the recognition of early
warning signs for depressive or manic relapse
(21). There was a positive correlation between the
frequency of monitoring and social ⁄occupational
functioning.
Psychosocial interventions
When used as adjuncts to pharmacotherapy, psy-
chosocial interventions such as group psychoedu-
cation, cognitive behavior therapy (CBT), and
interpersonal and social rhythm therapy (IPSRT)
have demonstrated signiﬁcant beneﬁts, both in the
treatment of acute depressive episodes and also
as long-term maintenance treatment, including
decreased relapse rates, mood ﬂuctuations, need
for medications, and hospitalizations, as well as
increased functioning and medication adherence
(1–3). Therefore, providing psychological treat-
ments –and, in particular, brief psychoeducation,
which has been demonstrated to be as eﬀective as
CBT at much lower cost (22) – is an essential
aspect of managing patients with BD.
A family-focused treatment approach designed to
help caregivers improve illness management skills
and their own self-care was shown to eﬀectively
reduce depressive symptoms and health-risk behav-
ior among caregivers and family members, and
reduce depressive symptoms in patients (23).
The availability of internet-based strategies has
grown substantially, with demonstrated eﬃcacy in
reducing depressive symptoms and improving psy-
chological quality of life (24–27).
Section 3. Acute management of bipolar mania
Emergency management of acute mania
The acutely manic bipolar patient may present in
an agitated state that acts as a barrier to therapy,
interrupts the physician–patient alliance, and
creates a disruptive, even hazardous, environ-
ment. Whenever possible, oral therapy should be
oﬀered ﬁrst, as evidence suggests that oral agents
can be as eﬀective as intramuscular agents (28,
29). Intramuscular injections oﬀer an alternative
when oral therapy cannot be reliably adminis-
tered.
Based on current data, the oral atypical anti-
psychotic agents, risperidone (level 2) (29, 30),
olanzapine (level 2) (30), and quetiapine (level 3)
(30, 31), should be considered ﬁrst in the treatment
of acute agitation. In patients who refuse oral
medications, intramuscular olanzapine (level 2)
(32–35), ziprasidone (level 2) (35–38), and aripip-
razole (level 2) (39) or a combination of intramus-
cular haloperidol and a benzodiazepine should
be considered (level 2) (29, 35, 38, 40, 41). In
general, benzodiazepines should not be used as
monotherapy, but are useful adjuncts to sedate
acutely agitated patients (1).
New data also support the use of intravenous
sodium valproate (level 3) (42) and oral divalproex
ER (level 3) (31) for rapid improvement of acute
mania.
Pharmacological treatment of manic episodes
Pharmacological management of acute manic epi-
sodes should follow the algorithm outlined in
Figure 3.1 (1–3). New clinical trial data, and the
availability of several agents, justify some changes
to the recommendations. Monotherapy with asen-
apine, paliperidone ER, and divalproex ER, as well
as adjunctive asenapine, have been added as ﬁrst-
line options (Table 3.3).
Step 1. Review general principles and assess medi-
cation status: Recommendations from 2005 guide-
lines remain unchanged.
Step 2. First-line therapies: A comprehensive meta-
analysis of 68 trials supported the eﬃcacy of
pharmacotherapy for the treatment of acute mania
(43). Lithium, divalproex, risperidone ER, pali-
peridone ER, olanzapine, quetiapine, aripiprazole,
ziprasidone, and asenapine (ﬁrst line), carbamaze-
pine, and haloperidol (second line), were signi-
ﬁcantly more eﬀective than placebo, whereas
gabapentin, lamotrigine, and topiramate were not
(not recommended) (43). Haloperidol was more
eﬀective than a number of antimanic agents but
not olanzapine or risperidone, both of which were
more eﬀective than valproate, ziprasidone, and
lamotrigine. Two other recent meta-analyses also
support the eﬃcacy of lithium ⁄divalproex and
atypical antipsychotic agents for the treatment of
acute mania (44, 45).
Lithium ⁄divalproex. The eﬃcacy of lithium and
divalproex in the management of acute mania is
Yatham et al.
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well established (level 1) (1–3). Two large, 12-week,
open, randomized trials comparing lithium to
divalproex found comparable eﬃcacy and
tolerability of these agents for the treatment of
acute mania (46, 47).
A large (n = 521), 12-week RCT compared
divalproex, olanzapine, and placebo in patients
with mild to moderate mania. At three weeks,
improvements in mania scores were signiﬁcant with
olanzapine versus placebo but not with divalproex
versus olanzapine or placebo. After 12 weeks of
treatment, improvements in both active treatment
groups were signiﬁcant versus placebo, but ola-
nzapine was signiﬁcantly more eﬃcacious than
divalproex (48).
The results of two three-week RCTs assessing
the eﬃcacy of the ER formulation of divalproex
for the treatment of acute mania have now been
published (49, 50) One study demonstrated
statistically signiﬁcant improvements in manic
symptoms compared to placebo (level 2) (49),
while the other did not (50). In the ﬁrst, Bowden
et al. (49) found signiﬁcantly greater improve-
ment in manic symptoms and higher response
rates (48% versus 34%, p = 0.012) with divalp-
roex ER versus placebo, while Hirschfeld et al.
(50) found no statistically signiﬁcant diﬀerence in
mania scores with divalproex ER versus placebo;
however, discontinuation rates were over 80%
and dosing may have been lower than optimal.
Table 3.3. Recommendations for pharmacological treatment of acute mania
First line Monotherapy: lithium, divalproex, divalproex ER a, olanzapineb, risperidone, quetiapine,
quetiapine XR, aripiprazole, ziprasidone, asenapine a, paliperidone ER a
Adjunctive therapy with lithium or divalproex: risperidone, quetiapine, olanzapine, aripiprazole, asenapine a
Second line Monotherapy: carbamazepine, carbamazepine ER, ECT, haloperidol a
Combination therapy: lithium + divalproex
Third line Monotherapy: chlorpromazine, clozapine, oxcarbazepine, tamoxifen, cariprazine a
(not yet commercially available)
Combination therapy: lithium or divalproex + haloperidol, lithium + carbamazepine, adjunctive tamoxifen
Not recommended Monotherapy: gabapentin, topiramate, lamotrigine, verapamil, tiagabine
Combination therapy: risperidone + carbamazepine, olanzapine + carbamazepine
ECT = electroconvulsive therapy; XR or ER = extended release.
aNew or change to recommendation.
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Fig. 3.1. Treatment algorithm for acute mania. Novel ⁄ experimental agents: zotepine, levetiracetam, phenytoin, mexiletine, omega-3-
fatty acids, calcitonin, rapid tryptophan depletion, allopurinol, amisulpride, folic acid, memantine. D ⁄C = discontinue;
Li = lithium; DVP = divalproex; AAP = atypical antipsychotic agent.
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Given the level 1 evidence to support the imme-
diate-release formulation of divalproex, as well as
the high discontinuation rate and dosing issues in
the negative trial, divalproex ER has been added
as a ﬁrst-line therapy, although, if prescribed,
attention should be paid to dosing and serum
levels.
Atypical antipsychotic monotherapy. Substantial
RCT data support the eﬃcacy of atypical anti-
psychotic monotherapy with olanzapine, risperi-
done, quetiapine, ziprasidone, and aripiprazole
for the ﬁrst-line treatment of acute mania (level 1)
(1–3).
As reviewed earlier, a large (n = 521), 12-week
RCT comparing divalproex, olanzapine, and
placebo in patients with mild to moderate mania
found that improvements in mania scores with ola-
nzapine were signiﬁcantly greater than with pla-
cebo after three weeks, and greater than with both
divalproex and placebo after 12 weeks (48).
In a meta-analysis of six aripiprazole monother-
apy RCTs in acute mania involving 2303 patients,
the eﬀect size was 0.34 versus placebo at week
three, with a response generally being seen at day
three (level 1) (51). A 12-week RCT of aripiprazole
monotherapy in acute mania found signiﬁcantly
greater improvements in the Young Mania Rating
Scale (YMRS) scores at week three with aripip-
razole ()12.0, p < 0.05) or haloperidol ()12.8,
p < 0.01) compared to placebo ()9.7), which were
maintained to week 12; haloperidol was included
as an active control and was not statistically
compared to aripiprazole (52).
Additional data are also available comparing
ziprasidone to placebo and haloperidol in a
12-week RCT. Improvements in mania scores and
response rates at week three were signiﬁcantly
greater than with placebo for both active treat-
ments, but haloperidol was signiﬁcantly more
eﬀective than ziprasidone. During the nine-week
extension phase, responses were maintained for the
majority of patients receiving active treatments.
Ziprasidone showed a superior tolerability proﬁle
and lower discontinuation rates during the exten-
sion phase (53).
Two three-week, double-blind RCTs demon-
strating the eﬃcacy of paliperidone ER in patients
with manic or mixed episodes, which were previ-
ously cited in abstract form, have now been
published (level 1) (54, 55). Paliperidone ER has
been upgraded to a ﬁrst-line option.
Two three-week, double-blind RCTs demon-
strating the eﬃcacy of asenapine as monotherapy
for acute mania (56, 57), as well as nine-week and
40-week extension phase results demonstrating the
maintenance of beneﬁts (58, 59), which were
previously cited in abstract form, have now been
published (level 1). Asenapine has been upgraded
to a ﬁrst-line option.
Atypical antipsychotic combination therapy. As
previously reported, a six-week, placebo-controlled
RCT showed that adding aripiprazole to lithium or
divalproex in 384 patients with an inadequate
response was signiﬁcantly more eﬀective than
placebo from week 1 onward (60). A 46-week
open-label extension of this study found that
aripiprazole as an adjunct to lithium or divalproex
provided continued improvement in mania but not
depression (61).
A 12-week RCT demonstrating signiﬁcant
improvements in mania symptoms with adjunctive
asenapine added to lithium ⁄divalproex compared
to placebo that was previously cited in abstract
form has still not been published, but 40-week
extension results have now been reported (level 2)
(62). Of the original 318 patients, 71 completed the
40-week extension; there were additional improve-
ments in mania scores at 52 weeks in both the
asenapine and placebo groups. Adjunctive asena-
pine has been moved to a ﬁrst-line option.
Step 3. Add-on or switch therapy (alternate ﬁrst-line
therapies): No changes from 2005 guidelines.
Step 4. Add-on or switch therapy (second- and third-
line therapies):
Second-line options. A small RCT in 44 patients
with manic, mixed, or depressive episodes found
that among patients who were on, or thought to
beneﬁt from, carbamazepine, there were no diﬀer-
ences in mood ratings or in the total level of
adverse events with immediate-release versus ER
carbamazepine (63, 64). However, there were
signiﬁcantly fewer autonomic and gastrointestinal
adverse events with carbamazepine ER (64).
While electroconvulsive therapy (ECT) can be
an eﬀective option, research studies have not been
rigorous and therefore it continues to be recom-
mended as a second-line therapy (level 3) (1). In
an RCT of ECT as adjunct to antipsychotic
therapy, bilateral, twice-weekly ECT delivered at
stimulus intensities just above seizure threshold
was as eﬀective and safe as ECT administered
at stimulus intensities 2.5 times the seizure
threshold in rapidly resolving the symptoms of
acute mania (65).
In a meta-analysis of 13 haloperidol-controlled
trials, the drug was signiﬁcantly more eﬀective than
lithium, divalproex, quetiapine, aripiprazole,
Yatham et al.
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ziprasidone, carbamazepine, asenapine, and lamo-
trigine (43). Given the strong data for eﬃcacy,
haloperidol has been upgraded to a second-line
option. However, haloperidol should only be used
on a short-term basis to treat acute mania as
continuation of haloperidol may increase the risk
of a depressive episode (43).
Third-line options. A small (n = 60), 12-week RCT
comparing oxcarbazepine to divalproex in patients
with acute mania found no signiﬁcant diﬀerences
in improvements in mania scores or remission rates
between the two treatments, but divalproex was
associated with more adverse events (66). In
another small (n = 52) RCT, adjunctive ox-
carbazepine was more eﬀective than carbamaze-
pine as add-on therapy in patients who had
previously been inadequate responders to lithium,
although both agents improved manic and depres-
sive scores versus baseline (67). As described in the
previous updates to these guidelines, there are
other small positive trials, but there is also a
negative placebo-controlled RCT, and these new
trials are small and do not include a placebo
control arm; therefore, oxcarbazepine remains as a
third-line option.
Cariprazine, a new dopamine D3 ⁄D2 receptor
antagonist, appears promising for the treatment of
acute mania, but has not yet been approved by
Canadian or US regulatory agencies. The results
of a three-week, phase 2, RCT, presented in
abstract form, reported signiﬁcant reductions in
mania scores with cariprazine compared to placebo
(level 2) (68).
Step 5. Add-on novel or experimental agents:
Zotepine is an antipsychotic agent that has been
approved in some European countries and in
Japan for the treatment of schizophrenia. In a
four-week, single-blind trial, adjunctive zotepine
added to lithium or divalproex therapy in 45
inpatients with moderate-to-severe mania was as
eﬀective as adjunctive haloperidol in improving
mania scores (69).
Two RCTs have now demonstrated the eﬃcacy
of adjunctive allopurinol for the treatment of acute
mania (level 1) (70, 71). In an eight-week RCT,
allopurinol as adjunct to lithium plus haloperidol
was found to be signiﬁcantly more eﬀective than
placebo in 82 patients hospitalized with acute
mania (70). In the second RCT (n = 180), com-
paring the addition of allopurinol, dipyridamole,
or placebo to lithium for four weeks, allopurinol
led to signiﬁcantly greater improvements in mania
scores and remission rates versus placebo (71).
Although there is level 1 evidence for the use of
allopurinol, given that it can cause hepatomegaly
as well as hypersensitivity reactions such as
Steven–Johnson syndrome and toxic epidermal
necrolysis, it is recommended only for those
patients that are refractory to other ﬁrst-, second,
and third-line treatments.
Preliminary evidence previously suggested
antimanic eﬃcacy associated with tamoxifen (1).
A six-week, placebo-controlled RCT has now
demonstrated signiﬁcantly greater improvements
in mania scores with tamoxifen as an adjunct to
lithium in 40 inpatients with acute mania com-
pared to lithium alone (level 2) (72).
In a three-week RCT in 88 acutely manic
patients on divalproex, adjunctive folic acid was
signiﬁcantly better than placebo in improving
mania scores (level 2) (73).
A three-week, open-label, pilot trial in 33 patients
with manic or mixed episode BD I found that 30–
50% of patients responded to doses of memantine
ranging from 20 mg to 40 mg (level 3) (74).
Given the limited data, at this time, these agents
can only be recommended as add-on therapies
after failure of standard therapies.
Adjunctive therapies with negative data requiring
further study: A six-week RCT that found no
signiﬁcant improvements in manic symptoms with
adjunctive ﬂexible-dose paliperidone in patients
with manic or mixed episodes who had not
responded to lithium or divalproex, was previously
cited in abstract form and has now been published
(level 2, negative) (75). Given that paliperidone
monotherapy is eﬀective, and that lithium or
valproate does not aﬀect the metabolism of pali-
peridone, the lack of eﬃcacy of combination
therapy is surprising. In spite of the fact that it
was a ﬂexible-dose trial, paliperidone ER may have
been under-dosed, since the monotherapy studies
suggest that 12 mg ⁄day is the most eﬀective dose
and the mean dose used was 8.1 (3.30) mg ⁄day,
with 45% of the patients receiving a ﬁnal dose of
6 mg ⁄day in this trial. In addition, a post-hoc
subgroup analysis found that adjunctive paliperi-
done ER was superior to lithium or divalproex
monotherapy for patients diagnosed with a manic
episode (p = 0.020).
A three-week RCT in over 600 patients with BD
mania ⁄mixed episodes found no signiﬁcant
beneﬁts with adjunctive ziprasidone at either high
(120–160 mg ⁄day) or low (40–80 mg ⁄day) doses
compared to placebo (76). The trial has not yet
been published, but the results are available at
http://www.clinicaltrials.gov.
In light of these negative trials, adjunctive use of
paliperidone ER or ziprasidone, at the dosages
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used by the above-noted studies, is not recom-
mended.
Mania with psychotic features
A meta-analysis of four RCTs of aripiprazole
supports its antipsychotic eﬀects, as measured
by the Positive and Negative Syndrome Scale
(PANSS) score, during the acute manic and
maintenance phases of BD (77). The eﬀect sizes
for aripiprazole versus placebo were highest for the
PANSS–positive subscale (0.28) and the PANSS–
hostility subscale (0.24).
Mixed states
A six-week RCT (n = 202) evaluating adjunctive
olanzapine compared to adjunctive placebo dem-
onstrated signiﬁcantly greater and earlier reduc-
tions in manic and depressive symptoms in patients
with mixed episodes inadequately controlled with
divalproex (78). Post-hoc analysis of this study
found that response (Clinical Global Impression–
Severity decrease ‡ 1) at day two was predictive of
mixed symptom remission (79).
A post-hoc analysis of two asenapine RCTs in
patients with manic or mixed episodes demon-
strated statistically signiﬁcant decreases in depres-
sion scores with asenapine versus placebo in
patients with severe baseline depressive symptoms
(n = 604); diﬀerences between the active compar-
ator olanzapine and placebo were not signiﬁcant,
which makes the interpretation of these results
more diﬃcult as it raises the possibility of a
negative study (80).
Section 4. Acute management of bipolar depression
Pharmacological treatment of depressive episodes
Pharmacological management of acute bipolar
depressive episodes should follow the algorithm
outlined in Figure 4.1 (1–3). The recommendations
for ﬁrst- and second-line therapies are largely
unchanged, except for the addition of lurasidone
monotherapy and lurasidone or lamotrigine plus
lithium or divalproex as second-line options. Based
on negative data, ziprasidone alone or as adjunc-
tive therapy, and adjunctive levetiracetam have
been added as not-recommended options for the
treatment of bipolar depression (Table 4.3).
Several meta-analyses have assessed the eﬃcacy
of atypical antipsychotic agents and other medica-
tions for the treatment of bipolar depression
(81, 82). A meta-analysis of atypical antipsychotic
agents for bipolar depression included ﬁve trials
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Fig. 4.1. Treatment algorithm for the management of bipolar I depression. Novel ⁄ experimental agents: adjunctive pramipexole,
eicosapentaenoic acid (EPA), riluzole, topiramate, N-acetyl cysteine (NAC), ketamine, armodaﬁnil, and chronotherapy.
DVP = divalproex; OLZ = olanzapine; RIS = risperidone; ARI = aripiprazole; ZIP = ziprasidone; SSRI = selective serotonin
reuptake inhibitor; BUP = bupropion; Li = lithium; LAM = lamotrigine; QUE = quetiapine; ECT = electroconvulsive therapy.
aExcept paroxetine. bOr switch the SSRI to another SSRI. cOr switch the SSRI or BUP to another SSRI or BUP.
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and aripiprazole, and one combination trial with
olanzapine) and found signiﬁcantly greater
improvement compared to placebo for weeks 1–6
but not for weeks seven and eight (primarily
accounted for by a tapering of eﬀect in aripiprazole
studies) (81). This suggests that the eﬃcacy of these
agents is not a class eﬀect and that individual
agents may show diﬀerential beneﬁts, and, as such,
generalizations on the role of atypical antipsy-
chotic agents for depressive symptoms cannot be
made. Another meta-analysis included 19 trials
assessing mainly quetiapine (ﬁve trials) and lamo-
trigine (six trials), but also paroxetine, lithium,
olanzapine, aripiprazole, phenelzine, and divalp-
roex for the treatment of bipolar depression (82).
This analysis found the highest reductions in
Montgomery–A˚sberg Depression Rating Scale
(MADRS) scores with the olanzapine plus ﬂuoxe-
tine combination and quetiapine monotherapy
compared to placebo. In this analysis, lamotrigine,
paroxetine, aripiprazole, and lithium were not
signiﬁcantly diﬀerent from placebo in improving
depression scores. However, as cited in previous
iterations, a meta-analysis of individual patient
data supported the eﬃcacy of lamotrigine mono-
therapy (83).
Step 1. Review general principles and assess medi-
cation status: Recommendations from 2005 guide-
lines remain unchanged.
Step 2. Initiate or optimize therapy and check
adherence (ﬁrst-line therapies): Lithium, lamotrigine,
quetiapine, and quetiapine extended release (XR)
monotherapies, as well as lithium or divalproex
plus selective serotonin reuptake inhibitor (SSRI),
olanzapine plus SSRI, lithium plus divalproex, and
lithium or divalproex plus bupropion all continue
to be recommended as ﬁrst-line choices for bipolar
depression.
Data suggest that the absence of early improve-
ment (2–3 weeks) may be a highly reliable predic-
tor of eventual non-response, suggesting that these
patients may beneﬁt from a change in therapy
(84, 85).
Lithium. The early results of the National Insti-
tute of Mental Health (NIMH) lithium treatment
moderate dose use study have been presented
(86). This pragmatic study randomized 283
patients with BD I or BD II to receive six
months of open-label moderate dose
(600 mg ⁄day) lithium plus optimized treatment
[per Texas Medication Algorithms (87)] versus
optimized treatment alone and found no signif-
icant diﬀerences between treatment groups. How-
ever, given that this was an open-label study, and
in the absence of further study details, recom-
mendations for adjunctive lithium use remain
unchanged.
Quetiapine monotherapy. The four large published
RCTs demonstrating the eﬃcacy of quetiapine
monotherapy in bipolar depression, which were
cited in previous iterations of these guidelines, have
now all been published: BipOLar DEpRession
(BOLDER) I (88) and II (89) and Eﬃcacy of
Monotherapy SEROQUEL in BipOLar DEpres-
Table 4.3. Recommendations for pharmacological treatment of acute bipolar I depressiona
First line Monotherapy: lithium, lamotrigine, quetiapine, quetiapine XR
Combination therapy: lithium or divalproex + SSRIb, olanzapine + SSRIb, lithium + divalproex, lithium or
divalproex + bupropion
Second line Monotherapy: divalproex, lurasidonec
Combination therapy: quetiapine + SSRIb, adjunctive modafinil, lithium or divalproex + lamotriginec, lithium
or divalproex + lurasidonec
Third line Monotherapy: carbamazepine, olanzapine, ECT d
Combination therapy: lithium + carbamazepine, lithium + pramipexole, lithium or divalproex + venlafaxine,
lithium + MAOI, lithium or divalproex or AAP + TCA, lithium or divalproex or carbamazepine + SSRIb +
lamotrigine, quetiapine + lamotriginec
Not recommended Monotherapy: gabapentin, aripiprazole, ziprasidone c
Combination therapy: adjunctive ziprasidonec, adjunctive levetiracetamc
AAP = atypical antipsychotic agent; ECT = electroconvulsive therapy; MAOI = monoamine oxidase inhibitor; TCA = tricyclic antide-
pressant; SSRI = selective serotonin reuptake inhibitor; XR = extended release.
aThe management of a bipolar depressive episode with antidepressants remains complex. The clinician must balance the desired effect
of remission with the undesired effect of switching. See detailed discussion in Clinical questions and controversies section.
bExcept paroxetine.
cNew or change to recommendation.
dCould be used as first- or second-line treatment in certain situations (see text).
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sioN (EMBOLDEN) I (90) and EMBOLDEN II
(91) (level 1).
The eight-week RCT demonstrating signiﬁcantly
greater improvement in depressive symptoms with
quetiapine XR monotherapy in patients with BD I
or BD II depression, which was previously cited,
has now been published (92).
Olanzapine + ﬂuoxetine. There are level 1 data
demonstrating the eﬃcacy of olanzapine–ﬂuoxe-
tine combination (OFC) therapy for the treatment
of BD I depression (1–3). Follow-up results from a
previously described RCT [seven-week outcome
data (93)] found signiﬁcantly greater improvements
in depressive and manic symptoms with OFC
versus lamotrigine in 410 patients with BD I at
study end (94). However, OFC treatment was
associated with a signiﬁcantly increased risk of
treatment-emergent hypercholesterolemia and
weight gain. In addition, a post-hoc analysis of a
previously cited combination study (95) found that
both OFC and olanzapine monotherapy were more
eﬃcacious than placebo in patients with BD I
mixed depression (i.e., syndromal depression and
subsyndromal mania ⁄hypomania).
Step 3. Add-on or switch therapy (alternate ﬁrst- or
second-line therapies):
Second-line options
Divalproex monotherapy. Four small RCTs have
assessed the eﬃcacy of divalproex or divalproex ER
for the treatment of BD I or BD II depression (level
1) (96, 97). Two meta-analyses of these trials (total
n = 142), by separate groups, concluded that
divalproex was more eﬀective than placebo for the
treatment of bipolar depression, but the strength of
the conclusions was limited by sample size (96, 97).
Therefore, given the limited evidence, divalproex
continues to be recommended as a second-line option.
Lurasidone. Two six-week RCTs have demon-
strated the eﬃcacy of lurasidone as monotherapy
(98) or as an adjunct (99) in patients with bipolar
depression. Lurasidone monotherapy signiﬁcantly
reduced depressive symptoms in patients with BD I
depression as early as week two compared to
placebo (level 2) (98). Similarly, when used as an
adjunct to lithium or divalproex, lurasidone
signiﬁcantly reduced depressive symptoms, and
improved functioning and quality of life compared
to placebo in patients with BD I depression who
had an inadequate response to lithium or divalp-
roex alone (level 2) (99). These data look very
promising and if clinical experience supports eﬃ-
cacy, lurasidone will be upgraded to one of the
ﬁrst-line treatments in the next revision.
Lamotrigine + lithium or divalproex. In an eight-
weekRCT, the acute eﬀect of lamotriginewas greater
than that of placebo as an add-on to lithium for BD I
or BD II depression (n = 124) (100). Non-respond-
ers in this trial entered a second phase in which
paroxetinewas added; this addition showedbeneﬁt in
non-responders to lithium + placebo, but not in
non-responders to lithium + lamotrigine (101).
Given the slow titration required for lamotrigine,
this treatment is recommended either in monother-
apy or as an add-on therapy primarily for those with
mild-to-moderate bipolar depression, and in partic-
ular for those with depression recurrences, given its
eﬃcacy in preventing depressive relapses.
Step 4. Add-on or switch therapy (alternate ﬁrst- or
second-line therapies): No changes from 2005
guideline (1).
Step 5. Add-on or switch therapy (third-line agents
and novel ⁄ experimental therapies):
Third-line options
Olanzapine monotherapy. There are now two large
RCTs demonstrating the eﬃcacy of olanzapine
monotherapy for the treatment of bipolar depres-
sion (level 1) (95, 102). In the earlier of these two
trials, olanzapine monotherapy demonstrated
a statistically signiﬁcant, but clinically modest
antidepressant eﬀect in a large (n = 833), eight-
week RCT in patients with bipolar depression (95),
and was recommended as a third-line option (1).
In the subsequent large RCT, available in
abstract form, 514 patients with bipolar depres-
sion achieved signiﬁcantly greater improvement in
depressive symptoms with olanzapine compared
to placebo (MADRS )13.8 versus )11.7, p =
0.018) over six weeks of treatment (102). How-
ever, olanzapine was also associated with signif-
icantly greater rates of metabolic changes (102). A
small (n = 20), open-label study provided addi-
tional support for the eﬃcacy of olanzapine
monotherapy in patients with BD I or BD II
depression (103).
Although there is level 1 evidence, the magnitude
of beneﬁt of olanzapine monotherapy was only
modestly greater than that of placebo (95, 102). In
the earlier trial (95), the increased eﬃcacy of
olanzapine relative to placebo was mainly
accounted for by changes in sleep, appetite, and
inner tension, which are not the core symptoms of
depression (81). In addition, as adverse events were
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marked in the recent trial (102), this strategy
continues to be recommended as a third-line
option.
Quetiapine + lamotrigine. A small, open trial in 39
patients with BD I and BD II found that the
combination of lamotrigine plus quetiapine was
beneﬁcial in treatment-resistant bipolar depression
(level 3) (104).
Carbamazepine. There is additional evidence to
support the use of carbamazepine (level 2), as a small
RCT in a mixed population of 44 patients with BD
found that ER carbamazepine was as eﬀective as the
immediate-release form, with fewer autonomic and
gastrointestinal adverse events (63, 64).
ECT. As stated in previous iterations of the guide-
lines, the use of ECT should be considered earlier in
patients who have psychotic bipolar depression, in
those at high risk for suicide, and in those with
signiﬁcant medical complications due to not drink-
ing and eating. Clinical experience and open-label
data continue to accumulate and support the eﬃcacy
of ECT. In an open trial, similar rates of response
and remissionwere observed in patientswith bipolar
depression (70% and 26%, respectively) and those
with mixed states (66% and 30%, respectively)
(105). A retrospective analysis of 201 patients with
BD receiving ECT concluded that those receiving
concomitant anticonvulsants achieved comparable
symptomatic improvement to those not on anticon-
vulsants; however, they required a signiﬁcantly
greater number of ECT sessions to achieve this
(106). Two RCTs comparing diﬀerent ECT proto-
cols found no diﬀerence in response rates in patients
with bipolar or unipolar depression (107, 108).
Novel or experimental agents
Data were previously described demonstrating the
beneﬁts of adjunctive use of the following agents:
pramipexole (level 2), eicosapentaenoic acid (EPA)
(level 2), riluzole (level 3), topiramate (level 3), and
N-acetyl cysteine (NAC) (level 2) (1–3).
Additional open-label data support the use of
adjunctive riluzole and adjunctive NAC (109, 110).
Patients in a small, open-label, imaging study
reported improvements in depressive symptoms
with riluzole (level 3) (109), while data from a large
(n = 149), eight-week, open-label trial found
signiﬁcant improvement in depressive symptoms
with adjunctive NAC in patients with BD I, II, or
NOS depression (110).
Preliminary data are also available to support
other novel treatments not previously investigated
in patients with bipolar depression, including
adjunctive ketamine, armodaﬁnil, and chronother-
apy. A two-week, crossover RCT assessing adjunc-
tive ketamine infusion in patients with treatment-
resistant bipolar depression identiﬁed a robust early
antidepressant eﬀect (within 40 min), with improve-
ment remaining signiﬁcant versus placebo through
day three (level 2) (111). An eight-week RCT in 257
patients with BD I depression reported a trend
toward greater improvement in depressive symp-
toms with adjunctive armodaﬁnil versus placebo on
some, but not all depression symptom scales (level 2)
(112). Adjunctive combined chronotherapy (sleep
deprivation, exposure to bright light, and sleep-
phase advance) demonstrated a more rapid and
sustained antidepressant response compared to
medication alone (lithium + antidepressant) in a
seven-week RCT in 49 patients with bipolar depres-
sion (level 3) (113). Patients receiving adjunctive
chronotherapy experienced a signiﬁcantly greater
reduction in depressive symptoms within 48 hours,
which was sustained throughout the seven weeks.
Not recommended for the treatment of acute bipolar
depression:
Ziprasidone monotherapy. Data are now available
from two negative RCTs of ziprasidone monother-
apy in BD I depression (level 1, negative) (114,
115). The trials have not yet been published, but
results are available at http://www.clinicaltrials.gov
(114, 115). Both were large trials (n = 381 and
n = 504, respectively) in patients with BD I
depression, and both demonstrated no signiﬁcant
improvements in depression scores compared to
placebo. While ziprasidone is not recommended
for bipolar depression, patients who are using
ziprasidone with beneﬁt (initiated during mania)
do not need to have it discontinued.
Adjunctive therapies with negative data requiring
further study:
Adjunctive ziprasidone. A large RCT assessing
adjunctive ziprasidone (mean dose 90 mg) added
to therapy with lithium, divalproex, or lamotrigine
in 298 patients with BD I depression found no
signiﬁcant diﬀerence between active treatment and
placebo (level 2, negative) (116).
Adjunctive aripiprazole. While open-label trials
suggest a beneﬁt of adjunctive aripiprazole for
the treatment of bipolar depression (level 3) (117,
118), a small RCT did not ﬁnd a signiﬁcant eﬀect
compared to placebo (level 2, negative) (119). In a
six-week RCT, 23 inpatients with bipolar depres-
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sion on lithium or divalproex were given open-label
citalopram, and randomized to adjunctive aripip-
razole or placebo. Depressive symptoms improved,
with no signiﬁcant diﬀerences between treatment
groups (level 2 negative) (119).
In a 16-week, prospective, open-label trial,
aripiprazole (add-on or monotherapy) was associ-
ated with a signiﬁcant decline in depressive symp-
toms over 16 weeks among 85 patients with bipolar
depression who were unresponsive to other med-
ications (lithium, anticonvulsants, or antipsychotic
agents) (level 3) (117). There was also a signiﬁcant
reduction in self-rated anhedonia among patients
with BD I depression treated with aripiprazole
in the same study (120). Another small (n = 20),
six-week, open-label trial demonstrated improve-
ment in depressive symptoms, with a 44% response
rate with aripiprazole as add-on or monotherapy
for BD I, II, or NOS depression (level 3) (118).
Adjunctive levetiracetam. A six-week RCT in 32
patients with bipolar depression found no signiﬁ-
cant diﬀerences in the change in depression scores
with adjunctive levetiracetam versus placebo (level
2, negative) (121).
Clinical questions and controversies
What is the role of antidepressants in patients with
bipolar depression?
The role of antidepressants in patients with
bipolar depression remains one of the most con-
troversial areas in psychiatry. Antidepressants are
the most commonly used treatments for bipolar
depression (122, 123) as clinicians continue to
believe that, based on their clinical experience,
these are eﬀective for bipolar depression. However,
the limited, but growing body of clinical trial data
has not been consistent in supporting their role.
For instance, OFC was shown to be more eﬀective
than placebo or olanzapine monotherapy (93, 95),
but the combination of paroxetine or bupropion
with a mood stabilizer was not more eﬀective than a
mood stabilizer plus placebo (124). However, this
study had severe methodological limitations; most
patients were also participating in a psychotherapy
trial, and an unknown proportion of patients
continued to use the previous antidepressant they
had been on at baseline. In another study, paroxe-
tine monotherapy (20 mg ⁄day) was not superior to
placebo in improving bipolar depressive symptoms
(125). It is unknown if higher doses of paroxetine
would have been more eﬀective.
Although individual studies are contradictory,
the most recent meta-analysis, which included 15
RCTs (126), found a strong trend for superiority of
antidepressants over placebo for the acute treatment
of bipolar depression (p = 0.06). Antidepressants
were not associated with a signiﬁcantly increased
risk of manic switch (126). Most negative studies of
antidepressants for bipolar depression to date have
employed paroxetine as the antidepressant (91, 125,
127). A meta-analysis of the eﬃcacy of antidepres-
sants in unipolar depression (128) suggested that
clinically important diﬀerences exist between vari-
ous antidepressants in terms of eﬃcacy and accept-
ability. Interestingly, paroxetine was inferior to a
number of other antidepressants in this meta-anal-
ysis. The risk of manic ⁄hypomanic switch does not
appear to be a major concern with modern antide-
pressants when used in conjunction with a mood
stabilizer or an atypical antipsychotic agent, at least
during short-term treatment; therefore, safety does
not appear to be a signiﬁcant issue during the acute
treatment of bipolar depression. An important
caveat is that the current deﬁnition of switch
requires threshold mania; milder switches, which
are common, are not captured by the default
deﬁnition (129). Similarly, the metrics of cycle
acceleration are not captured in current deﬁnitions
or trial designs (130).
Given the above, we believe that the following
conclusions and recommendations are warranted
regarding the use of antidepressants for bipolar
depression: (i) SSRIs (other than paroxetine) and
bupropion could be used as ﬁrst-line treatments in
conjunction with a mood stabilizer for acute short-
term treatment of bipolar depression, with the
objective of tapering and discontinuing antidepres-
sants 6–8 weeks after full remission of depression;
(ii) avoid the use of tricyclic antidepressants and
venlafaxine (131, 132) as they are associated with
an increased risk of manic switch; (iii) antidepres-
sants should not be used to treat a current mixed
episode or in patients with a history of rapid
cycling; (iv) monotherapy with antidepressants is
not recommended for bipolar depression.
Section 5. Maintenance therapy for bipolar disorder
Adherence
New data provide further insight into adherence to
maintenance therapy in patients with BD. In
several analyses, adherence was positively associ-
ated with higher satisfaction with medication,
monotherapy, a college degree, and fear of relapse,
and was negatively associated with illness factors
(substance use, previous hospitalization, psychotic
symptoms, reduced insight into illness), medication
factors (side eﬀects, no perceived daily beneﬁt,
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diﬃculties with medication routines), and patient
attitudes (belief that medications are unnecessary,
negative attitudes toward medications, perceived
change in appearance, perceived interference with
life goals) (133–139). Under-dosing can also lead to
higher discontinuation rates; patients receiving
lower doses of ziprasidone had signiﬁcantly higher
discontinuation rates than those receiving medium
or high doses (140).
Non-adherence has been linked to a high
frequency of episodes (particularly depressive
episodes), a higher risk of hospitalization and
emergency room visits, as well as higher employee
costs of absenteeism, short-term disability, and
workers compensation (137, 141–144). In an
analysis involving UK data, the direct costs of
care were two to three times higher in patients who
relapsed compared to those who did not over the
6–12-month follow-up (145).
Predictors of recurrence
In observational studies, predictors of symptom-
atic remission and recovery during 1–2 years of
follow-up in patients with manic episodes included:
Caucasian ethnicity, a previous manic episode,
good social functioning (no work or social impair-
ment, living independently or with family), outpa-
tient treatment, and being neither satisﬁed nor
dissatisﬁed with life (146, 147).
In patients with rapid cycling treated with lithium
or divalproex, increased risk for non-stabilization
was associatedwith a history of recent substance use
disorder (SUD), early-life verbal abuse, female
gender, and late onset of ﬁrst depressive episode
(148). Among responders to long-term lithium
therapy, the risk of recurrence was higher in those
with atypical features (mainly mood-incongruent
psychotic symptoms), inter-episodic residual symp-
tomatology, and rapid cycling (149).
Psychosocial interventions for maintenance therapy
As reported in previous iterations of these guide-
lines, data have supported the beneﬁts of adjunc-
tive psychoeducation, CBT, family therapy, and
IPSRT in reducing recurrences and improving
symptoms in patients with BD (1–3). However,
recent meta-analyses assessing the eﬃcacy of psy-
chotherapies for patients with BD have reached
discordant conclusions. One meta-analysis of four
RCTs concluded that CBT had a small eﬀect size
for depressive symptoms compared to treatment as
usual or wait-list controls (150). A second analysis
included 12 trials and found low to medium eﬀect
sizes associated with adjunctive CBT at the end of
treatment and at follow-up (151). Another
meta-analysis concluded that CBT was likely not
an eﬀective treatment strategy for the prevention of
relapse in BD (152).
Given the transient beneﬁt of CBT in the ﬁrst
major studyof this strategy inpatientswithBD(153)
and the negative results of a large RCT (154), the
true beneﬁt of CBT is unclear, beyond its common
core element of psychoeducation (155). However,
two new RCTs provide some promise. In one study
comparing a group CBT intervention to treatment
as usual in 50 patients, group CBT was associated
with a longer median time to relapse, but no
diﬀerences in time to recurrence or number of
episodes (156). In a 14-week study comparing the
CBT (n = 27) and control pharmacotherapy
(n = 14) groups, there was a slight, although non-
signiﬁcant, reduction in depressive symptoms in the
CBT group (157). Both of these small studies
demonstrated the feasibility of group CBT rather
than its eﬃcacy, and proper replication is needed. In
addition, a previously reported RCT (n = 204)
(22), which has now been published, compared six
sessions of group psychoeducation to 20 sessions of
individual CBT. Both treatments demonstrated a
signiﬁcant beneﬁt in terms of mood stability and
reduction of recurrence, but there were no diﬀer-
ences between the two treatments. Since the
psychoeducation treatment was designed to be
delivered by psychiatric nurses and was documen-
ted to be much less expensive than individual
CBT, the study suggested that group psychoedu-
cation should be prioritized as a ﬁrst universal
psychosocial treatment for BD.
RCTs of adjunctive group psychoeducation
programs demonstrated a longer time to recur-
rence, fewer recurrences of any type, less time
acutely ill, and fewer days of hospitalization during
1–5 years of follow-up (158, 159). A 12-week
dyadic (patient–companion) group-based psycho-
education program demonstrated signiﬁcantly low-
er relapse rates and a longer time to relapse
compared to treatment as usual during a 60-week
follow-up (160).
Pharmacological treatments for maintenance therapy
As discussed in previous guideline iterations, almost
all modern maintenance studies have used an
enriched design. The only exceptions are some of
the older maintenance studies with lithium, which
showed the eﬃcacy of lithium for maintenance
treatment in non-enriched samples. Given the eﬃ-
cacy of various treatments with enriched design
studies, it makes intuitive sense that, in general, the
treatment that worked during the acute phase is
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likely to be eﬀective in themaintenance phase [please
see the original 2005 guidelines: Section 5. Mainte-
nance therapy for bipolar disorder: General principles
(1)]. Based on new evidence, asenapine alone and as
adjunctive therapy have been added as third-line
options (Table 5.5) (1–3).
First-line options: Lithium, divalproex, olanzapine,
and quetiapine (for both depression and mania), as
well as lamotrigine (primarily for preventing depres-
sion), risperidone long-acting injection (LAI) and
ziprasidone (primarily for preventing mania) con-
tinue to be ﬁrst-line monotherapy options for
maintenance treatment of BD (1–3). Quetiapine,
risperidone LAI (mania), aripiprazole (mania), and
ziprasidone (mania) are also recommended as
adjunctive therapy with lithium or divalproex.
A systematic review of pharmacological inter-
ventions for the prevention of relapse in BD
included 34 RCTs and quasi-RCTs, and concluded
that lithium, olanzapine, and aripiprazole had
signiﬁcant eﬀects in the prevention of manic
relapses, as did divalproex, lamotrigine, and imip-
ramine in the prevention of depressive symptoms
(161). A meta-analysis of 20 RCTs (n = 5364)
assessing the relative risk for relapse in patients
with BD in remission conﬁrmed the eﬃcacy of
lithium, divalproex, lamotrigine, and a number of
atypical antipsychotic agents in preventing relapse
to any episode versus placebo (162).
Lithium ⁄divalproex. The Bipolar Aﬀective disorder
Lithium ⁄ANti-Convulsant Evaluation (BAL-
ANCE) study randomized 330 patients with BD
to open-label lithium monotherapy, divalproex
monotherapy, or the combination after an active
run-in period on the combination (163). Both the
combination and lithium monotherapy were
signiﬁcantly more eﬀective than divalproex mono-
therapy in preventing relapse during up to two
years of follow-up. Combination therapy was not
signiﬁcantly more eﬀective than lithium alone. This
study, however, had a number of methodological
limitations, including an open design; hence, these
ﬁndings need to be conﬁrmed in double-blind trials
before ﬁrm conclusions can be drawn.
Lamotrigine. During a one-year extension phase of
an RCT, median time to relapse or recurrence was
longer among responders receiving lamotrigine
compared to those receiving placebo as an add-
on to lithium ± paroxetine (ten versus 3.5months)
(164).
An open, randomized trial in patients with BD I
found no diﬀerences in maintenance eﬀectiveness
between lithium (n = 78) and lamotrigine (n = 77)
(165). Among patients followed for at least ﬁve
years, practically no patients were maintained
successfully on monotherapy with either drug.
Olanzapine.Ameta-analysis ofﬁveRCTs found that
olanzapine as monotherapy or an adjunct to lithium
or divalproex was more eﬀective than adjunct
placebo in preventing a manic, but not any type of
depressive, episode (166). The analysis concluded
that olanzapine may prevent manic episodes only in
patients who have responded to olanzapine for an
acute episode and who have not previously had a
satisfactory response to lithium or valproate.
In two recent RCTs, olanzapine was included as
an active control arm, and in the continuation
phase demonstrated a signiﬁcantly longer time to
recurrence than either risperidone LAI (167) or
paliperidone ER (168).
Table 5.5. Recommendations for maintenance pharmacotherapy of bipolar disorder
First line Monotherapy: lithium, lamotrigine (limited efficacy in preventing mania), divalproex, olanzapinea,
quetiapine, risperidone LAIb, aripiprazoleb
Adjunctive therapy with lithium or divalproex: quetiapine, risperidone LAIb, aripiprazoleb, ziprasidoneb
Second line Monotherapy: carbamazepine, palideridone ERc
Combination therapy: lithium + divalproex, lithium + carbamazepine, lithium or divalproex + olanzapine,
lithium + risperidone, lithium + lamotrigine, olanzapine + fluoxetine
Third line Monotherapy: asenapinec
Adjunctive therapy: phenytoin, clozapine, ECT, topiramate, omega-3-fatty acids, oxcarbazepine,
gabapentin, asenapinec
Not recommended Monotherapy: gabapentin, topiramate, or antidepressants
Adjunctive therapy: flupenthixol
LAI = long-acting injection; ER = extended release; ECT = electroconvulsive therapy.
aGiven the metabolic side effects, use should be carefully monitored.
bMainly for the prevention of mania.
cNew or change to recommendation.
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A large, observational study (EMBLEM) in-
cluded 1076 patients in a comparison of olanzapine
monotherapy or as an adjunct and found no
signiﬁcant diﬀerence in rates of improvement,
remission, or recovery, but signiﬁcantly lower
relapse rates with olanzapine alone compared to
adjunctive olanzapine (p = 0.01) over the two-
year follow-up (169).
Quetiapine. Three of the ﬁve large RCTs described
in the 2009 guidelines (3), which demonstrated the
eﬃcacy of quetiapine alone or in combination with
lithium ⁄divalproex for maintenance therapy in
BD, have now been published (level 1) (170–172).
The eight-week acute-phase results of the EM-
BOLDEN I (90) and II (91) trials have also been
published but the long-term data remain available
only in abstract form.
Risperidone LAI. Risperidone LAI monotherapy
(level 2) (173) and adjunct (level 2) (174) were
previously recommended as ﬁrst-line maintenance
therapies (3), based on RCTs presented in abstract
form that have now been published. An additional
18-month continuation study has now provided
level 1 evidence for maintenance risperidone LAI.
Time to recurrence of any mood episode was
signiﬁcantly longer with risperidone LAI compared
to placebo (level 1) (168). However, risperidone
LAI was less eﬀective in preventing relapse
compared to olanzapine.
In addition, a small (n = 29), long-term, open
trial demonstrated improvements in treatment
adherence, reductions in any relapse rates, and
reductions in re-hospitalization rates with adjunc-
tive risperidone LAI during a mean two-year
follow-up (175).
Aripiprazole. Aripiprazole monotherapy has dem-
onstrated eﬃcacy for the prevention of manic
episodes in the maintenance treatment of patients
with BD I and was included in the 2009 guideline
as a ﬁrst-line maintenance therapy for the treat-
ment and prevention of mania (level 1) (3).
A 52-week, relapse prevention RCT demon-
strated the eﬃcacy of aripiprazole as an adjunct to
lithium or divalproex in patients with manic ⁄mixed
episodes and an inadequate response to lithium or
divalproex (176). Patients (n = 337) in remission
for 12 weeks who were randomized to continue
adjunctive aripiprazole had a lower rate of relapse
to manic (5% versus 15%, p = 0.013) but not
depressive (10% versus 13%, p = 0.384) episodes.
Since adjunctive aripiprazole demonstrated eﬃcacy
for the prevention of any mood episode or manic
episodes, but not depressive episodes, it has been
added as a ﬁrst-line maintenance therapy for the
prevention of manic episodes (level 2).
Another 52-week relapse prevention study in 351
BD I patients with a manic ⁄mixed episode, avail-
able in abstract form, showed a non-signiﬁcant
trend to lower rates of manic ⁄mixed relapse with
aripiprazole versus placebo added to lamotrigine
(11% versus 23%, p = 0.058) (177). There was a
non-signiﬁcant trend to lower rates of any relapse,
and no eﬀect on depressive relapse rates.
Ziprasidone. An RCT demonstrating the eﬃcacy of
adjunctive ziprasidone for maintenance treatment
of BD, previously available in abstract form, has
now been published (level 2) (178). Adjunctive
ziprasidone (80–160 mg ⁄day) demonstrated eﬃ-
cacy for the prevention of manic, but not depres-
sive, episodes.
Second-line options:
Carbamazepine. A meta-analysis of four RCTs,
including 464 patients, supports previous conclu-
sions that maintenance treatment with carbamaz-
epine has a similar eﬃcacy to lithium for rates of
relapses, with the caveat that there were fewer
withdrawals due to adverse eﬀects with lithium
(level 2) (179). Given the signiﬁcant tolerability
issues with carbamazepine and the diﬃculty in
combining this agent with other psychotropic
medications because of its hepatic microsomal
enzyme induction properties, carbamazepine con-
tinues to be recommended as a second-line option.
OFC. A six-month, continuation, RCT comparing
OFC and lamotrigine monotherapy in patients
with bipolar depression that was previously cited in
abstract form has now been published (94). OFC
was associated with a signiﬁcantly greater improve-
ment in depressive and manic symptoms, but there
were no diﬀerences in relapse rates of bipolar
depression among responders to acute treatment.
In the observational EMBLEM study in 1076
patients with BD mania, adjunctive olanzapine was
less eﬀective than olanzapine monotherapy in
preventing any relapse (169). By contrast, another
study of open-label continuation treatment, in 114
patients with bipolar depression who were re-
sponders to OFC found that signiﬁcantly more
patients maintained their response to OFC com-
pared to olanzapine monotherapy (180).
Paliperidone ER. In a three-month continuation
study, continued paliperidone ER was signiﬁcantly
more eﬀective than placebo in preventing relapse in
prior paliperidone ER responders (level 2) (168).
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However, paliperidone ER was less eﬀective in
preventing relapse compared to the olanzapine
active control group.
Third-line options:
Asenapine. Nine-week and 40-week extension
phase results from two pooled three-week RCTs
demonstrated the maintenance of beneﬁts with
asenapine monotherapy and olanzapine in pa-
tients with BD mania (YMRS reduction )24.4
and )23.9 at week 12, )28.6 and )28.2 at week
52, respectively) (level 2) (58, 59). At one year, a
worsening of mania was reported in 2.6% of
asenapine patients and 1.9% of olanzapine
patients, while a switch to a depressive episode
occurred in 0% of asenapine and 3.0% of
olanzapine patients (59). Time to response was
signiﬁcantly longer with asenapine compared to
olanzapine (p = 0.0127). In this trial, patients in
the placebo groups of the original RCTs were
blindly switched to asenapine.
In addition, 40-week extension phase results
have now been reported in abstract form from
the trial of adjunctive asenapine added to lith-
ium ⁄divalproex compared to placebo (62). Of the
original 318 patients, 71 completed the 40-week
extension; improvements in mania ()17.2 versus
)19.7) and depression ()3.3 versus )3.9) scores at
52 weeks were seen in both the asenapine and
placebo groups, but the extension was not powered
for statistical comparisons.
Based on evidence of maintenance of beneﬁts,
but in the absence of relapse prevention data and
clinical experience, asenapine is recommended as a
third-line option for maintenance therapy.
Rapid cycling
In a six-monthRCT, patientswith BD (recentmanic
episode), SUD, and rapid cycling, who were
responders to lithium plus divalproex, were ran-
domized to continue combination therapyor lithium
alone (181). Of 149 patients enrolled into the open-
label acute stabilization phase, 31 were assigned to
maintenance treatment and 55% relapsed. There
were no signiﬁcant diﬀerences between combination
and monotherapy in the rate of relapse or time to
relapse. However, given the small sample size, the
study was likely underpowered to detect this.
In the STEP-BD study, among patients who
were responders to adjunctive antidepressants and
continued this treatment, those with a rapid-
cycling course had three times more depressive
episodes compared to those without rapid cycling
(1.29 versus 0.42 episodes ⁄year, p = 0.04) (182).
Mixed states
Several open-label and post-hoc analyses provide
additional insight into the role of atypical antipsy-
chotic agents in the management of patients with
mixed episodes or psychotic symptoms. In a post-
hoc analysis of patients with mixed episodes
(n = 121), where responders to olanzapine were
randomized to continue olanzapine or switch to
placebo, there were signiﬁcant reductions in relapse
rates with olanzapine compared to placebo (59.2%
versus 91.1%, p < 0.001) (183). During 52 weeks
of ﬂexible-dosed ziprasidone (40–160 mg ⁄day)
open-label extension treatment (n = 65), patients
with manic or mixed episodes, with or without
psychotic symptoms, showed comparable improve-
ments in mania and overall subtypes across
subgroups (184). In a 24-week, open-label trial of
adjunctive risperidone in 114 patients with mixed
or manic episodes, signiﬁcant reductions from
baseline in manic, depressive, and overall symptom
scores were observed with combination therapy in
both the manic and mixed groups (185).
Section 6. Special populations
Issues in the management of BD in women
The management of BD in women can present
additional challenges associated with the repro-
ductive cycle.
Premenstrual syndrome (PMS) ⁄premenstrual dys-
phoric disorder(PMDD): In the longitudinal STEP-
BD study, among women with BD (n = 293),
those with premenstrual exacerbation had more
episodes (primarily depressive), more depressive
and manic symptoms overall, a shorter time to
relapse, and greater symptom severity (186). Pre-
menstrual exacerbation may predict a more symp-
tomatic and relapse-prone phenotype in women
with BD.
A study in 61 women with BD I or BD II and
122 healthy women found that moderate-to-severe
PMS ⁄PMDD occurred signiﬁcantly more fre-
quently in patients with BD II (51.6%) compared
to the healthy women (19.7%) (187). Similarly, in a
study of 92 women with BD I or BD II, patients
with PMDD were more likely to have BD II and
cyclothymia than were patients without PMDD
(188).
Among patients seen at a specialty gynecology
clinic for chronic pelvic pain, those with endometri-
osis (n = 27) were more likely to have BD (44.4%)
and a poorer quality of life than women with non-
endometriosis pelvic pain (n = 12) (0%) (189).
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Pre-conception: Providing appropriate education
and guidance to patients considering pregnancy or
who may have recently become pregnant is
an important component of BD management.
Pre-conception counseling should include a careful
review of risks and beneﬁts and a treatment
plan for ongoing monitoring. An analysis of a
large claims database including 16385 women of
child-bearing age with BD or MDD revealed 1308
women who were receiving a category D (12%) or
category X (1%) medication during pregnancy
(190). The most frequently used psychotropic
drugs were paroxetine, alprazolam, lorazepam,
divalproex, lithium, and temazepam.
Pregnancy: The management of pregnant women
with BD should incorporate careful planning.
Updated recommendations on the use of psychiat-
ric medications during pregnancy and lactation are
available from the American Congress of Obste-
tricians and Gynecologists (ACOG), and the read-
er is referred to this Practice Bulletin for more
information (191). In addition, please visit the
Canadian Hospital for Sick Children Motherisk
website (http://www.Motherisk.org). Therefore, in
the following section, we will provide only a brief
update of some of the new data in patients with
BD.
The risk of teratogenicity associated with use
of psychotropic medications (please see ACOG
recommendations in Table 6.2) during the ﬁrst
trimester should be carefully weighed against the
risks to the mother and the fetus of an untreated
mood episode. Psychotropic medications can be
used in the second and third trimester if necessary.
If lithium is used during the second and third
trimester, the serum lithium levels should be
monitored closely because of changes in blood
volume during pregnancy, and the dose should be
adjusted accordingly to maintain levels in the
therapeutic range.
Cohort studies in various patient populations
conﬁrm the teratogenic risk associated with
divalproex (192–194) and carbamazepine (195)
during pregnancy. In a case-controlled series of
52 pregnancies, topiramate was associated with
reduced birth weight but no decrease in gestational
age and no increase in structural defects (196).
Several cohort studies in various patient popu-
lations found that, during pregnancy, antidepres-
sants did not confer an increased risk of major
congenital anomalies compared to unexposed
controls (197, 198). However, in one analysis
antidepressant use was associated with increased
rates of pregnancy complications, including in-
duced delivery, caesarean section, and preterm
birth, as well as increased risk of persistent
pulmonary hypertension of the newborn (199).
Some analyses suggest increased risks with
individual antidepressants (198–200), while others
do not (197). In one analysis, there were associa-
tions of ﬂuoxetine with ventricular septal defects,
paroxetine with right ventricular outﬂow tract
defects, and citalopram with neural tube defects,
although the absolute risk for these speciﬁc eﬀects
was small (198). The rate of major anomalies
(primarily cardiovascular) in birth outcome among
pregnant patients (n = 314) with ﬁrst trimester
exposure was 4.7% with ﬂuoxetine and 5.2%
with paroxetine, compared to 2.5% in control
patients (n = 1467), in a multicentre, prospective,
controlled study (200). Cardiovascular defects have
also been associated with paroxetine (199, 201) and
tricyclic antidepressant exposure (199).
A Canadian neonatal record analysis (n =
119547 live births) concluded that prenatal expo-
sure to combination therapy with SSRI and
benzodiazepines conferred a higher incidence of
congenital heart disease when compared to no
exposure (202). SSRI monotherapy was not asso-
ciated with an increased risk for major congenital
anomalies, but was associated with an increased
incidence of atrial septal defects.
A retrospective chart review including 30092
total deliveries identiﬁed one major malformation
among 16 of the mothers who were treated with
atypical antipsychotic agents during their preg-
nancy (203). The Food and Drug Administration
(FDA) issued a safety alert regarding the risks to
newborns associated with prenatal exposure to
typical or atypical antipsychotic drugs (204). The
new drug labels now contain information about the
potential risk for abnormal muscle movements and
withdrawal symptoms including agitation, abnor-
mal muscle tone, tremor, sleepiness, breathing, and
feeding diﬃculties in newborns.
In an observational, prospective study in 14
women with BD undergoing maintenance treat-
ment with lithium during pregnancy, the lithium
concentration ratio from infant to mother was 0.96
and congenital malformations were greater in those
receiving higher doses versus lower doses; however,
no signiﬁcant diﬀerences in neonatal outcomes
(gestational age ⁄weight, Apgar scores, or hospital
stay) were noted (205).
Postpartum period: Distinguishing bipolar depres-
sion from MDD can be challenging in the
postpartum period because of a lack of screening
instruments designed speciﬁcally for use during this
period (206). A Mood Disorder Questionnaire
(MDQ) validation study concluded that, with
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Alprazolam D Unknown, of concern L3
Chlordiazepoxide D N ⁄A L3
Clonazepam D N ⁄A L3
Clorazepate D N ⁄A L3
Diazepam D Unknown, of concern L3, L4 if used chronically
Lorazepam D Unknown, of concern L3
Oxazepam D N ⁄A L3
Benzodiazepines for insomnia
Estazolam X N ⁄A L3
Flurazepam X N ⁄A L3
Quazepam X Unknown, of concern L2
Temazepam X Unknown, of concern L3
Triazolam X N ⁄A L3
Non-benzodiazepine anxiolytics and hypnotics
Buspirone B N ⁄A L3
Chloral hydrate C Compatible L3
Eszoplicone C N ⁄A N ⁄A
Zaleplon C Unknown, of concern L2
Zolpidem B N ⁄A L3
Antiepileptic and mood-stabilizing medications
Lithium carbonate D Contraindicated L4
Valproic acid D Compatible L2
Carbamazepine D Compatible L2
Lamotrigine C Unknown L3
Antidepressants
Tricyclic and heterocyclic antidepressants
Amitriptyline C Unknown, of concern L2
Amoxapine C Unknown, of concern L2
Clomipramine C Unknown, of concern L2
Desipramine C Unknown, of concern L2
Doxepin C Unknown, of concern L5
Imipramine C Unknown, of concern L2
Maprotiline B N ⁄A L3
Nortriptyline C Unknown, of concern L2
Protriptyline C N ⁄A N ⁄A
Selective serotonin reuptake inhibitors
Citalopram C N ⁄A L3
Escitalopram C N ⁄A L3 in older infants
Fluoxetine C Unknown, of concern L2 in older infants, L3 if used in
neonatal period
Fluvoxamine C Unknown, of concern L2
Paroxetine D Unknown, of concern L2
Sertraline C Unknown, of concern L2
Other antidepressants
Bupropion B Unknown, of concern L3
Duloxetine C N ⁄A N ⁄A
Mirtazapine C N ⁄A L3
Nefazodone C N ⁄A L4
Trazodone C Unknown, of concern L2
Venlafaxine C N ⁄A L3
Antipsychotic medications
Typical antipsychotic agents
Chlorpromazine C Unknown, of concern L3
Fluphenazine C N ⁄A L3
Haloperidol C Unknown, of concern L2
Loxapine C N ⁄A L4
Perphenazine C Unknown, of concern N ⁄A
Pimozide C N ⁄A L4
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alternate scoring, the MDQ may be a useful
screening instrument for BD in the postpartum
period (206, 207). The optimal cut-oﬀ score was
eight or more endorsed symptoms without the
supplementary questions (sensitivity 88% and
speciﬁcity 85%) (208).
In a well-designed longitudinal study involving
344 pregnant women, there was an 8.4-fold
increase in hypomanic symptoms in the early
postpartum period (11.7%) compared to during
the ﬁrst trimester (1.4%) and to eight weeks
postpartum (4.9%) (209). Although hypomanic
symptoms are common in the early puerperium,
they are often overlooked, leading to a misdiag-
nosis of MDD (210). This may be due in part to the
absence of hypomania from the postpartum-onset
speciﬁer in the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition–text revised
(DSM-IV-TR) (211). However, a study from
Spain suggested reconsideration of the DSM
postpartum-onset speciﬁer, as it did not appear
to inﬂuence prognosis or functioning in women
with BD (212).
According to a Danish population-based study
of new mothers, the period of highest risk for
psychiatric readmission was 10 to 19 days post-
partum [relative risk (RR) = 2.7], and the period
of lowest risk was during pregnancy (RR = 0.5).
Previous diagnosis of BD was the strongest
predictor of readmissions 10–19 days postpartum
(RR = 37.2), with 27% of women with BD
being readmitted within the ﬁrst year (213).
Similarly, psychotic illness has been shown to
peak immediately following a ﬁrst childbirth
(214).
ACOG recommendations for the use of psychi-
atric medications during lactation are also shown
in Table 6.2 (191).
Menopause: In a STEP-BD analysis of 164 patients
with BD followed for an average of 30 months,
menopausal transition was associated with signif-
icantly more visits due to depressive symptoms and
fewer euthymic visits compared to a comparison
group of non-menopausal women and men (215).
Issues in the management of BD in children and
adolescents
Complete treatment recommendations for pediat-
ric BD are beyond the scope of these guidelines; the
reader is referred to speciﬁc guidelines for the
management of children and adolescents with BD,
such as those developed by the American Academy
of Child and Adolescent Psychiatry (AACAP)
(216). Therefore, in the following section, we will
provide only a brief overview of some of the issues
in this population without oﬀering recommenda-
tions for levels of treatment.
Presentation and diagnosis:Across the world, BD is
the fourth leading cause of disability among
adolescents (15–19 years) (217). The presentation
and diagnosis of BD in children and adolescents
remains controversial. Increasing billing and dis-
charge diagnoses of pediatric BD contradict a
stable epidemiologic prevalence, suggesting that
diagnostic criteria for BD may not be systemati-
cally applied in some clinical settings (218, 219).
However, much of the controversy regarding
pediatric BD has focused on the group of youth
with severe, chronic, non-episode irritability, which
has led to the proposed DSM-5 diagnosis of
disruptive mood dysregulation disorder (DMDD)
(220). The reader is referred to recent publications
focusing speciﬁcally on diﬀerential diagnosis and









Thioridazine C N ⁄A L4
Thiothixene C N ⁄A L4
Trifluoperazine C Unknown, of concern N ⁄A
Atypical antipsychotic agents
Aripiprazole C N ⁄A L3
Clozapine B Unknown, of concern L3
Olanzapine C N ⁄A L2
Quetiapine C Unknown, of concern L4
Risperidone C N ⁄A L3
Ziprasidone C Unknown, of concern L4
[Copyright (2008) Wolters Kluwer Health; reprinted with permission from (191)]. N ⁄A = not available.
aThe US Food and Drug Administration classifies drug safety using the following categories: A = controlled studies show no risk; B = no
evidence of risk in humans; C = risk cannot be ruled out; D = positive evidence of risk; X = contraindicated in pregnancy.
bLactation risk categories are listed as follows: L1 = safest; L2 = safer; L3 = moderately safe; L4 = possibly hazardous; L5 = contra-
indicated.
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manic symptoms (221, 222), and regarding con-
cerns about the DMDD diagnosis (223). Prospec-
tive studies of children and adolescents with
rigorously deﬁned BD demonstrate that this is an
episodic illness that continues into young adult-
hood and is characterized by substantial impair-
ment and morbidity (224–226).
Based on a meta-analysis of 12 epidemiological
studies in patients between the ages of seven and
21 years (n = 16222), the overall prevalence of BD
was 1.8% (219). Of note, rates of BD in these
epidemiologic studies did not increase over time
and did not diﬀer for studies within versus outside
of the USA. Among Canadian adolescents and
young adults (15–24 years), the CCHS 1.2 survey
recorded a lifetime prevalence of BD of 3.0%
(2.1% in those aged 15–18 years; 3.8% in those
aged 19–24 years) (227). In a claims database, the
one-year rate of a new diagnosis of BD among
patients £17 years of age was 0.23%. Misdiagnosis
was common, with 47% being diagnosed with
depressive disorder and 37% with disruptive
behavior disorder in the previous year (228). In
the Course and Outcome of Bipolar Youth
(COBY) study (n = 364), ﬁrst episodes in patients
‡ 12 years were generally depressive, while those in
patients <12 years were more likely to be sub-
syndromal manic ⁄hypomanic symptoms (229).
A claims analysis of younger (age 6–18 years)
patients with BD (n = 423) showed that the
majority did not receive guideline-concordant care,
with only 26% receiving anti-manic treatments and
33% receiving antidepressant monotherapy (230).
Similarly, eight-year follow-up data from an
NIMH study on the course of BD I in children
found that 37% of patients had never received
anti-manic treatment (231).
Over a ﬁve-year follow-up period in the COBY
study (n = 413) in youth (age 7–17 years), the rate
of suicide attempts was 18%. (232). Predictive
variables included female gender, severity of
depressive symptoms, familial history of depres-
sion, and lifetime history of exposure to antide-
pressants. Non-suicidal self-injury has also been
reported in more than 20% of children and
adolescents with BD (233).
Comorbidities and mimics: In the COBY study,
44% of youth had at least one lifetime anxiety
disorder, and nearly 20% had two or more, with
the most prevalent being separation anxiety (24%)
and generalized anxiety disorder (GAD) (16%)
(234). A family history study that included 157
patients (age 6–17 years) with BD I revealed
extremely high rates of comorbid attention-deﬁcit
hyperactivity disorder (ADHD) (85%), oppositional
deﬁant disorder (90%), two or more anxiety
disorders (64%), conduct disorder (51%), and
SUD (12%) (235).
Early BD onset (age <12 years) has been asso-
ciated with ADHD, whereas later BD onset (age
‡ 12 years) was associated with panic, conduct, and
SUD (229). Psychotic symptoms have been re-
ported in about one-third of youth with BD, and
confer a signiﬁcantly greater likelihood of lifetime
GAD, agoraphobia, social phobia, and obsessive
compulsive disorder (OCD) (236).
Medical comorbidities including obesity, type 2
diabetes mellitus, other endocrine disorders,
migraine headaches, central nervous system disor-
ders ⁄ epilepsy, organic brain disorders ⁄mental
retardation, cardiovascular disorders, and asthma
in a large cohort study were signiﬁcantly more
prevalent among children and adolescents with
BD (n = 1841) compared to a control group
(n = 4500) (237). In the COBY study (n = 348),
overweight ⁄obesity was seen in 42% of youth with
BD, and was associated with increased psychiatric
burden (238). Moreover, in a pilot study on
inﬂammatory markers among 30 adolescents in
the COBY study, 40% had levels of high-sensitivity
C-reactive protein that are considered to confer a
high risk for cardiovascular disease among adults
(‡ 2 lg ⁄mL) (239).
Acute and maintenance treatment of pediatric BD:
Most RCTs in youth with BD have investigated the
acute treatment of manic ⁄mixed symptoms, with
few assessing maintenance therapy. Thus, taking
into account that not all treatments that are
eﬃcacious in adults will also be so in children
and adolescents, and until further studies become
available, the guidelines developed for adults with
BD should be cautiously applied to youth.
Psychosocial interventions
The two-year follow-up results of an RCT in
adolescent patients (n = 58) with BD which com-
pared adjunctive family-focused treatment (FFT)
and enhanced care found no diﬀerences in time to
recurrence of depression or mania, but patients in
the FFT group spent fewer weeks in depressive
episodes (240). In a one-year open trial, a modiﬁed
FFT was associated with improved depression,
hypomania, and psychosocial functioning scores in
youth who were thought to be at high risk for
developing BD (241). Preliminary ﬁndings suggest
that child and family-focused CBT (242), dialecti-
cal behavior therapy (DBT) (243), and IPSRT
(244) may be promising in the management of BD




Atypical antipsychotics. The AACAP published a
practice parameter on the use of psychotropic
medication in children and adolescents, and the
reader is referred to those guidelines for more
details (245). Provided below is an overview of
current data of the eﬃcacy of atypical antipsy-
chotic agents for the treatment of BD in younger
patients.
The US FDA has now approved quetiapine for
the ﬁrst-line treatment of acute manic ⁄mixed
episodes in pediatric patients. In light of safety ⁄ tol-
erability concerns, olanzapine (weight gain and
metabolic disturbances) and ziprasidone (QT pro-
longation) were approved as second-line treat-
ments only (246).
A meta-analysis of nine RCTs included 1609
pediatric patients with acute BD mania and found
signiﬁcantly greater improvements in YMRS
scores in the atypical antipsychotic agent group
and mood stabilizer group relative to placebo. The
eﬀect sizes were greater for the atypical antipsy-
chotic agent group compared to a mood stabilizer
group (eﬀect size 0.65 versus 0.20). However, the
mood stabilizer group included studies on topira-
mate and oxcarbazepine, neither of which demon-
strated eﬃcacy as mood stabilizers. Further,
medication-associated weight gain was greater with
atypical antipsychotic agents than with mood
stabilizers (eﬀect size 0.53 versus 0.10) (44).
In a small eight-week RCT in 32 adolescents (age
12–18 years), quetiapine monotherapy was not
signiﬁcantly better than placebo for the treatment
of bipolar depression (247). This negative trial
requires replication in light of the small sample
size, high placebo response rates, and robust
evidence of quetiapine eﬃcacy in bipolar depres-
sion in adults group (1–3). Quetiapine monotherapy
has also demonstrated eﬃcacy as acute and main-
tenance treatment in small, open-label studies (248,
249).
A pooled analysis of four olanzapine trials
(two RCTs, two open-label) in adolescents (age
13–17 years) with BD or schizophrenia revealed
signiﬁcantly more weight gain compared to adult
patients (7.4 kg versus 3.2 kg) in up to 32 weeks
of treatment (250). Adolescents also experienced
signiﬁcant changes in fasting glucose, total choles-
terol, triglycerides, alanine aminotransferase, and
prolactin. In an eight-week, open-label study the
addition of topiramate to olanzapine therapy in 40
pediatric patients with BD resulted in signiﬁcantly
less weight gain than with olanzapine monothera-
py, with no diﬀerences in mania symptom scores
(251).
In addition to the previously cited RCT data,
further open-label data support the eﬃcacy and
tolerability of ziprasidone therapy in youth with
BD (252, 253).
A three-week RCT in 169 pediatric patients with
BD mania ⁄mixed episodes demonstrated greater
reductions in mania scores with risperidone versus
placebo (254). In a six-week RCT in 66 youth,
risperidone resulted in more rapid improvement in
manic symptoms and a signiﬁcantly greater rate of
remission (63% versus 33%) compared to divalp-
roex (255). Primary outcomes from the eight-week
Treatment of Early-Age Mania (TEAM) study of
279 medication-naı¨ve youth (age 6–15 years)
with BD I mania ⁄mixed episodes were recently
published (256). TEAM was a controlled, random-
ized, no-patient-choice study comparing lithium,
divalproex, and risperidone. The response rate for
risperidone (68.5%) was signiﬁcantly greater than
for lithium (35.6%) and divalproex (24.0%), which
did not diﬀer signiﬁcantly from each other. How-
ever, increasedweight gain, bodymass index (BMI),
and serum prolactin levels were also signiﬁcantly
greater with risperidone than with the other medi-
cations. Similar results were seen in a small cohort
study in which risperidone resulted in a faster and
greater reduction of symptom scores versus divalp-
roex (257). Hence, although it is premature to
conclude that atypical antipsychotic agents have
greater eﬃcacy than mood stabilizers in pediatric
mania, a convergence of data suggest that this may
be the case.
An RCT demonstrating the eﬃcacy of aripip-
razole for BD I manic ⁄mixed episodes in pediatric
patients that was previously cited in abstract form
has now been published (258). Another six-week
RCT in 43 pediatric patients with BD manic
⁄mixed episodes and comorbid ADHD demon-
strated signiﬁcant reductions in manic, but not
depressive or ADHD, symptoms with aripiprazole
versus placebo (level 1) (259).
Analyses suggest a poorer response to atypical
antipsychotic agent therapy in pediatric patients
with BD and comorbid OCD, but not in those with
comorbid autism (260, 261).
Anticonvulsants. Several small, open-label trials
demonstrated signiﬁcant improvements with lamo-
trigine monotherapy in both manic and depressive
clinical endpoints (262, 263), and as an adjunct to
atypical antipsychotic agents (264) in youth with
BD mania ⁄mixed episodes during 3–6 months of
follow-up.
A four-week RCT of divalproex ER in 150
pediatric patients (age 10–17 years) with BD
mania ⁄mixed episodes found no beneﬁt of active
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treatment over placebo on primary or secondary
outcomes, and there was only modest improvement
in mania scores during the six-month, open-label
extension phase (265). However, a six-month, open-
label study in 226 youth with BD I mania ⁄mixed
episodes found that divalproex ER reduced mania
scores and was generally well tolerated (266).
In an eight-week, open-label trial in 27 youth
with bipolar spectrum disorders, carbamazepine
ER was associated with improvements in mania,
depression, psychosis, and ADHD symptoms, but
drop-out rates were high (267).
Issues in the management of BD in older patients
Presentation and course: The two-year EMBLEM
study included 475 patients >60 years with acute
BD mania ⁄mixed, and found that older patients
had a history of more rapid cycling, fewer suicide
attempts, and less severe manic and psychotic
symptoms, but no diﬀerence in depressive symp-
tomatology (268). Older patients with late-onset
BD (age ‡ 50 years) experienced a better 12-week
outcome with a faster recovery and earlier dis-
charge compared to older patients with early-onset
BD (age <50 years). The prevalence of mixed
episodes was reported at 10% in patients
‡ 60 years in an RCT (269).
Comorbidity: In a case-controlled study, there was
a higher prevalence among older patients (n = 82,
age >60 years) with BD of diabetes mellitus
(27%), atopic diseases (20%), smoking (24%),
and unfavourable social functioning (22%) when
compared to age-matched controls (270).
A large survey of geriatric patients in a Veterans
Health Administration database found the use of
anticonvulsants to be associated with an over
twofold increased risk of fracture. In addition,
patients with BD had a 20% increased risk of
fracture compared to those without BD, indepen-
dent of the use of anticonvulsants (271).
Older adults with BD have been shown to have
greater levels of cognitive dysfunction than
age-matched mentally healthy control subjects
(272–275). Among older patients with BD, a
greater burden from vascular risk factors has been
associated with poorer outcomes on some cognitive
measures (276, 277). Several analyses have failed to
detect a signiﬁcant association between dementia
or cognitive performance in older patients and the
use of lithium (277, 278).
Treatment of BD in older patients: Data assessing
pharmacotherapy speciﬁcally in older patients
with BD remain scarce. In a post-hoc, pooled
analysis of two quetiapine monotherapy RCTs
in patients with acute BD mania, subgroup
analysis of 59 older adults (age ‡ 55 years) dem-
onstrated a signiﬁcant improvement in manic
symptoms as early as day four, and this was
sustained over the 12 weeks of follow-up versus
placebo (279).
At 12 weeks, the results from an open-label
study of adjunctive lamotrigine in older patients
(n = 57, age ‡ 60 years) with BD I or BD II
indicated an overall signiﬁcant decline in depres-
sive symptoms, with a 65% response rate and a low
rate of discontinuations because of adverse events
(10%) (280).
Issues in the management of BD in patients with comorbid
conditions
The reader is also referred to a task force report on
the management of patients with mood disorders
and comorbid psychiatric and medical conditions
developed by the CANMAT Comorbidity Task
Force (281).
Prevalence and impact
Medical. In the large US National Epidemiologic
Survey on Alcohol and Related Conditions study,
which included 1548 patients with BD I, the
prevalence of one or more general medical con-
ditions was 32% (282). In another analysis,
patients with BD I or BD II were found to have
a mean of 2.5 comorbid medical conditions (283).
Cardiovascular disease and hypertension were
almost ﬁvefold more prevalent among patients
with BD than controls (284). The risk of cardio-
vascular mortality was found to be more than
double in patients with BD I compared to those
with BD II, in a long-term follow-up study (285).
In addition, patients with BD had a signiﬁcantly
greater risk for hospital readmission due to a
cardiovascular event (286).
The increased rate of metabolic syndrome in
patients with BD, by up to twofold compared to
the general population, has been documented in
countries around the world (287). Comorbid met-
abolic disturbances in patients with BD have been
associated with a more complex illness presenta-
tion, less favourable response to treatment, and
worse course of illness (283, 287, 288).
In patients with BD, a higher BMI has been
associated with more frequent manic and depres-
sive relapses, more suicide attempts, and poorer
psychosocial functioning, as well as a greater
frequency of type II diabetes, hypertension, and
subthreshold anxiety disorders (289–291). Over-
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weight ⁄obesity has also been shown to have a
negative impact on long-term treatment response
(283, 289) and on cognitive function in euthymic
patients with BD (292).
Comorbid migraine aﬀects nearly one in four
patients with BD (293), and confers signiﬁcantly
increased risk for suicidal behavior, comorbid
psychiatric disorders, and rapid cycling, as well as
a greater number of mood episodes and lifetime
hospitalizations compared to patients without
migraine (293, 294). The prevalence of migraine is
reportedly higher in patients with BD II than in
those with BD I (35% versus 19%) (293).
Up to 12% of patients with epilepsy may have a
diagnosis of BD; however, only 1.4% had pure BD,
as all other caseswere associatedwith diﬀering states
relating to the primary diagnoses of epilepsy (295).
Psychiatric. A retrospective analysis of four trials
including 566 patients with rapid-cycling BD I or
BD II found lifetime rates of anxiety disorders and
SUD of 46% and 67%, respectively (296). Comor-
bid SUD has been linked to an increased risk
of suicide and other unnatural deaths, suicide
attempts, nicotine dependence, and other SUDs in
patients with BD (297–299). Patients with BD have
a ﬁvefold higher risk of current cigarette smoking
compared to the general population (300). Ciga-
rette smoking has also been associated with
suicidal behavior in patients with BD (301, 302).
In addition, suicidal behavior has been associated
with borderline personality disorder (BPD), panic
disorder, alcoholism, other drug addictions, and
GAD, although only BPD and alcoholism were
independently associated (301). Comorbid SUD in
patients with BD confers substantially greater
impairment in social functioning compared to
patients without SUD (303).
In patients with rapid-cycling BD, comorbid
SUD was associated with a twofold increased risk
of being incorrectly medicated (not receiving a
mood stabilizer after the onset of ﬁrst mania ⁄hypo-
mania) (296). In addition, an uncontrolled study
suggested that comorbid SUD may be associated
with a very high risk of antidepressant-induced
switch to mania (76%) (304, 305).
A functional assessment of patients (n = 206)
with BD I or BD II noted that more than one-third
had missed ‡ 2 years of work time over a ﬁve-year
period, and extended unemployment was associated
with increased rates of panic disorder and alcohol
abuse (306). The presence of comorbid panic disor-
der in patients with BD I (compared to thosewith no
panic disorder) was associated with signiﬁcantly
more depressive, manic, and any mood episodes, as
well as increased risk of lifetime SUD or eating
disorders (307). In theNIMHCollaborativeDepres-
sion Study, the presence of psychic and somatic
anxiety symptoms was associated with a greater
proportion of weeks in depressive episodes during
long-term follow-up (mean 17 years) of patients
with BD (308). The prevalence of lifetime eating
disorders, particularly binge eating disorder, is high
(14%) in patients with BD (309).
It is of note that patients with BPD are at high
risk of being misdiagnosed as having BD, and vice
versa (310, 311).
The International Mood Disorders Collabora-
tive Project reported the prevalence of lifetime
ADHD in adults with BD as 18%, which was
substantially higher than that found in patients
with MDD (5%). Comorbid ADHD has been
associated with a greater number of comorbid
psychiatric conditions (312), a negative impact on
the course of BD in adulthood (313), impaired
psychosocial functioning, and poorer overall qual-
ity of life (312, 314).
Treatment of BD in patients with comorbidities: In a
retrospective analysis, a bipolar collaborative
chronic care model was as eﬀective in patients
with BD and comorbid conditions (SUD, psychi-
atric, and ⁄or medical) as in those without,
although it may be necessary to pay speciﬁc
attention to physical quality of life in patients with
cardiovascular disease (315). A six-month pilot
study of a BD medical care model demonstrated a
slowing of decline in physical health-related quality
of life compared with usual care in patients with
BD and cardiovascular disease-related risk factors
(316). Improvements in mental health-related qual-
ity of life were also seen, but were not signiﬁcant.
Medical. A small (n = 10), 14-week pilot study of
an integrated psychosocial treatment model
including three treatment modules (nutri-
tion ⁄weight loss, exercise, and wellness treatment)
administered in group sessions, as well as weekly
exercise, demonstrated improvements in quality of
life, depressive symptoms, and weight (317).
Open-label adjunctive ziprasidone was eﬀective
in signiﬁcantly improving weight-related parame-
ters while maintaining or improving mood symp-
toms in 25 obese ⁄overweight patients with BD
taking atypical antipsychotic agents, lithium, or
divalproex (318).
In a recent report, bariatric surgery for weight
reduction was as eﬀective in patients with BD as in
those without (319).
Psychiatric. An RCT in 61 patients with BD and
comorbid SUD compared a modiﬁed version of
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integrated group therapy (12 sessions instead of 20)
to group drug counseling (320). The integrated
group therapy, which employed a cognitive-behav-
ioral model integrating treatment of both condi-
tions, resulted in an increased likelihood of
achieving total abstinence and a better overall
composite outcome compared to regular group
counseling. A review of psychosocial interventions
for the treatment of comorbid anxiety in patients
with BD concluded that CBT, mindfulness-based
CBT, and relaxation training may be eﬀective,
while interpersonal and family therapy, and psy-
choeducation alone did not seem to be beneﬁcial in
treating comorbid anxiety (321).
Two large, 12-week RCTs (n = 362 and
n = 115) of adjunctive quetiapine in patients with
BD and comorbid alcohol abuse or dependence did
not show signiﬁcant improvements in measures of
alcohol use and dependence compared to placebo,
although depressive symptoms improved in one trial
(322, 323). A 12-weekRCT of adjunctive naltrexone
in 50 patients with BD I or BD II and comorbid
alcohol dependence demonstrated a trend toward
greater decrease in alcohol-related outcomes com-
pared to placebo (324). Response to naltrexone was
signiﬁcantly related to medication adherence.
In a 20-week RCT involving 80 patients with BD
and comorbid SUD (cocaine or methamphetamine
dependence), both quetiapine and risperidone
improved manic and depressive symptoms, as well
as drug cravings and use, with no signiﬁcant
diﬀerences between treatments (325); however, this
study lacked a placebo group. In another placebo-
controlled, 12-weekRCT, involving 44 patients with
BD I or BD II and cocaine dependence, citicoline
signiﬁcantly improved some aspects of declarative
memory and cocaine use, but not mood (326).
In a small RCT involving 31 patients with rapid-
cycling BD and comorbid SUD who were stabilized
on the combination of lithium plus divalproex, there
was no signiﬁcant diﬀerence in mood relapse rates
between patients randomized to continue combina-
tion therapy and those who received lithium alone
(181). An analysis of 98 patients from the acute
open-label phase of this study found that these
patients have a poor response to treatment and a
high burden of serious medical comorbidity (327).
A small, six-week RCT in 43 pediatric patients
with BD manic ⁄mixed episodes and comorbid
ADHD demonstrated signiﬁcant reductions in
manic, but not depressive or ADHD, symptoms
with aripiprazole versus placebo (level 1) (259).
In a randomized, crossover trial in 16 youth with
BD (age 8–17 years) who had responded to
aripiprazole, the addition of methylphenidate did
not result in signiﬁcant improvements in ADHD or
mania symptoms compared to placebo (328);
however, depressive symptoms did improve.
In an eight-week RCT of risperidone in 111
patients with BD and comorbid panic disorder or
GAD, risperidone was no more eﬀective than
placebo on any of the anxiety measures (329).
A post-hoc analysis of the BOLDER I and
BOLDER II trials including 1051 patients with BD
I or BD II depression reported signiﬁcant improve-
ments in anxiety symptom scores as early as week
one, and these were sustained through week eight
with quetiapine compared to placebo (330). This
suggests that quetiapine should be investigated in
patients with BD and comorbid anxiety disorders.
Section 7. Acute and maintenance management of
bipolar II disorder
Acute management of hypomania
The preponderance of depressive symptoms in
patients with BD II likely contributes to the
under-investigation of treatments for hypomania
in this patient group. The only studies carried out
to date examined mixed samples of patients with
BD I and BD II and did not report results
separately for BD II. Nonetheless, due to the
paucity of information on the treatment of hypo-
mania, we will describe them brieﬂy here. Two
small, eight-week RCTs indicated that quetiapine
(n = 39) (331) and divalproex ER (n = 60) (332)
were superior to placebo in treating patients with
hypomania or mild mania. In addition, a previ-
ously described six-month, open-label trial sug-
gested eﬃcacy for risperidone (333).
Table 7.2. Recommendations for pharmacological treatment of acute bipolar II depression
First line Quetiapine, quetiapine XR a
Second line Lithium, lamotrigine, divalproex, lithium or divalproex + antidepressants, lithium + divalproex, atypical
antipsychotic agents + antidepressants
Third line Antidepressant monotherapy (primarily for those with infrequent hypomanias), switch to alternate
antidepressant, quetiapine + lamotrigine a, adjunctive ECT a, adjunctive NAC a,
adjunctive T3 a
Not recommended See text on antidepressants for recommendations regarding antidepressant monotherapy
ECT = electroconvulsive therapy; NAC = N-acetylcysteine; T3 = triiodothyronine; XR = extended release.
aNew or change to recommendation.
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Due to the methodological limitations of these
trials, and the lack of systematic study of many
commonly used mood-stabilizing medications, it is
diﬃcult to formulate evidence-based treatment
recommendations for hypomania. However, clini-
cal practice suggests that medications that are
eﬀective in mania are eﬃcacious in treating hypo-
manic symptoms. Thus, in patients with persistent
and ⁄or impairing symptoms of hypomania, clini-
cians should treat according to their clinical
judgment, using lithium, divalproex, or atypical
antipsychotic agents and tapering potentially
contributory medications such as antidepressants.
Acute management of bipolar II depression
Psychotherapy: The role of psychotherapy in the
treatment of BD II depression has also been
understudied. Nonetheless, the predominance of
depressive symptoms in patients with BD II, and
the fact that BD II depression shares many clinical
characteristics with MDD suggest that psychother-
apy may improve outcomes in these patients.
Supporting this is one small (n = 17), 12-week
feasibility study demonstrating that 41% of
patients with BD II depression achieved a response
(‡ 50% reduction in depression scores) with IPSRT
monotherapy without an increase in mania scores
(334).
Pharmacotherapy: Table 7.2 illustrates the recom-
mendations for the pharmacological treatment of
acute BD II depression (1–3). Quetiapine XR joins
quetiapine as a ﬁrst-line option. Quetiapine plus
lamotrigine, adjunctive NAC, and adjunctive tri-
iodothyronine (T3) have been added as third-line
options.
First-line options
Quetiapine. The four large RCTs demonstrating
the eﬃcacy of quetiapine monotherapy in com-
bined groups of patients with BD I or BD II
depression, which were cited in previous iterations
of these guidelines, have now all been published:
BOLDER I (88) and II (89), and EMBOLDEN I
(90) and EMBOLDEN II (91). A pooled analysis
of data in 776 patients with BD II from all four
studies has been presented in abstract form (level 1)
(335). Quetiapine doses of 300 mg ⁄day and
600 mg ⁄day were both associated with signiﬁcantly
greater improvements in MADRS total scores
compared to placebo, beginning at week one and
continuing through week eight. Response and
remission rates were also signiﬁcantly greater with
both doses of quetiapine than placebo. There were
signiﬁcant improvements in core depressive symp-
toms, including reported sadness, anhedonia, neg-
ative thoughts, and suicidality, as well as anxiety
symptoms.
In an eight-week RCT in patients with BD I and
BD II depression, among the patients with BD II
(n = 53), quetiapine XR 300 mg ⁄day was associ-
ated with a signiﬁcantly greater improvement in
MADRS total score at study end compared to
placebo (level 2) (92).
Second-line options
Lithium. The EMBOLDEN I trial included a
lithium comparator arm, and provides the only
placebo-controlled, parallel-group RCT data for
lithium in acute BD II depression (90). In this
trial, neither lithium nor quetiapine were superior
to placebo in improving depression scores in
patients with BD II, raising the possibility that
this was a failed, rather than negative, trial. In
addition, the mean lithium levels were
< 0.8 mEq ⁄L.
Divalproex. A meta-analysis of four small studies
(total n = 142) in patients with BD I or BD II
depression found that the RR of response was
double, and of remission almost two-thirds greater,
with divalproex monotherapy compared to placebo
(96). Two of the trials reported results separately
for BD I and BD II, with one reporting greater
improvement in patients with BD I than BD II (as
outcomes for the BD II group showed no separa-
tion from placebo) (336), and the other reporting
greater improvements in BD II than BD I (337).
Additional, open-label data supporting the eﬃcacy
of divalproex ER in BD II depression, previously
cited in abstract form, have now been published
(338). Thus, the data in aggregate are mixed.
Further studies are clearly warranted to fully
understand the role of divalproex in BD II
depression.
Lamotrigine. The results of two previously unpub-
lished RCTs of lamotrigine have been published in
a review article (339). In the ﬁrst study, 221
patients with BD II received lamotrigine
200 mg ⁄day or placebo for eight weeks, while in
the second 206 patients with BD I or BD
II depression were randomized to lamotrigine
100–400 mg ⁄day or placebo. In neither trial was
lamotrigine superior to placebo. The negative
results may be related to the slow titration of
lamotrigine and high placebo response rates.
Further, a meta-analysis of lamotrigine trials in
BD I or BD II depression showed greater response
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rates with lamotrigine than placebo, although the
eﬀect size was very modest (83). Based on this
evidence, and its excellent tolerability proﬁle,
lamotrigine continues to be recommended as a
second-line option for the acute treatment of BD II
depression.
Third-line options
Antidepressant monotherapy. Relatively few stud-
ies have assessed antidepressant monotherapy in
BD II because of concerns about induction of
mood elevation. A paroxetine comparator arm in
the EMBOLDEN II trial represents the largest
placebo-controlled sample to evaluate antidepres-
sant monotherapy in BD II depression (91).
Paroxetine was not superior to placebo, although
the dose may be considered low (20 mg), and
quetiapine did not separate from placebo in this
study, suggesting that this was a failed, rather
than negative, study. Interestingly, switch rates
into hypo ⁄mania were similar with paroxetine
and placebo.
In a 14-week, open-label study of ﬂuoxetine
monotherapy (n = 148), 60% of patients responded
and 58% remitted (340). Although about 24%
experienced hypomania ⁄ subsyndromal hypoma-
nia, this did not result in treatment discontinua-
tion. In a post-hoc analysis of a previously
reported open-label study in 83 patients with BD
II, the signiﬁcantly greater improvements in
depression scores with venlafaxine compared to
lithium were independent of rapid-cycling status,
and venlafaxine did not result in a higher propor-
tion of mood conversions (versus lithium) in either
the rapid or non-rapid-cycling patients (341).
Patients in this study who were unresponsive to
lithium therapy (n = 14) and who were subse-
quently crossed over to venlafaxine experienced
signiﬁcantly greater reductions in depression and
overall mood scores, with no diﬀerences in mania
scores versus prior lithium (342). The main limita-
tion of these studies is their open-label design.
Quetiapine + lamotrigine. A 12-week, open-label
trial assessed the beneﬁt of adding lamotrigine or
quetiapine to pre-existing therapy in amixed sample
of patients with BD (BD I n = 15, BD II n = 22, or
BD NOS n = 1) on multiple medications (level 3)
(104). Adding quetiapine to lamotrigine in patients
who had not responded to lamotrigine (n = 17
patients with BD II), and adding lamotrigine to
quetiapine in patients who had not responded to
quetiapine,was associatedwith improvements in the
overall sample (level 3) (104). Data were not
reported separately for patients with BD II.
Adjunctive ECT. An open-label study of twice-
weekly bilateral ECT included patients with BD II
who were medication refractory (n = 67). They
achieved a response rate of 79% and a remission
rate of 57% (343). This response rate was inter-
mediate between patients with MDD (94%) and
those with BD I (67%).
Novel treatments. In a sub-analysis of a small
number of patients with BD II (n = 14) partici-
pating in a 24-week RCT, signiﬁcantly more
patients achieved full remission of both depressive
and manic symptoms with adjunctive NAC com-
pared to placebo (344). In a retrospective chart
review of patients with treatment-resistant BD II
or BD NOS depression (n = 159), treatment with
supraphysiologic doses of T3 was associated with
response in a majority of patients (345).
Maintenance therapy for bipolar II disorder
Psychotherapy: A post-hoc analysis of 20 patients
with BD II who participated in a single-blind
RCT demonstrated the beneﬁts of adjunctive psy-
choeducation (21 sessions over six months) com-
pared to unstructured support groups, with lasting
beneﬁts for up to ﬁve years (346). Signiﬁcantly
fewer patients in the psychoeducation group expe-
rienced any mood, depressive, or hypomanic
relapse during follow-up, and had signiﬁcantly
better psychosocial functioning at both two- and
ﬁve-year follow-up.
Pharmacotherapy: The major focus of maintenance
therapy for patients with BD II is prevention of
depressive episodes. New data support the addition
of quetiapine monotherapy as ﬁrst-line, and
adjunctive quetiapine as second-line options for
maintenance treatment for BD II (Table 7.4) (1–3).
Lithium and lamotrigine continue to be recom-
mended as ﬁrst-line agents and ﬂuoxetine has been
added as a third-line treatment option.
First-line options
Quetiapine. A pooled analysis of maintenance data
from the EMBOLDEN I and II trials has been
presented in abstract form (335). Among patients
with BD II (n = 231) who achieved remission
during acute-phase treatment with quetiapine,
those who continued quetiapine monotherapy for
up to 52 weeks were signiﬁcantly less likely to
experience relapse into any mood episode [hazard
ratio (HR) 0.47 for 300 mg and 0.18 for 600 mg] or
depressive mood episode (HR 0.35 and 0.21) com-
pared to those who switched to placebo (level 1).
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Rates of mania ⁄hypomania were low, and similar
for quetiapine and placebo.
Second-line options
Adjunctive lamotrigine. In a 52-week, open-label
study in 109 patients with treatment-refractory BD
II, adjunctive lamotrigine was associated with a
signiﬁcant improvement in depressive symptoms
and sustained response (level 3) (347). Depressive
symptoms continued to improve over a 52-week
period, suggesting that the two negative acute-
phase RCTs discussed above may have been too
short to detect a diﬀerence between lamotrigine
and placebo. Similarly, a retrospective chart review
reported that the majority of 31 patients with
treatment-resistant BD II depression who received
adjunctive lamotrigine for ‡ 6 months were much
or very much improved (348). The mean dose of
lamotrigine was 199 mg ⁄day and the maximum
400 mg ⁄day, suggesting that a substantial number
of patients required ‡ 200 mg for maximal beneﬁt.
Adjunctive quetiapine. Naturalistic studies in com-
bined populations of patients with BD I and BD II
demonstrated high rates of sustained euthymia
with adjunctive quetiapine, in spite of the fact that
the quetiapine doses used in clinical practice were
substantially lower than those used in clinical trials
(level 3) (349, 350). Unfortunately, neither of these
studies reported separate results for patients with
BD II.
Third–line options
Carbamazepine ⁄oxcarbazepine. In an RCT in BD I
(n = 27) or BD II (n = 25) patients who dis-
played residual manic or depressive symptoms on
maintenance lithium treatment, the addition of
eight weeks of carbamazepine or oxcarbazepine
resulted in signiﬁcant symptom reduction, with
oxcarbazepine being more eﬀective than carba-
mazepine (67). Results were not presented
separately for patients with BD II.
Fluoxetine monotherapy. There are now two small
RCT extension studies with ﬂuoxetine in patients
with BD II depression. The ﬁrst was a six-month
RCT in patients with BD II and BD NOS who had
responded to ﬂuoxetine, in which relapse rates were
43% with continued ﬂuoxetine versus 100% with
placebo (p = 0.08) (351). The second was a one-
year RCT (n = 81) in patients with BD II depres-
sion who had responded to ﬂuoxetine. It reported
that patients were signiﬁcantlymore likely to remain
well if they continued on ﬂuoxetine than if they
switched to lithium (352). However, neither ﬂuoxe-
tine nor lithiumwas signiﬁcantly better than placebo
in mean time to relapse (ﬂuoxetine 249.9 days,
lithium 156.4 days, placebo 186.9 days). The lack
of superiority of ﬂuoxetine over placebo in these
studies may be related to a lack of statistical power
due to a smaller sample size.
Data from STEP-BD and other naturalistic
studies provided additional information on the
eﬃcacy and safety of antidepressants in real-world
settings. In a STEP-BD randomized, open-label
trial, patients with depressive symptoms (n = 70;
n = 21 with BD II) who responded acutely to
adjunctive antidepressants had a signiﬁcantly long-
er time until relapse into depression if they
continued the antidepressant for 1–3 years versus
discontinuing after resolution of the depression
(182). Patients with BD II in this trial showed
similar beneﬁts to those with BD I, with no
increase in hypo ⁄manic switch. Similarly, in the
entire STEP-BD sample (n = 3640; 30.7% with
BD II), there was no increased frequency of switch
from depression to hypo ⁄mania without an inter-
vening period of wellness in antidepressant-treated
patients (19.6%) compared to patients receiving
non-antidepressant treatments (24.9%) (353). Con-
sistent with previous studies (354), the risk of
antidepressant-associated switch was lower in BD
II than BD I. The results from another open-label
study in patients with BD II who discontinued
antidepressant treatment showed that relapse
occurred 2.5 times more quickly when discontinu-
ation was rapid versus gradual (355).
ECT. Information on the use of ECT in BD II
remains limited. In one small case series of 14
patients with rapid-cycling BD (nine with BD II)
who received maintenance ECT for a mean of
Table 7.4. Recommendations for maintenance treatment of bipolar II disorder
First line Lithium, lamotrigine, quetiapinea
Second line Divalproex; lithium or divalproex or atypical antipsychotic + antidepressant; adjunctive quetiapine a;
adjunctive lamotrigine a; combination of two of: lithium, divalproex, or atypical antipsychotic
Third line Carbamazepine, oxcarbazepine, atypical antipsychotic agent, ECT, fluoxetine a
Not recommended Gabapentin
ECT = electroconvulsive therapy.
aNew or change to recommendation.
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21 months, all patients experienced signiﬁcant
improvement and a resolution of rapid-cycling
status (356).
Clinical questions and controversies
Is cognitive dysfunction an issue in patients with
BD II?
Persisting cognitive dysfunction is common and
debilitating in patients with BD II. In a meta-
analysis, patients with BD II had lower perfor-
mance scores than healthy controls in all cognitive
domains (357). In addition, cognitive impairment
in BD II was as severe as in BD I, with the
exception of memory and semantic ﬂuency.
In a case series of 58 BD I, BD II, or BD NOS
patients who received donepezil for memory prob-
lems, 84% with BD II (36 ⁄43) showed improve-
ment, compared to 0% of patients with BD I (0 ⁄7)
and 50% of patients with BD NOS (4 ⁄8) (358).
More than half of the patients with BD I had
worsening of aﬀective symptoms compared to only
2% of those with BD II and 25% of those with BD
NOS.
Do the clinical features of depressive episodes inform
treatment decisions in BD II?
Data from STEP-BD show that mixed hypo-
manic symptoms are common during depressive
episodes, occurring in 70% of patients with BD II,
compared to 66% of patients with BD I (129).
Adjunctive antidepressants did not lead to greater
recovery rates among patients with mixed symp-
toms in STEP-BD, and were in fact associated with
greater manic symptom severity at the three-month
follow-up (359). Although recovery rates were not
reported separately for patients with BD II in this
sample, this suggests that antidepressants should
be avoided in BD II depressive episodes with
concomitant hypomanic symptoms.
Psychotic symptoms are also relatively com-
mon in BD II depression, and were present in
20% of patients with BD II in a Spanish study
(n = 164) (360). There is little information to
guide the treatment of psychotic depression in
patients with BD II, but clinical experience and
studies in MDD suggest that antipsychotic med-
ications either as monotherapy (e.g., quetiapine)
or in combination with mood stabilizers may be
required.
Bipolar spectrum disorders
Diagnosis: Formulating treatment recommenda-
tions for patients with bipolar spectrum disorders
(BSDs; also referred to as BD NOS in the
DSM-IV) remains hampered by both a lack of
consensus regarding which disorders should be
included in this category, and also an almost
complete absence of well-designed clinical trials in
this patient group. The issue is further com-
pounded by uncertainty regarding the diagnostic
stability of BSDs. In fact, BSDs may be prodromal
to BD I and BD II in a substantial number of
patients, according to one longitudinal study of 57
people with cyclothymia or BD NOS, where 42%
progressed to BD II and 10% to BD I over a
4.5-year follow-up period (361).
Epidemiology: The results from two large studies
which measured the prevalence of BSDs indicate
that they are relatively common in the general
population. The World Mental Health Survey
Initiative, including 61392 people in nine countries
in North and South America, Europe, and Asia,
reported that 1.4% of the population met lifetime
criteria for subthreshold BD (4). This was similar
to the lifetime prevalence of 2.4% reported in
the National Comorbidity Survey Replication
(NCS-R) in the USA (n = 9282) (362). In both
studies, the prevalence of BSDs was greater than
those of BD I and BD II combined. The NCS-R
further suggested that BSDs are also common in
clinical populations, as over 35% of people with
major depressive episodes also met the lifetime
criteria for subthreshold hypomania (363).
Although a liberal deﬁnition of subthreshold
hypomania was utilized (lifetime presence of ‡ 1
hypomanic symptom), the NCS-R reported that,
compared to people with major depressive episodes
alone, those who had subthreshold hypomania
shared a number of clinical features with those
suﬀering from BD I or BD II, including an earlier
age of onset, more frequent depressive episodes, a
greater number of suicide attempts, and higher
rates of comorbidity.
Management: Very few studies have investigated
treatment options for BSDs. The only RCT that
has been reported to date was conducted in 56
youth with BSD or cyclothymia who were ran-
domized to divalproex or placebo for up to
ﬁve years. At study end there were no diﬀerences
between treatment groups in time to study discon-
tinuation due to a mood episode or for any reason,
severity of mood symptoms, or psychosocial func-
tioning (364).
A small case series reported rapid and sustained
symptom remission in four patients with BD NOS
and depressive or mixed symptoms with low-
dose quetiapine (50–75 mg) (365). In addition, a
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retrospective chart review of 34 patients with
treatment-refractory BD NOS found that adjunc-
tive treatment with supraphysiologic doses of T3
was associated with an improvement in depressive
symptoms in 85% of patients, and remission in
38% (345). In a case series of 58 patients with BD
prescribed donepezil for memory problems, 50%
of those with BD NOS (4 ⁄8) had improvements in
memory; however, 25% had a worsening of aﬀec-
tive symptoms (358).
In the absence of well-designed clinical trials,
speciﬁc treatment suggestions for patients with BD
NOS cannot be made. Clinicians should formulate
treatment plans based on patients presenting
symptoms, course of illness, previous treatment
responses, and family history. Given the probabil-
ity that subthreshold bipolarity is present in a
substantial proportion of patients with MDD,
clarifying the nature and best treatment options
for BD NOS is a major unmet need in mood
disorders research.
Section 8. Safety and monitoring
Monitoring
Previous iterations of the guidelines provided rec-
ommendations for initial and follow-up laboratory
investigations andmonitoring strategies for patients
with BD (1–3). BD and some of its treatments can
increase the risk of comorbid medical conditions, as
well as risk factors for cardiovascular disease such
as overweight ⁄obesity, diabetes, metabolic syn-
drome, and dyslipidemia. Complete medical and
laboratory investigations should be performed at
baseline, with ongoing monitoring for weight
changes and adverse eﬀects of medication.
The ISBD has also published consensus recom-
mendations for general safety monitoring for all
BD patients receiving treatment, as well as speciﬁc
monitoring recommendations for individual
agents, and the reader is also referred to this
document for more details (366).
Unfortunately, the UNITE global survey of
1300 patients with BD found that monitoring
of safety parameters does not occur in the majority
of patients, with less than 30% undergoing weight
and blood pressure measurements, and less than
5% undergoing a physical examination or blood
tests during interactions with their principal health
care provider (11).
Safety and tolerability of pharmacotherapy for BD
The previous iterations of the guidelines have
extensively reviewed the safety and tolerability of
pharmacotherapeutic options; only new data are
included here (1–3).
An analysis of 48 RCTs in patients with BD or
schizophrenia found that, compared to risperidone,
quetiapine was associated with signiﬁcantly less
anxiety, restlessness, and extrapyramidal symptoms
(EPS); and also compared to risperidone, olanza-
pine was associated with increased weight gain and
ziprasidone with decreased weight gain (367).
Weight gain: The naturalistic STOP-EM trial
concluded that, in 47 patients with BD receiving
maintenance therapy following their ﬁrst manic
episode, the mean 12-month weight gain was
signiﬁcantly greater compared to healthy control
subjects (4.76 kg versus 1.50 kg; p = 0.047). In
addition, 12-month rates of overweight ⁄obesity
were > 50% in patients with BD, almost double
those in healthy subjects (368).
A review of RCTs conﬁrmed that long-term
olanzapine treatment (‡ 48 weeks) was associated
with a substantial weight gain (mean 5.6 kg), with
64% of patients gaining ‡ 7% of their baseline
weight (369). During short-term treatment,
olanzapine orally disintegrating tablet was not
associated with any reduction in weight gain com-
pared to the standard tablet formulation (370). By
contrast, a post-hoc analysis of a six-month RCT
found that adjunctive ziprasidone had no negative
impact on metabolic parameters or body weight
compared to adjunctive placebo (371). Post-hoc
analyses of two studies found a modest increase in
weight with adjunctive aripiprazole that was not
signiﬁcantly diﬀerent from that using lithium ⁄di-
valproex alone (372). When used as an adjunct to
lamotrigine, aripiprazole plus lamotrigine was asso-
ciated with an increased weight gain compared to
lamotrigine alone, which was associated with
decreased body weight over the one-year period.
The non-randomized Second-generation Anti-
psychotic Treatment Indications, Eﬀectiveness and
Tolerability in Youth cohort study found that after
a median of 10.8 weeks of treatment, weight
increased by 8.5 kg with olanzapine (n = 45), 6.1
kg with quetiapine (n = 36), 5.3 kg with risperi-
done (n = 135), and 4.4 kg with aripiprazole
(n = 41) compared to 0.2 kg in the untreated
group (n = 15) (373).
An 11-month, RCT in 50 patients on pharma-
cotherapy for BD found that a multimodal
lifestyle intervention (11 group sessions and weekly
ﬁtness training) signiﬁcantly reduced BMI, at end
of treatment (ﬁve months) and at a six-month
follow-up, compared to a wait-list control group;
however, the eﬀect was only signiﬁcant in women
(374).
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Metabolic syndrome and type 2 diabetes: Addi-
tional data continue to demonstrate high rates of
diabetes and metabolic syndrome associated with
atypical antipsychotic agent use in patients with
BD (375). However, in a post-hoc analysis of a six-
month RCT, the incidence of metabolic syndrome
with aripiprazole maintenance therapy was similar
to that of placebo (376).
Additional data conﬁrm the potential for met-
abolic disturbances with divalproex treatment. In a
cohort study, divalproex was associated with
signiﬁcantly higher plasma insulin, triglyceride
levels, and BMI, as well as lower fasting glucose
and high-density lipoprotein cholesterol (HDL-C)
levels (377).
Dyslipidemia: Dyslipidemia is an important car-
diovascular risk factor. As discussed in previous
iterations of the guidelines, atypical antipsychotic
agents, as well as lithium ⁄divalproex, can cause
dyslipidemia (1–3). Additional data from a cohort
study found that divalproex was associated with
low HDL-C levels and high adiponectin levels in
patients with BD compared to non-psychiatric
matched control subjects (378). Lipid proﬁles
should be monitored and appropriate lipid-lower-
ing medications prescribed as needed, according to
published recommendations for the management
of dyslipidemia.
Endocrine side eﬀects: The results from a case-
controlled study indicated higher risks of hypothy-
roidism in patients with BD who had used
carbamazepine alone [odds ratio (OR) = 1.68],
combination lithium and valproate (OR = 2.40),
combination lithium and carbamazepine (OR =
1.52), or all three agents (OR = 2.34) compared to
patients who had never used any of these agents
(379). A meta-analysis of 390 RCTs and observa-
tional studies found that lithiumwas associatedwith
an increased risk of clinical hypothyroidism
(OR = 5.78), as well as increases in thyroid-stimu-
lating hormone and parathyroid hormone (380).
Suicide: A 2.5-year RCT of 98 patients with BD
and past suicide attempts found no signiﬁcant
diﬀerences between lithium and divalproex in time
to suicide attempt or suicide event, although the
trial was statistically underpowered to detect
diﬀerences (381).
Cognitive impairment: Three meta-analyses have
demonstrated persistent cognitive impairments in
euthymic patients with BD, including deﬁcits in
executive functions, verbal memory, learning,
processing speed, and attention (357, 382, 383).
In addition, patients tested during a manic ⁄mixed
or depressed state showed exaggerated impairment
on measures of verbal learning (383).
Several cohort studies have demonstrated great-
er cognitive dysfunction in euthymic patients with
BD taking antipsychotic medications compared to
healthy control subjects (384–386) or to those not
taking antipsychotic agents (385). Two cohort
studies have shown fewer cognitive impairments
associated with quetiapine than with olanzapine or
risperidone (385, 387).
An eight-week RCT in 35 euthymic patients with
BD found that adjunctive pramipexole signiﬁcantly
improved visual–verbal processing speed and
working memory compared to placebo (388).
A small (n = 16), three-month RCT in minimally
symptomatic patients with BD found that adjunc-
tive galantamine improved episodic memory per-
formance; however, placebo improved processing
speed (389).
Hypersensitivity and dermatological reactions:
Additional data demonstrate the risk of serious
rash, erythema multiforme, Stevens–Johnson
syndrome, or toxic epidermal necrolysis with
lamotrigine, carbamazepine, and divalproex (390,
391). A 12-week trial demonstrated a statistically
signiﬁcant reduction in the development of rashes
with a slow titration of lamotrigine compared to a
standard titration schedule (392).
The US FDA issued a warning that type I
hypersensitivity reactions (including anaphylaxis
and angioedema) can occur with asenapine use,
after as little as one dose (393).
Sedation: In a pooled analysis of data from three
short-term trials in patients with BD, asenapine
monotherapy and as an adjunct was associated
with higher rates of somnolence than placebo,
which occurred after 1–9 days of treatment and
persisted for 1–4 weeks (394).
Gastrointestinal symptoms: In a three-month RCT,
ER carbamazepine resulted in signiﬁcantly fewer
autonomic and gastrointestinal adverse events com-
pared to the immediate-release formulation (64).
Neurological side eﬀects including EPS: An in-
creased risk of neuroleptic malignant syndrome
associated with the use of antipsychotic medica-
tions (OR = 2.36) has been reported in patients
with BD (395).
A post-hoc analyses of pooled data in patients
with a mood disorder reported an increased rate of
akathisia in patients receiving aripiprazole (18%)
compared to placebo (5%) (396).
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Fracture risk: In a Veterans Administration pro-
spective cohort study, the use of anticonvulsants
was associated with a twofold greater risk of
fracture among patients (age ‡ 50 years) with BD
(271). In addition, a diagnosis of BD was associ-
ated with a 20% increased risk of fracture,
independent of anticonvulsant use. Antidepres-
sants and antipsychotic agents can similarly
decrease bone mineral density (397). Screening
for bone mineral density may be indicated in high-
risk populations (398).
Closing statement
The purpose of this update is to add previously
unpublished material to the CANMAT guidelines
for the treatment of BD, ensuring that they remain
current and practical. When a ﬁrst-line treatment is
unsuccessful, clinicians are advised to try alterna-
tive ﬁrst-line treatments before proceeding to
second-line options, and the same recommendation
applies when second-line treatments fail. Judicious
use of psychosocial interventions, alternative
somatic treatments such as ECT, and the numer-
ous experimental agents oﬀer additional promise
for the management of BD.
Affiliations
aDepartment of Psychiatry, University of British Columbia,
Vancouver, BC, bDepartment of Psychiatry, University of
Toronto, Toronto, ON, cDepartment of Psychiatry, McGill
University, Montreal, QC, dDepartment of Psychiatry,
Dalhousie University, Halifax, NS, eDepartment of Psychiatry,
University of Calgary, Calgary, AB, fDepartment of Psychia-
try, University of Western Ontario, London, ON, gDepartment
of Psychiatry, Queens University, Kingston, ON, hDepartment
of Psychiatry and Behavioural Neurosciences, McMaster
University, Hamilton, ON, iSunnybrook Health Sciences
Centre, Toronto, ON, Canada, jInstitute of Psychiatry, Uni-
versity of Sa˜o Paulo Medical School, Sa˜o Paulo, Brazil,
kDepartment of Psychiatry, Western Psychiatric Institute and
Clinic, University of Pittsburgh, Pittsburgh, PA, USA,
lDepartment of Psychiatry, Seoul National University, Seoul,
Korea, mDepartment of Psychiatry, University Medical
Center, Groningen, The Netherlands, nSchool of Medicine,
Deakin University, Geelong, oDepartment of Psychiatry,
University of Melbourne, Parkville, Victoria, Australia
Disclosure
LNY has received research grants from or is on speaker ⁄ advi-
sory boards for AstraZeneca, Bristol-Myers Squibb, Canadian
Institutes of Health Research, Canadian Network for Mood
and Anxiety Treatments, Eli Lilly & Co., GlaxoSmithKline,
Janssen, Michael Smith Foundation for Health Research,
Novartis, Pﬁzer, Ranbaxy, Servier, and the Stanley Founda-
tion. SHK has received research support from AstraZeneca,
Bristol Myers Squibb, Eli Lilly & Co., GlaxoSmithKline,
Lundbeck, and St. Jude Medical, Inc.; has received peer-review
research funding from CIHR, NARSAD, OMHF, POGRS,
and the Stanley Foundation; and is on speaker ⁄ advisory
boards for ANS, AstraZeneca, Biovail, Eli Lilly & Co.,
Lundbeck, Pﬁzer, Servier, and Wyeth. SVP has received
honoraria or research or educational conference grants in the
past two years from Apotex, AstraZeneca, Biovail, Bristol-
Myers Squibb, GlaxoSmithKline, Janssen, Eli Lilly & Co.,
Lundbeck, Novartis, Pﬁzer, and Wyeth. AS has received
grant ⁄ research support from or is on speaker ⁄ advisory boards
for AstraZeneca Canada, BrainCells, Inc., Bristol-Myers
Squibb, Canadian Institute of Health Research, Eli Lilly
Canada, Lundbeck Canada, Pﬁzer Canada, and PSI Founda-
tion. SB has received research grants from or is on speak-
ers ⁄ advisory boards for AstraZeneca, Biovail, Eli Lilly & Co.,
GlaxoSmithKline, Janssen-Ortho, Lundbeck, Organon, Oryx,
Wythe-Ayerst, Pﬁzer, CIHR, FRSQ, NARSAD, RSMQ, the
Stanley Foundation, and Servier; and has received research
support from and has contracts with AstraZeneca, Biovail, Eli
Lilly & Co., Janssen-Ortho, Lundbeck, Merck-Frosst, Novar-
tis, Pﬁzer, Servier, and Bristol-Myers Squibb. MA has received
peer-reviewed research funding from CIHR, NARSAD, the
Stanley Medical Research Institute, Genome Quebec, Nova
Scotia Health Research Foundation, Neuroscience Research
Fund (Eli Lilly Canada); and research contract support from
Cephalon. COD has received clinical trial support from or
served as consultant, advisor, or speaker for AstraZeneca,
Bristol-Myers Squibb, Lundbeck, Pﬁzer and Servier. GM has
received grant support from or acted as a consultant or
speaker for AstraZeneca, Bristol-Myers Squibb, Canadian
Psychiatric Association, Canadian Institutes of Health
Research, Eli Lilly & Co., Lundbeck, Ontario Mental Health
Foundation, NCE AllerGen, Inc., Pﬁzer, and the Scottish Rite
Foundation. RSM has received research or grant support from
the Stanley Medical Research Institute, NARSAD, NIMH, Eli
Lilly & Co., Janssen-Ortho, Shire, AstraZeneca, Pﬁzer, Lund-
beck, Forest, and Sepracor; is on the advisory boards for
AstraZeneca, Bristol-Myers Squibb, Janssen-Ortho, Eli Lilly &
Co., Lundbeck, Pﬁzer, Shire, and Merck; has served on
speakers bureaus for Janssen-Ortho, AstraZeneca, Eli Lilly &
Co., Lundbeck, Merck, Pﬁzer, and Otsuka; and has partici-
pated in CME activities sponsored by AstraZeneca, Bristol-
Myers Squibb, Physicians Postgraduate Press, CME Outﬁt-
ters, Merck, Eli Lilly & Co., Pﬁzer, Lundbeck, and Otsuka. VS
has received grant support from and served as consultant,
advisor, or speaker for AstraZeneca, Bristol-Myers Squibb, Eli
Lilly & Co., Janssen-Ortho, Lundbeck, Novartis, Pﬁzer,
Servier, and the Ontario Mental Health Foundation. AR has
received grant support from, served on advisory boards for,
and has participated in sponsored lectures in the past three
years for AstraZeneca, Eli Lilly & Co., Pﬁzer Canada, Bristol-
Myers Squibb, Janssen Ortho, and Cephalon. LTY is on the
speakers bureau for Eli Lilly & Co. and AstraZeneca; and
serves on advisory boards for Eli Lilly & Co., AstraZeneca,
Pﬁzer, and Bristol-Myers Squib. RM has received grant
support from, and has served as consultant, advisor, or
speaker for AstraZeneca, BCI, Bristol-Myers Squib, Cephalon,
CIHR, Eli Lilly & Co., Janssen-Ortho, Lundbeck, Pﬁzer,
Servier, Shering-Plough, Takeda, and Wyeth. DJB has
received research grants from or is on speaker ⁄ advisory
boards for AstraZeneca, Bristol-Myers Squibb, Otsuka, Jans-
sen, Pﬁzer, Canadian Institutes of Health Research, Canadian
Network for Mood and Anxiety Treatments, and the Coast
Capital Depression Research Fund ⁄UBC Institute of Mental
Health. BNF has received grant ⁄ research support from CIHR,
Father Sean OSullivan Research Centre, Stanley Medical
Research Foundation, Eli Lilly & Co., Wyeth, and Bristol-
Myers Squibb; has received speaker fees from AstraZeneca
and Bristol-Myers Squibb; and has received travel support
CANMAT guidelines for bipolar disorder
31
from Pﬁzer. BG has received investigator-initiated research
support from Pﬁzer and has served as a speaker for Purdue
Pharma. BL has received grant ⁄ research support from
CAPES, FAPESP, and CNPq (Brazilian State and Federal
Agencies). BB has received research support from the National
Institutes of Mental Health; and receives royalties form
Random House, Inc. and Lippincott Williams & Wilkins.
KH has received grant ⁄ research support from and served as
consultant, advisor, or speaker for Korea Healthcare Tech-
nology Research and Development Project, Ministry of Health
and Welfare of Korea, Janssen, Eli Lilly & Co., Otsuka, Pﬁzer,
AstraZeneca, Lundbeck, and Servier. WAN has received grant
support from the Netherlands Organisation for Health
Research and Development, European Union, Stanley Med-
ical Research Institute, AstraZeneca, Eli Lilly & Co., Glaxo-
SmithKline, and Wyeth; has received honoraria ⁄ speakers fees
from AstraZeneca, Lundbeck, Pﬁzer, and Wyeth; and is on
advisory boards for AstraZeneca. MB has received grant ⁄ re-
search support from the Stanley Medical Research Founda-
tion, MBF, NHMRC, Beyond Blue, Geelong Medical
Research Foundation, Bristol-Myers Squibb, Eli Lilly & Co.,
GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and
Servier; has served as a speaker for AstraZeneca, Bristol-
Myers Squibb, Eli Lilly & Co., GlaxoSmithKline, Janssen
Cilag, Lundbeck, Pﬁzer, Sanoﬁ Synthelabo, Servier, Solvay,
and Wyeth; and has served as a consultant to AstraZeneca,
Bristol-Myers Squibb, Eli Lilly & Co., GlaxoSmithKline,
Janssen Cilag, Lundbeck, and Servier.
References
1. Yatham LN, Kennedy SH, ODonovan C et al. Canadian
Network for Mood and Anxiety Treatments (CANMAT)
guidelines for the management of patients with bipolar
disorder: consensus and controversies. Bipolar Disord
2005; 7 (Suppl. 3): 5–69.
2. Yatham LN, Kennedy SH, ODonovan C et al. Cana-
dian Network for Mood and Anxiety Treatments
(CANMAT) guidelines for the management of patients
with bipolar disorder: update 2007. Bipolar Disord 2006;
8: 721–739.
3. Yatham LN, Kennedy SH, Schaﬀer A et al. Canadian
Network for Mood and Anxiety Treatments (CANMAT)
and International Society for Bipolar Disorders (ISBD)
collaborative update of CANMAT guidelines for the
management of patients with bipolar disorder: update
2009. Bipolar Disord 2009; 11: 225–255.
4. Merikangas KR, Jin R, He JP et al. Prevalence and
correlates of bipolar spectrum disorder in the world
mental health survey initiative. Arch Gen Psychiatry
2011; 68: 241–251.
5. Schaﬀer A, Cairney J, Cheung A, Veldhuizen S, Kurdyak
P, Levitt A. Diﬀerences in prevalence and treatment of
bipolar disorder among immigrants: results from an
epidemiologic survey. Can J Psychiatry 2009; 54: 734–742.
6. Novick DM, Swartz HA, Frank E. Suicide attempts in
bipolar I and bipolar II disorder: a review and meta-
analysis of the evidence. Bipolar Disord 2010; 12: 1–9.
7. Dennehy EB, Marangell LB, Allen MH, Chessick C,
Wisniewski SR, Thase ME. Suicide and suicide attempts
in the Systematic Treatment Enhancement Program for
Bipolar Disorder (STEP-BD). J Aﬀect Disord 2011; 133:
423–427.
8. Nordentoft M, Mortensen PB, Pedersen CB. Absolute
risk of suicide after ﬁrst hospital contact in mental
disorder. Arch Gen Psychiatry 2011; 68: 1058–1064.
9. Stensland MD, Zhu B, Ascher-Svanum H, Ball DE. Costs
associated with attempted suicide among individuals with
bipolar disorder. J Ment Health Policy Econ 2010; 13:
87–92.
10. Reed C, Goetz I, Vieta E, Bassi M, Haro JM. Work
impairment in bipolar disorder patients–results from a
two-year observational study (EMBLEM). Eur Psychia-
try 2010; 25: 338–344.
11. McIntyre RS. Understanding needs, interactions, treat-
ment, and expectations among individuals aﬀected by
bipolar disorder or schizophrenia: the UNITE global
survey. J Clin Psychiatry 2009; 70 (Suppl. 3): 5–11.
12. Nilsson KK, Jørgensen CR, Craig TKJ, Straarup KN,
Licht RW. Self-esteem in remitted bipolar disorder
patients: a meta-analysis. Bipolar Disord 2010; 12:
585–592.
13. Van Dorn RA, Andel R, Boaz TL et al. Risk of arrest in
persons with schizophrenia and bipolar disorder in a
Florida Medicaid program: the role of atypical antipsy-
chotics, conventional neuroleptics, and routine outpatient
behavioral health services. J Clin Psychiatry 2011; 72:
502–508.
14. Azorin JM, Aubrun E, Bertsch J, Reed C, Gerard S,
Lukasiewicz M. Mixed states vs. pure mania in the French
sample of the EMBLEM study: results at baseline and
24 months—European mania in bipolar longitudinal
evaluation of medication. BMC Psychiatry 2009; 9: 33.
15. Yatham LN, Kauer-SantAnna M, Bond DJ, Lam RW,
Torres I. Course and outcome after the ﬁrst manic episode
in patients with bipolar disorder: prospective 12-month
data from the Systematic Treatment Optimization
Program For Early Mania project. Can J Psychiatry
2009; 54: 105–112.
16. Solomon DA, Leon AC, Coryell WH et al. Longitudinal
course of bipolar I disorder: duration of mood episodes.
Arch Gen Psychiatry 2010; 67: 339–347.
17. Ghaemi SN, Bauer M, Cassidy F et al. Diagnostic
guidelines for bipolar disorder: a summary of the
International Society for Bipolar Disorders Diagnostic
Guidelines Task Force Report. Bipolar Disord 2008; 10:
117–128.
18. American Psychiatric Association. DSM-5 Development:
Bipolar and Related Disorders. Arlington, VA: American
Psychiatric Association, 2011.
19. Lobban F, Taylor L, Chandler C et al. Enhanced relapse
prevention for bipolar disorder by community mental
health teams: cluster feasibility randomised trial. Br J
Psychiatry 2010; 196: 59–63.
20. Bauer MS, Biswas K, Kilbourne AM. Enhancing mul-
tiyear guideline concordance for bipolar disorder
through collaborative care. Am J Psychiatry 2009; 166:
1244–1250.
21. Lobban F, Solis-Trapala I, Symes W, Morriss R. Early
warning signs checklists for relapse in bipolar depression
and mania: utility, reliability and validity. J Aﬀect Disord
2011; 133: 413–422.
22. Parikh SV, Zaretsky A, Beaulieu S et al. A randomized
controlled trial of psychoeducation or cognitive-behav-
ioral therapy in bipolar disorder: a Canadian Network for
Mood and Anxiety treatments (CANMAT) study. J Clin
Psychiatry 2012; 73: 803–810.
23. Perlick DA, Miklowitz DJ, Lopez N et al. Family-focused
treatment for caregivers of patients with bipolar disorder.
Bipolar Disord 2010; 12: 627–637.
24. Perini S, Titov N, Andrews G. Clinician-assisted internet-
based treatment is eﬀective for depression: randomized
controlled trial. Aust N Z J Psychiatry 2009; 43: 571–578.
Yatham et al.
32
25. Clarke G, Kelleher C, Hornbrook M, Debar L, Dickerson
J, Gullion C. Randomized eﬀectiveness trial of an
internet, pure self-help, cognitive behavioral intervention
for depressive symptoms in young adults. Cogn Behav
Ther 2009; 38: 222–234.
26. Barnes E, Simpson S, Griﬃths E, Hood K, Craddock N,
Smith DJ. Developing an online psychoeducation package
for bipolar disorder. J Ment Health 2011; 20: 21–31.
27. Smith DJ, Griﬃths E, Poole R et al. Beating bipolar:
exploratory trial of a novel internet-based psychoeduca-
tional treatment for bipolar disorder. Bipolar Disord
2011; 13: 571–577.
28. Foster S, Kessel J, Berman M, Simpson G. Eﬃcacy of
lorazepam and haloperidol for rapid tranquilization in a
psychiatric emergency room setting. Int Clin Psychophar-
macol 1997; 12: 175–179.
29. Currier GW, Chou JC, Feifel D et al. Acute treatment of
psychotic agitation: a randomized comparison of oral
treatment with risperidone and lorazepam versus intra-
muscular treatment with haloperidol and lorazepam.
J Clin Psychiatry 2004; 65: 386–394.
30. Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P,
Bogetto F. Oral risperidone, olanzapine and quetiapine
versus haloperidol in psychotic agitation. Prog Neuro-
psychopharmacol Biol Psychiatry 2008; 32: 405–413.
31. Feifel D, Galangue B, Macdonald K et al. A naturalistic,
single-blind comparison of rapid dose administration of
divalproex ER versus quetiapine in patients with acute
bipolar mania. Innov Clin Neurosci 2011; 8: 29–35.
32. Meehan K, Zhang F, David S et al. A double-blind,
randomized comparison of the eﬃcacy and safety of
intramuscular injections of olanzapine, lorazepam, or
placebo in treating acutely agitated patients diagnosed
with bipolar mania. J Clin Psychopharmacol 2001; 21:
389–397.
33. Centorrino F, Meyers AL, Ahl J et al. An observational
study of the eﬀectiveness and safety of intramuscular
olanzapine in the treatment of acute agitation in
patients with bipolar mania or schizophrenia ⁄ schizoaf-
fective disorder. Hum Psychopharmacol 2007; 22: 455–
462.
34. Chandrasena R, Dvorakova D, Lee SI et al. Intramuscu-
lar olanzapine vs. intramuscular short-acting antipsychot-
ics: safety, tolerability and the switch to oral antipsychotic
medication in patients with schizophrenia or acute mania.
Int J Clin Pract 2009; 63: 1249–1258.
35. Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP.
Rapid tranquilization for agitated patients in emergency
psychiatric rooms: a randomized trial of olanzapine,
ziprasidone, haloperidol plus promethazine, haloperidol
plus midazolam and haloperidol alone. Rev Bras Psiqu-
iatr 2011; 33: 30–39.
36. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan
EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the
short-term management of agitated psychotic patients.
J Clin Psychiatry 2001; 62: 12–18.
37. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan
EP. Intramuscular (IM) ziprasidone 20 mg is eﬀective in
reducing acute agitation associated with psychosis: a
double-blind, randomized trial. Psychopharmacology
2001; 155: 128–134.
38. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone
compared with intramuscular haloperidol in the treatment
of acute psychosis. Ziprasidone I.M. Study Group. J Clin
Psychiatry 2000; 61: 933–941.
39. Zimbroﬀ DL, Marcus RN, Manos G et al. Management
of acute agitation in patients with bipolar disorder:
eﬃcacy and safety of intramuscular aripiprazole. J Clin
Psychopharmacol 2007; 27: 171–176.
40. Bieniek S, Ownby R, Penalver A, Dominguez R. A
double-blind study of lorazepam versus the combination
of haloperidol and lorazepam in managing agitation.
Pharmacotherapy 1998; 18: 57–62.
41. Chouinard G, Annable L, Turnier L, Holobow N,
Szkrumelak N. A double-blind randomized clinical trial
of rapid tranquilization with I.M. clonazepam and I.M.
haloperidol in agitated psychotic patients with manic
symptoms. Can J Psychiatry 1993; 38 (Suppl. 4): S114–
S121.
42. Sekhar S, Kalra B, Mendhekar DN, Tekur U. Eﬃcacy of
sodium valproate and haloperidol in the management of
acute mania: a randomized open-label comparative study.
J Clin Pharmacol 2010; 50: 688–692.
43. Cipriani A, Barbui C, Salanti G et al. Comparative
eﬃcacy and acceptability of antimanic drugs in acute
mania: a multiple-treatments meta-analysis. Lancet 2011;
378: 1306–1315.
44. Correll CU, Sheridan EM, DelBello MP. Antipsychotic
and mood stabilizer eﬃcacy and tolerability in pediatric
and adult patients with bipolar I mania: a comparative
analysis of acute, randomized, placebo-controlled trials.
Bipolar Disord 2010; 12: 116–141.
45. Tamayo JM, Zarate CA Jr, Vieta E, Vazquez G, Tohen
M. Level of response and safety of pharmacological
monotherapy in the treatment of acute bipolar I disorder
phases: a systematic review and meta-analysis. Int J
Neuropsychopharmacol 2010; 13: 813–832.
46. Bowden C, Gogus A, Grunze H, Haggstrom L, Ryba-
kowski J, Vieta E. A 12-week, open, randomized trial
comparing sodium valproate to lithium in patients with
bipolar I disorder suﬀering from a manic episode. Int Clin
Psychopharmacol 2008; 23: 254–262.
47. Bowden CL, Mosolov S, Hranov L et al. Eﬃcacy of
valproate versus lithium in mania or mixed mania: a
randomized, open 12-week trial. Int Clin Psychopharma-
col 2010; 25: 60–67.
48. Tohen M, Vieta E, Goodwin GM et al. Olanzapine versus
divalproex versus placebo in the treatment of mild to
moderate mania: a randomized, 12-week, double-blind
study. J Clin Psychiatry 2008; 69: 1776–1789.
49. Bowden CL, Swann AC, Calabrese JR et al. A random-
ized, placebo-controlled, multicenter study of divalproex
sodium extended release in the treatment of acute mania.
J Clin Psychiatry 2006; 67: 1501–1510.
50. Hirschfeld RM, Bowden CL, Vigna NV, Wozniak P,
Collins M. A randomized, placebo-controlled, multicenter
study of divalproex sodium extended-release in the acute
treatment of mania. J Clin Psychiatry 2010; 71: 426–432.
51. Fountoulakis KN, Vieta E, Schmidt F. Aripiprazole
monotherapy in the treatment of bipolar disorder: a meta-
analysis. J Aﬀect Disord 2011; 133: 361–370.
52. Young AH, Oren DA, Lowy A et al. Aripiprazole
monotherapy in acute mania: 12-week randomised pla-
cebo- and haloperidol-controlled study. Br J Psychiatry
2009; 194: 40–48.
53. Vieta E, Ramey T, Keller D, English PA, Loebel AD,
Miceli J. Ziprasidone in the treatment of acute mania: a
12-week, placebo-controlled, haloperidol-referenced
study. J Psychopharmacol 2010; 24: 547–558.
54. Vieta E, Nuamah IF, Lim P et al. A randomized, placebo-
and active-controlled study of paliperidone extended
release for the treatment of acute manic and mixed
episodes of bipolar I disorder. Bipolar Disord 2010; 12:
230–243.
CANMAT guidelines for bipolar disorder
33
55. Berwaerts J, Xu H, Nuamah I, Lim P, Hough D.
Evaluation of the eﬃcacy and safety of paliperidone
extended-release in the treatment of acute mania: a
randomized, double-blind, dose-response study. J Aﬀect
Disord 2012; 136: e51–e60.
56. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA,
Panagides J. A 3-week, randomized, placebo-controlled
trial of asenapine in the treatment of acute mania in
bipolar mania and mixed states. Bipolar Disord 2009; 11:
673–686.
57. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA,
Panagides J. Asenapine in the treatment of acute mania in
bipolar I disorder: a randomized, double-blind, placebo-
controlled trial. J Aﬀect Disord 2010; 122: 27–38.
58. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA,
Panagides J. Asenapine versus olanzapine in acute mania:
a double-blind extension study. Bipolar Disord 2009; 11:
815–826.
59. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA,
Panagides J. Asenapine for long-term treatment of
bipolar disorder: a double-blind 40-week extension study.
J Aﬀect Disord 2010; 126: 358–365.
60. Vieta E, Tjoen C, McQuade RD et al. Eﬃcacy of
adjunctive aripiprazole to either valproate or lithium in
bipolar mania patients partially nonresponsive to valpro-
ate ⁄ lithium monotherapy: a placebo-controlled study.
Am J Psychiatry 2008; 165: 1316–1325.
61. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R,
Marcus RN. Assessment of safety, tolerability and
eﬀectiveness of adjunctive aripiprazole to lithium ⁄ valpro-
ate in bipolar mania: a 46-week, open-label extension
following a 6-week double-blind study. Curr Med Res
Opin 2010; 26: 1485–1496.
62. Calabrese J, Stet L, Kotari H et al. Asenapine as
adjunctive treatment for bipolar mania: a placebo-con-
trolled 12-week study and 40-week extension. Eur Psy-
chiatry 2010; 25 (Suppl. 1): 1447.
63. El-Mallakh RS, Salem MR, Chopra A, Mickus GJ,
Penagaluri P, Movva R. A blinded, randomized compar-
ison of immediate-release and extended-release carbamaz-
epine capsules in manic and depressed bipolar subjects.
Ann Clin Psychiatry 2010; 22: 3–8.
64. El-Mallakh RS, Salem MR, Chopra AS, Mickus GJ,
Penagaluri P. Adverse event load in bipolar participants
receiving either carbamazepine immediate-release or
extended-release capsules: a blinded, randomized study.
Int Clin Psychopharmacol 2009; 24: 145–149.
65. Mohan TSP, Tharyan P, Alexander J, Raveendran NS.
Eﬀects of stimulus intensity on the eﬃcacy and safety of
twice-weekly, bilateral electroconvulsive therapy (ECT)
combined with antipsychotics in acute mania: a rando-
mised controlled trial. Bipolar Disord 2009; 11: 126–
134.
66. Kakkar AK, Rehan HS, Unni KE, Gupta NK, Chopra
D, Kataria D. Comparative eﬃcacy and safety of
oxcarbazepine versus divalproex sodium in the treatment
of acute mania: a pilot study. Eur Psychiatry 2009; 24:
178–182.
67. Juruena MF, Ottoni GL, Machado-Vieira R et al. Bipolar
I and II disorder residual symptoms: oxcarbazepine and
carbamazepine as add-on treatment to lithium in a
double-blind, randomized trial. Prog Neuro-psychophar-
macol Biol Psychiatry 2009; 33: 94–99.
68. Knesevich M, Papadakis K, Bose A, Wang Q, Korotzer
A, Laszlovszky I. The Eﬃcacy and Tolerability of
Cariprazine in Acute Mania Associated With Bipolar I
Disorder: A Phase II Trial [Abstract NR1-049]. New
Research Abstracts, Annual Meeting of the American
Psychiatric Association. Washington, D.C.: American
Psychiatric Association, 2009: p20.
69. Chan HY, Jou SH, Juang YY et al. A single-blind,
comparative study of zotepine versus haloperidol in
combination with a mood stabilizer for patients with
moderate-to-severe mania. Psychiatry Clin Neurosci 2010;
64: 162–169.
70. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost
M. Allopurinol as an adjunct to lithium and haloperidol
for treatment of patients with acute mania: a double-
blind, randomized, placebo-controlled trial. Bipolar
Disord 2006; 8: 485–489.
71. Machado-Vieira R, Soares JC, Lara DR et al. A double-
blind, randomized, placebo-controlled 4-week study on
the eﬃcacy and safety of the purinergic agents allopurinol
and dipyridamole adjunctive to lithium in acute bipolar
mania. J Clin Psychiatry 2008; 69: 1237–1245.
72. Amrollahi Z, Rezaei F, Salehi B et al. Double-blind,
randomized, placebo-controlled 6-week study on the eﬃ-
cacy and safety of the tamoxifen adjunctive to lithium in
acute bipolar mania. J Aﬀect Disord 2011; 129: 327–331.
73. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M.
Folic acid eﬃcacy as an alternative drug added to sodium
valproate in the treatment of acute phase of mania in
bipolar disorder: a double-blind randomized controlled
trial. Acta Psychiatr Scand 2009; 120: 441–445.
74. Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr.
Memantine eﬃcacy and safety in patients with acute
mania associated with bipolar I disorder: a pilot evalu-
ation. Clin Neuropharmacol 2009; 32: 199–204.
75. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B,
Hough DW. Paliperidone extended-release as adjunctive
therapy to lithium or valproate in the treatment of acute
mania: a randomized, placebo-controlled study. J Aﬀect
Disord 2011; 129: 252–260.
76. Pﬁzer Inc. 3-Week Study to Evaluate Eﬃcacy and Safety of
ZiprasidoneWith Either Lithium or Divalproex in Acutely
Manic Subjects. ClinicalTrials.gov. Bethesda, MD:
National Institutes of Health, 2010.
77. Fountoulakis KN, Gonda X, Vieta E, Schmidt F.
Treatment of psychotic symptoms in bipolar disorder
with aripiprazole monotherapy: a meta-analysis. Ann Gen
Psychiatry 2009; 8: 27.
78. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu
LL, Ketter TA. Olanzapine-divalproex combination ver-
sus divalproex monotherapy in the treatment of bipolar
mixed episodes: a double-blind, placebo-controlled study.
J Clin Psychiatry 2009; 70: 1540–1547.
79. Houston JP, Ketter TA, Case M et al. Early symptom
change and prediction of subsequent remission with
olanzapine augmentation in divalproex-resistant bipolar
mixed episodes. J Psychiatr Res 2011; 45: 169–173.
80. Szegedi A, Zhao J, van Willigenburg A, Nations KR,
Mackle M, Panagides J. Eﬀects of asenapine on depres-
sive symptoms in patients with bipolar I disorder expe-
riencing acute manic or mixed episodes: a post hoc
analysis of two 3-week clinical trials. BMC Psychiatry
2011; 11: 101.
81. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM,
Valenti M, Vieta E. Eﬃcacy of modern antipsychotics in
placebo-controlled trials in bipolar depression: a meta-
analysis. Int J Neuropsychopharmacol 2010; 13: 5–14.
82. Vieta E, Locklear J, Gunther O et al. Treatment options
for bipolar depression: a systematic review of randomized,




83. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine
for treatment of bipolar depression: independent meta-
analysis and meta-regression of individual patient data
from ﬁve randomised trials. Br J Psychiatry 2009; 194:
4–9.
84. Kemp DE, Ganocy SJ, Brecher M et al. Clinical value of
early partial symptomatic improvement in the prediction
of response and remission during short-term treatment
trials in 3369 subjects with bipolar I or II depression.
J Aﬀect Disord 2011; 130: 171–179.
85. Kemp DE, Calabrese JR, Eudicone JM et al. Predictive
value of early improvement in bipolar depression trials: a
post-hoc pooled analysis of two 8-week aripiprazole
studies. Psychopharmacol Bull 2010; 43: 5–27.
86. Ketter T. Overview of LiTMUS eﬃcacy ﬁndings
[Symposium S8-5]. In: American Psychiatric Association
ed. Presented at 164th Ann Mtg American Psychiatric
Association. Honolulu, HI, 2011.
87. Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas
implementation of medication algorithms: update to the
algorithms for treatment of bipolar I disorder. J Clin
Psychiatry 2005; 66: 870–886.
88. Calabrese JR, Keck PE Jr, Macfadden W et al. A
randomized, double-blind, placebo-controlled trial of
quetiapine in the treatment of bipolar I or II depression.
Am J Psychiatry 2005; 162: 1351–1360.
89. Thase ME, Macfadden W, Weisler RH et al. Eﬃcacy of
quetiapine monotherapy in bipolar I and II depression: a
double-blind, placebo-controlled study (the BOLDER II
study). J Clin Psychopharmacol 2006; 26: 600–609.
90. Young AH, McElroy SL, Bauer M et al. A double-blind,
placebo-controlled study of quetiapine and lithium mono-
therapy in adults in the acute phase of bipolar depression
(EMBOLDEN I). J Clin Psychiatry 2010; 71: 150–162.
91. McElroy SL, Weisler RH, Chang W et al. A double-blind,
placebo-controlled study of quetiapine and paroxetine as
monotherapy in adults with bipolar depression (EMBOL-
DEN II). J Clin Psychiatry 2010; 71: 163–174.
92. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker
C, Darko D. Eﬀectiveness of the extended release
formulation of quetiapine as monotherapy for the treat-
ment of acute bipolar depression. J Aﬀect Disord 2010;
121: 106–115.
93. Brown EB, McElroy SL, Keck PE Jr et al. A 7-week,
randomized, double-blind trial of olanzapine ⁄ ﬂuoxetine
combination versus lamotrigine in the treatment of bipolar
I depression. J Clin Psychiatry 2006; 67: 1025–1033.
94. Brown E, Dunner DL, McElroy SL et al. Olanzapine ⁄ ﬂu-
oxetine combination vs. lamotrigine in the 6-month
treatment of bipolar I depression. Int J Neuropsycho-
pharmacol 2009; 12: 773–782.
95. Tohen M, Vieta E, Calabrese J et al. Eﬃcacy of olanza-
pine and olanzapine-ﬂuoxetine combination in the treat-
ment of bipolar I depression. Arch Gen Psychiatry 2003;
60: 1079–1088.
96. Bond DJ, Lam RW, Yatham LN. Divalproex sodium
versus placebo in the treatment of acute bipolar depression:
a systematic review and meta-analysis. J Aﬀect Disord
2010; 124: 228–234.
97. SmithLA,CorneliusVR,AzorinJMet al.Valproate for the
treatmentofacutebipolardepression:systematicreviewand
meta-analysis. J Aﬀect Disord 2010; 122: 1–9.
98. Loebel A, Cucchiaro J, Silva R et al. Lurasidone Mono-
therapy for the Treatment of Bipolar I Depression:
Results of a 6-Week, Double-Blind, Placebo-Controlled
Study. Philadelphia, PA: American Psychiatric Associa-
tion, 2012.
99. Loebel A, Cucchiaro J, Silva R et al. Lurasidone Adjunc-
tive to Lithium or Valproate for the Treatment of Bipolar
I Depression: Results of a 6-Week, Double-Blind, Pla-
cebo-Controlled. Philadelphia, PA: American Psychiatric
Association, 2012.
100. van der Loos ML, Mulder PG, Hartong EG et al.
Eﬃcacy and safety of lamotrigine as add-on treatment
to lithium in bipolar depression: a multicenter, double-
blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:
223–231.
101. van der Loos ML, Mulder P, Hartong EG et al. Eﬃcacy
and safety of two treatment algorithms in bipolar
depression consisting of a combination of lithium, lamo-
trigine or placebo and paroxetine. Acta Psychiatr Scand
2010; 122: 246–254.
102. Tohen M, McDonnell DP, Case M et al. Randomized,
double-blind, placebo-controlled study of olanzapine in
patients with bipolar I depression. BRJ Psychiatry 2012;
201: 376–382.
103. Bobo WV, Epstein RA, Shelton RC. Olanzapine mono-
therapy for acute depression in patients with bipolar I or
II disorder: results of an 8-week open label trial. Human
psychopharmacol 2010; 25: 30–36.
104. Ahn YM, Nam JY, Culver JL, Marsh WK, Bonner JC,
Ketter TA. Lamotrigine plus quetiapine combination
therapy in treatment-resistant bipolar depression. Ann
Clin Psychiatry 2011; 23: 17–24.
105. Medda P, Perugi G, Zanello S, Ciuﬀa M, Rizzato S,
Cassano GB. Comparative response to electroconvulsive
therapy in medication-resistant bipolar I patients with
depression and mixed state. J ECT 2010; 26: 82–86.
106. Virupaksha HS, Shashidhara B, Thirthalli J, Kumar CN,
Gangadhar BN. Comparison of electroconvulsive therapy
(ECT) with or without anti-epileptic drugs in bipolar
disorder. J Aﬀect Disord 2010; 127: 66–70.
107. Bailine S, Fink M, Knapp R et al. Electroconvulsive
therapy is equally eﬀective in unipolar and bipolar
depression. Acta Psychiatr Scand 2010; 121: 431–436.
108. Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J.
Ultra-brief pulse ECT in bipolar and unipolar depressive
disorder: diﬀerences in speed of response. Bipolar Disord
2009; 11: 418–424.
109. Brennan BP, Hudson JI, Jensen JE et al. Rapid enhance-
ment of glutamatergic neurotransmission in bipolar
depression following treatment with riluzole. Neuropsy-
chopharmacology 2010; 35: 834–846.
110. Berk M, Dean O, Cotton SM et al. The eﬃcacy of
N-acetylcysteine as an adjunctive treatment in bipolar
depression: an open label trial. J Aﬀect Disord 2011; 135:
389–394.
111. Diazgranados N, Ibrahim L, Brutsche NE et al. A
randomized add-on trial of an N-methyl-D-aspartate
antagonist in treatment-resistant bipolar depression. Arch
Gen Psychiatry 2010; 67: 793–802.
112. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang
R, Frye MA. Adjunctive armodaﬁnil for major depressive
episodes associated with bipolar I disorder: a randomized,
multicenter, double-blind, placebo-controlled, proof-of-
concept study. J Clin Psychiatry 2010; 71: 1363–1370.
113. Wu JC, Kelsoe JR, Schachat C et al. Rapid and sustained
antidepressant response with sleep deprivation and chro-
notherapy in bipolar disorder. Biol Psychiatry 2009; 66:
298–301.
114. Pﬁzer Inc. A Six-Week Study Evaluating the Eﬃcacy and
Safety of GEODON in Patients With a Diagnosis of
Bipolar I Depression. ClinicalTrials.gov. Bethesda, MD:
National Institutes of Health, 2009.
CANMAT guidelines for bipolar disorder
35
115. Pﬁzer Inc. A Six-Week Flexible Dose Study Evaluating
the Eﬃcacy and Safety of Geodon in Patients With
Bipolar I Depression. ClinicalTrials.gov. National Insti-
tutes of Health, 2009.
116. Sachs GS, Ice KS, Chappell PB et al. Eﬃcacy and safety
of adjunctive oral ziprasidone for acute treatment of
depression in patients with bipolar I disorder: a random-
ized, double-blind, placebo-controlled trial. J Clin
Psychiatry 2011; 72: 1413–1422.
117. Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P.
Beneﬁcial acute antidepressant eﬀects of aripiprazole as
an adjunctive treatment or monotherapy in bipolar
patients unresponsive to mood stabilizers: results from a
16-week open-label trial. Expert Opin Pharmacother
2008; 9: 3145–3149.
118. Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi
SN. A prospective, open-label study of aripiprazole
mono- and adjunctive treatment in acute bipolar depres-
sion. J Aﬀect Disord 2008; 110: 70–74.
119. Quante A, Zeugmann S, Luborzewski A et al. Aripipraz-
ole as adjunct to a mood stabilizer and citalopram in
bipolar depression: a randomized placebo-controlled pilot
study. Human psychopharmacol 2010; 25: 126–132.
120. Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P.
Eﬀect of aripiprazole on self-reported anhedonia in bipolar
depressed patients. Psychiatry Res 2009; 165: 193–196.
121. Saricicek A, Maloney K, Muralidharan A et al. Leveti-
racetam in the management of bipolar depression: a
randomized, double-blind, placebo-controlled trial. J Clin
Psychiatry 2011; 72: 744–750.
122. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W,
Hennen J. Patterns of psychotropic drug prescription for
U.S. patients with diagnoses of bipolar disorders. Psychi-
atr Serv 2007; 58: 85–91.
123. Schaﬀer A, Cairney J, Veldhuizen S, Cheung A, Levitt A.
Comparison of antidepressant use between subjects with
bipolar disorder and major depressive disorder with or
without comorbid anxiety. J Clin Psychiatry 2007; 68:
1785–1792.
124. Sachs GS, Nierenberg AA, Calabrese JR et al. Eﬀective-
ness of adjunctive antidepressant treatment for bipolar
depression. N Engl J Med 2007; 356: 1711–1722.
125. Shelton RC, Stahl SM. Risperidone and paroxetine given
singly and in combination for bipolar depression. J Clin
Psychiatry 2004; 65: 1715–1719.
126. Sidor MM, Macqueen GM. Antidepressants for the acute
treatment of bipolar depression: a systematic review and
meta-analysis. J Clin Psychiatry 2011; 72: 156–167.
127. Nemeroﬀ CB, Evans DL, Gyulai L et al. Double-blind,
placebo-controlled comparison of imipramine and par-
oxetine in the treatment of bipolar depression. Am J
Psychiatry 2001; 158: 906–912.
128. Cipriani A, Furukawa TA, Salanti G et al. Comparative
eﬃcacy and acceptability of 12 new-generation antide-
pressants: a multiple-treatments meta-analysis. Lancet
2009; 373: 746–758.
129. Goldberg JF, Perlis RH, Bowden CL et al. Manic
symptoms during depressive episodes in 1,380 patients
with bipolar disorder: ﬁndings from the STEP-BD. Am J
Psychiatry 2009; 166: 173–181.
130. Berk M, Ng F, Dodd S, Goldberg JF, Malhi GS. Do we
need to ﬂick the switch? The need for a broader
conceptualization of iatrogenic course aggravation in
clinical trials of bipolar disorder. Psychiatry Clin Neuro-
sci 2010; 64: 367–371.
131. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch
in mood polarity to hypomania or mania in patients with
bipolar depression during acute and continuation trials of
venlafaxine, sertraline, and bupropion as adjuncts to
mood stabilizers. Am J Psychiatry 2006; 163: 232–239.
132. Vieta E, Martinez-Aran A, Goikolea JM et al. A
randomized trial comparing paroxetine and venlafaxine
in the treatment of bipolar depressed patients taking
mood stabilizers. J Clin Psychiatry 2002; 63: 508–512.
133. Devulapalli KK, Ignacio RV, Weiden P et al. Why do
persons with bipolar disorder stop their medication?
Psychopharmacol Bull 2010; 43: 5–14.
134. Sajatovic M, Ignacio RV, West JA et al. Predictors of
nonadherence among individuals with bipolar disorder
receiving treatment in a community mental health clinic.
Compr Psychiatry 2009; 50: 100–107.
135. Gonzalez-Pinto A, Reed C, Novick D, Bertsch J, Haro
JM. Assessment of medication adherence in a cohort of
patients with bipolar disorder. Pharmacopsychiatry 2010;
43: 263–270.
136. Hou R, Cleak V, Peveler R. Do treatment and illness
beliefs inﬂuence adherence to medication in patients with
bipolar aﬀective disorder? A preliminary cross-sectional
study. Eur Psychiatry 2010; 25: 216–219.
137. Lang K, Korn J, Muser E, Choi JC, Abouzaid S, Menzin
J. Predictors of medication nonadherence and hospital-
ization in Medicaid patients with bipolar I disorder given
long-acting or oral antipsychotics. J Med Econ 2011; 14:
217–226.
138. Bates JA, Whitehead R, Bolge SC, Kim E. Correlates of
medication adherence among patients with bipolar disor-
der: results of the bipolar evaluation of satisfaction and
tolerability (BEST) study: a nationwide cross-sectional
survey. PCC J Clin Psychiatry 2010; 12: e1–e8.
139. Gianfrancesco FD, Sajatovic M, Tafesse E, Wang RH.
Association between antipsychotic combination therapy
and treatment adherence among individuals with bipolar
disorder. Ann Clin Psychiatry 2009; 21: 3–16.
140. Citrome L, Reist C, Palmer L et al. Impact of real-world
ziprasidone dosing on treatment discontinuation rates in
patients with schizophrenia or bipolar disorder. Schizophr
Res 2009; 115: 115–120.
141. Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM,
Gurpegui M. Poor adherence to treatment associated
with a high recurrence in a bipolar disorder outpatient
sample. J Aﬀect Disord 2010; 127: 77–83.
142. Bagalman E, Yu-Isenberg KS, Durden E, Crivera C,
Dirani R, Bunn WB 3rd. Indirect costs associated with
nonadherence to treatment for bipolar disorder. J Occup
Environ Med 2010; 52: 478–485.
143. Lage MJ, Hassan MK. The relationship between anti-
psychotic medication adherence and patient outcomes
among individuals diagnosed with bipolar disorder: a ret-
rospective study. Ann Gen Psychiatry 2009; 8: 7.
144. Hassan M, Lage MJ. Risk of rehospitalization among
bipolar disorder patients who are nonadherent to anti-
psychotic therapy after hospital discharge. AJHP 2009;
66: 358–365.
145. Hong J, Reed C, Novick D, Haro JM, Windmeijer F,
Knapp M. The cost of relapse for patients with a
manic ⁄mixed episode of bipolar disorder in the EM-
BLEM study. Pharmacoeconomics 2010; 28: 555–566.
146. Dikeos D, Badr MG, Yang F et al. Twelve-month
prospective, multinational, observational study of factors
associated with recovery from mania in bipolar disorder
in patients treated with atypical antipsychotics. World J
Biol Psychiatry 2010; 11: 667–676.
147. Haro JM, Reed C, Gonzalez-Pinto A, Novick D, Bertsch
J, Vieta E. 2-year course of bipolar disorder type I
Yatham et al.
36
patients in outpatient care: factors associated with remis-
sion and functional recovery. Eur Neuropsychopharma-
col 2011; 21: 287–293.
148. Gao K, Kemp DE, Wang Z et al. Predictors of non-
stabilization during the combination therapy of lithium
and divalproex in rapid cycling bipolar disorder: a post-
hoc analysis of two studies. Psychopharmacol Bull 2010;
43: 23–38.
149. Pfennig A, Schlattmann P, Alda M et al. Inﬂuence of
atypical features on the quality of prophylactic eﬀective-
ness of long-term lithium treatment in bipolar disorders.
Bipolar Disord 2010; 12: 390–396.
150. Gregory VL Jr. Cognitive-behavioral therapy for depres-
sion in bipolar disorder: a meta-analysis. J Evid Based Soc
Work 2010; 7: 269–279.
151. Szentagotai A, David D. The eﬃcacy of cognitive-
behavioral therapy in bipolar disorder: a quantitative
meta-analysis. J Clin Psychiatry 2010; 71: 66–72.
152. Lynch D, Laws KR, McKenna PJ. Cognitive behavioural
therapy for major psychiatric disorder: does it really
work? A meta-analytical review of well-controlled trials.
Psychol Med 2010; 40: 9–24.
153. Lam DH, Watkins ER, Hayward P et al. A randomized
controlled study of cognitive therapy for relapse preven-
tion for bipolar aﬀective disorder: outcome of the ﬁrst
year. Arch Gen Psychiatry 2003; 60: 145–152.
154. Scott J, Paykel E, Morriss R et al. Cognitive-behavioural
therapy for severe and recurrent bipolar disorders:
randomised controlled trial. Br J Psychiatry 2006; 188:
313–320.
155. Parikh S, Scott J. Cognitive behaviour therapy for bipolar
disorder. In: Yatham L, Maj M eds. Textbook of Bipolar
Disorders. Chichester: Wiley-Blackwell, 2010: 422–429.
156. Gomes BC, Abreu LN, Brietzke E et al. A randomized
controlled trial of cognitive behavioral group therapy for
bipolar disorder. Psychother Psychosom2011; 80: 144–150.
157. Costa RT, Cheniaux E, Rosaes PA et al. The eﬀectiveness
of cognitive behavioral group therapy in treating bipolar
disorder: a randomized controlled study. Rev Bras
Psiquiatr 2011; 33: 144–149.
158. Colom F, Vieta E, Sanchez-Moreno J et al. Group
psychoeducation for stabilised bipolar disorders: 5-year
outcome of a randomised clinical trial. Br J Psychiatry
2009; 194: 260–265.
159. Castle D, White C, Chamberlain J et al. Group-based
psychosocial intervention for bipolar disorder: rando-
mised controlled trial. Br J Psychiatry 2010; 196: 383–388.
160. DSouza R, Piskulic D, Sundram S. A brief dyadic group
based psychoeducation program improves relapse rates in
recently remitted bipolar disorder: a pilot randomised
controlled trial. J Aﬀect Disord 2010; 120: 272–276.
161. Beynon S, Soares-Weiser K, Woolacott N, Duﬀy S,
Geddes JR. Pharmacological interventions for the pre-
vention of relapse in bipolar disorder: a systematic review
of controlled trials. J Psychopharmacol 2009; 23: 574–591.
162. Vieta E, Gunther O, Locklear J et al. Eﬀectiveness of
psychotropic medications in the maintenance phase of
bipolar disorder: a meta-analysis of randomized con-
trolled trials. Int J Neuropsychopharmacol 2011; 14:
1029–1049.
163. Geddes JR, Goodwin GM, Rendell J et al. Lithium plus
valproate combination therapy versus monotherapy for
relapse prevention in bipolar I disorder (BALANCE): a
randomised open-label trial. Lancet 2010; 375: 385–395.
164. van der Loos MLM, Mulder P, Hartong EG et al. Long-
term outcome of bipolar depressed patients receiving
lamotrigine as add-on to lithium with the possibility of the
addition of paroxetine in nonresponders: a randomized,
placebo-controlled trial with a novel design. Bipolar
Disord 2011; 13: 111–117.
165. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz
H. Lamotrigine versus lithium as maintenance treatment
in bipolar I disorder: an open, randomized eﬀectiveness
study mimicking clinical practice. The 6th trial of the
Danish University Antidepressant Group (DUAG-6).
Bipolar Disord 2010; 12: 483–493.
166. Cipriani A, Rendell J, Geddes JR. Olanzapine in the
long-term treatment of bipolar disorder: a systematic
review and meta-analysis. J Psychopharmacol 2010; 24:
1729–1738.
167. Vieta E, Montgomery S, Sulaiman AH et al. A random-
ized, double-blind, placebo-controlled trial to assess
prevention of mood episodes with risperidone long-acting
injectable in patients with bipolar I disorder. Eur
Neuropsychopharmacol 2012; 22: 825–835.
168. Berwaerts J, Melkote R, Nuamah I, Lim P. A random-
ized, placebo- and active-controlled study of paliperidone
extended-release as maintenance treatment in patients
with bipolar I disorder after an acute manic or mixed
episode. J Aﬀect Disord 2012; 138: 247–258.
169. Gonzalez-Pinto A, Vieta E, Reed C et al. Eﬀectiveness
of olanzapine monotherapy and olanzapine combination
treatment in the long term following acute mania -
results of a two year observational study in bipolar
disorder (EMBLEM). J Aﬀect Disord 2011; 131: 320–
329.
170. Suppes T, Vieta E, Liu S, BrecherM, Paulsson B, Trial 127
Investigators. Maintenance treatment for patients with
bipolar I disorder: results from a North American study of
quetiapine in combination with lithium or divalproex (trial
127). Am J Psychiatry 2009; 166: 476–488.
171. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B,
Brecher M. Eﬃcacy and safety of quetiapine in combina-
tion with lithium or divalproex for maintenance of
patients with bipolar I disorder (international trial 126).
J Aﬀect Disord 2008; 109: 251–263.
172. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson
B. Continuation of quetiapine versus switching to placebo
or lithium for maintenance treatment of bipolar I disorder
(trial 144: a randomized controlled study). J Clin Psychi-
atry 2011; 72: 1452–1464.
173. Quiroz JA, Yatham LN, Palumbo JM, Karcher K,
Kushner S, Kusumakar V. Risperidone long-acting
injectable monotherapy in the maintenance treatment
of bipolar I disorder. Biol Psychiatry 2010; 68: 156–
162.
174. Macfadden W, Alphs L, Haskins JT et al. A randomized,
double-blind, placebo-controlled study of maintenance
treatment with adjunctive risperidone long-acting therapy
in patients with bipolar I disorder who relapse frequently.
Bipolar Disord 2009; 11: 827–839.
175. Vieta E, Nieto E, Autet A et al. A long-term prospective
study on the outcome of bipolar patients treated with
long-acting injectable risperidone. World J Biol Psychia-
try 2008; 9: 219–224.
176. Marcus R, Khan A, Rollin L et al. Eﬃcacy of aripipraz-
ole adjunctive to lithium or valproate in the long-term
treatment of patients with bipolar I disorder with an
inadequate response to lithium or valproate monothera-
py: a multicenter, double-blind, randomized study. Bipo-
lar Disord 2011; 13: 133–144.
177. Carlson B, Sun W, Timko K et al. Eﬃcacy and Safety of
Aripiprazole in Combination With Lamotrigine in a
Long-Term Maintenance Study in Manic or Mixed
CANMAT guidelines for bipolar disorder
37
Subjects With Bipolar I Disorder (CN138-392) [Abstract].
50th Ann Mtg New Clinical Drug Evaluation Unit
(NCDEU). June 14–17. Boca Raton, FL, 2010.
178. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP,
Versavel M. Ziprasidone plus a mood stabilizer in subjects
with bipolar I disorder: a 6-month, randomized, placebo-
controlled, double-blind trial. J Clin Psychiatry 2010; 71:
130–137.
179. Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima
MS. Comparison of carbamazepine and lithium in
treatment of bipolar disorder: a systematic review of
randomized controlled trials. Hum Psychopharmacol
2009; 24: 19–28.
180. Tamayo JM, Sutton VK, Mattei MA et al. Eﬀectiveness
and safety of the combination of ﬂuoxetine and olanza-
pine in outpatients with bipolar depression: an open-label,
randomized, ﬂexible-dose study in Puerto Rico. J Clin
Psychopharmacol 2009; 29: 358–361.
181. Kemp DE, Gao K, Ganocy SJ et al. A 6-month,
double-blind, maintenance trial of lithium monotherapy
versus the combination of lithium and divalproex for
rapid-cycling bipolar disorder and co-occurring sub-
stance abuse or dependence. J Clin Psychiatry 2009; 70:
113–121.
182. Ghaemi SN, Ostacher MM, El-Mallakh RS et al.
Antidepressant discontinuation in bipolar depression: a
Systematic Treatment Enhancement Program for Bipolar
Disorder (STEP-BD) randomized clinical trial of long-
term eﬀectiveness and safety. J Clin Psychiatry 2010; 71:
372–380.
183. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden
CL. Maintenance of response following stabilization of
mixed index episodes with olanzapine monotherapy in a
randomized, double-blind, placebo-controlled study of
bipolar 1 disorder. J Aﬀect Disord 2009; 116: 43–50.
184. Keck PE Jr, Versiani M, Warrington L, Loebel AD,
Horne RL. Long-term safety and eﬃcacy of ziprasidone
in subpopulations of patients with bipolar mania. J Clin
Psychiatry 2009; 70: 844–851.
185. Woo YS, Bahk WM, Jon DI et al. Risperidone in the
treatment of mixed state bipolar patients: results from a
24-week, multicenter, open-label study in Korea. Psychi-
atry Clin Neurosci 2010; 64: 28–37.
186. Dias RS, Lafer B, Russo C et al. Longitudinal follow-up
of bipolar disorder in women with premenstrual exacer-
bation: ﬁndings from STEP-BD. Am J Psychiatry 2011;
168: 386–394.
187. Choi J, Baek JH, Noh J et al. Association of seasonality
and premenstrual symptoms in bipolar I and bipolar II
disorders. J Aﬀect Disord 2011; 129: 313–316.
188. Fornaro M, Perugi G. The impact of premenstrual
dysphoric disorder among 92 bipolar patients. Eur
Psychiatry 2010; 25: 450–454.
189. Kumar V, Khan M, Vilos GA, Sharma V. Revisiting the
association between endometriosis and bipolar disorder.
J Obstet Gynaecol Can 2011; 33: 1141–1145.
190. Li X,Guo J,Wigle P, KeltonC, Jing Y.DrugUtilization of
Pregnancy Category D or X Drugs Among Child-Bearing
Age Women With Depression or Bipolar Disorder in
Medicaid [Abstract]. 25th Int Con Pharmacoepidemiol
TherapeuticRiskManagement,August 16–19. Providence,
RI, USA, 2009.
191. ACOG Practice Bulletin: Clinical management guidelines
for obstetrician-gynecologists number 92, April 2008
(replaces practice bulletin number 87, November 2007).
Use of psychiatric medications during pregnancy and
lactation. Obstet Gynecol 2008; 111: 1001–1020.
192. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D,
Arnon J, Ornoy A. Pregnancy outcome after in utero
exposure to valproate : evidence of dose relationship in
teratogenic eﬀect. CNS Drugs 2008; 22: 325–334.
193. Jentink J, Loane MA, Dolk H et al. Valproic acid
monotherapy in pregnancy and major congenital malfor-
mations. N Engl J Med 2010; 362: 2185–2193.
194. McVearry KM, Gaillard WD, VanMeter J, Meador KJ. A
prospective study of cognitive ﬂuency and originality in
children exposed in utero to carbamazepine, lamotrigine, or
valproatemonotherapy. Epilepsy Behav 2009; 16: 609–616.
195. Jentink J, Dolk H, Loane MA et al. Intrauterine exposure
to carbamazepine and speciﬁc congenital malformations:
systematic review and case-control study. BMJ 2010; 341:
c6581.
196. Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S,
Diav-Citrin O. The outcome of pregnancy following
topiramate treatment: a study on 52 pregnancies. Reprod
Toxicol 2008; 25: 388–389.
197. Einarson A, Choi J, Einarson TR, Koren G. Incidence of
major malformations in infants following antidepressant
exposure in pregnancy: results of a large prospective
cohort study. Can J Psychiatry 2009; 54: 242–246.
198. Malm H, Artama M, Gissler M, Ritvanen A. Selective
serotonin reuptake inhibitors and risk for major
congenital anomalies. Obstet Gynecol 2011; 118: 111–120.
199. Reis M, Kallen B. Delivery outcome after maternal use of
antidepressant drugs in pregnancy: an update using
Swedish data. Psychol Med 2010; 40: 1723–1733.
200. Diav-Citrin O, Shechtman S, Weinbaum D et al. Paroxe-
tine and ﬂuoxetine in pregnancy: a prospective, multicen-
tre, controlled, observational study. Br J Clin Pharmacol
2008; 66: 695–705.
201. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de
Walle HE, de Jong-van den Berg LT. First-trimester use
of paroxetine and congenital heart defects: a population-
based case-control study. Birth Defects Res A Clin Mol
Teratol 2010; 88: 94–100.
202. Oberlander TF, Warburton W, Misri S, Riggs W,
Aghajanian J, Hertzman C. Major congenital malforma-
tions following prenatal exposure to serotonin reuptake
inhibitors and benzodiazepines using population-based
health data. Birth Defects Res B Dev Reprod Toxicol
2008; 83: 68–76.
203. Wichman CL. Atypical antipsychotic use in pregnancy: a
retrospective review. Arch Womens Ment Health 2009;
12: 53–57.
204. Food and Drug Administration. Antipsychotic Drugs:
Class Labeling Change—Treatment During Pregnancy
and Potential Risk to Newborns. Silver Spring, MD:
Food and Drug Administration, 2011.
205. Imaz ML, Herna´ndez C, Torra M et al. Obstetrical and
neonatal outcomes following prenatal exposure to lith-
ium. Bipolar Disord 2011; 13 (Suppl. 1): 56.
206. Chessick CA, Dimidjian S. Screening for bipolar disorder
during pregnancy and the postpartum period. Arch
Womens Ment Health 2010; 13: 233–248.
207. Chessick C, Schwartz E, McDonald J et al. Sensitivity and
speciﬁcity of the Mood Disorder Questionnaire in the
perinatalpopulation.BipolarDisord2011;13 (Suppl. 1): 35.
208. Sharma V, Xie B. Screening for postpartum bipolar
disorder: validation of the Mood Disorder Questionnaire.
J Aﬀect Disord 2011; 131: 408–411.
209. Heron J, Haque S, Oyebode F, Craddock N, Jones I. A
longitudinal study of hypomania and depression symptoms




210. Sharma V, Burt VK, Ritchie HL. Bipolar II postpartum
depression: detection, diagnosis, and treatment. Am J
Psychiatry 2009; 166: 1217–1221.
211. Sharma V, Burt VK. DSM-V: modifying the postpartum-
onset speciﬁer to include hypomania. Arch Womens Ment
Health 2011; 14: 67–69.
212. Colom F, Cruz N, Pacchiarotti I et al. Postpartum
bipolar episodes are not distinct from spontaneous
episodes: implications for DSM-V. J Aﬀect Disord 2010;
126: 61–64.
213. Munk-Olsen T, Laursen TM, Mendelson T, Pedersen CB,
Mors O, Mortensen PB. Risks and predictors of read-
mission for a mental disorder during the postpartum
period. Arch Gen Psychiatry 2009; 66: 189–195.
214. Valdimarsdottir U, Hultman CM, Harlow B, Cnattingius
S, Sparen P. Psychotic illness in ﬁrst-time mothers with no
previous psychiatric hospitalizations: a population-based
study. PLoS Med 2009; 6: e13.
215. Marsh WK, Ketter TA, Rasgon NL. Increased depressive
symptoms in menopausal age women with bipolar disor-
der: age and gender comparison. J Psychiatr Res 2009; 43:
798–802.
216. McClellan J, Kowatch R, Findling RL. Practice param-
eter for the assessment and treatment of children and
adolescents with bipolar disorder. J Am Acad Child
Adolesc Psychiatry 2007; 46: 107–125.
217. Gore FM, Bloem PJ, Patton GC et al. Global burden of
disease in young people aged 10-24 years: a systematic
analysis. Lancet 2011; 377: 2093–2102.
218. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB,
Olfson M. National trends in the outpatient diagnosis and
treatment of bipolar disorder in youth. Arch Gen
Psychiatry 2007; 64: 1032–1039.
219. Van Meter AR, Moreira AL, Youngstrom EA. Meta-
analysis of epidemiologic studies of pediatric bipolar
disorder. J Clin Psychiatry 2011; 72: 1250–1256.
220. American Psychiatric Association. DSM-5 Proposed
Revision: Disruptive Mood Dysregulation Disorder.
Arlington, VA: American Psychiatric Association, 2012.
221. Goldstein BI. Recent progress in understanding pediatric
bipolar disorder. Arch Pediatr Adolesc Med 2012; 166:
362–371.
222. Youngstrom EA, Birmaher B, Findling RL. Pediatric
bipolar disorder: validity, phenomenology, and recommen-
dations for diagnosis. Bipolar Disord 2008; 10: 194–214.
223. Axelson DA, Birmaher B, Findling RL et al. Concerns
regarding the inclusion of temper dysregulation disorder
with dysphoria in the Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition. J Clin Psychiatry
2011; 72: 1257–1262.
224. Birmaher B, Axelson D, Goldstein B et al. Four-year
longitudinal course of children and adolescents with
bipolar spectrum disorders: the Course and Outcome of
Bipolar Youth (COBY) study. Am J Psychiatry 2009; 166:
795–804.
225. Geller B, Tillman R, Bolhofner K, Zimerman B. Child
bipolar I disorder: prospective continuity with adult
bipolar I disorder; characteristics of second and third
episodes; predictors of 8-year outcome. Arch Gen
Psychiatry 2008; 65: 1125–1133.
226. DelBello MP, Hanseman D, Adler CM, Fleck DE,
Strakowski SM. Twelve-month outcome of adolescents
with bipolar disorder following ﬁrst hospitalization for a
manic or mixed episode. Am J Psychiatry 2007; 164: 582–
590.
227. Kozloﬀ N, Cheung AH, Schaﬀer A et al. Bipolar disorder
among adolescents and young adults: results from an
epidemiological sample. J Aﬀect Disord 2010; 125:
350–354.
228. Olfson M, Crystal S, Gerhard T, Huang CS, Carlson GA.
Mental health treatment received by youths in the year
before and after a new diagnosis of bipolar disorder.
Psychiatr Serv 2009; 60: 1098–1106.
229. Birmaher B, Axelson D, Strober M et al. Comparison of
manic and depressive symptoms between children and
adolescents with bipolar spectrum disorders. Bipolar
Disord 2009; 11: 52–62.
230. Evans-Lacko SE, Dosreis S, Kastelic EA, Paula CS,
Steinwachs DM. Evaluation of guideline-concordant care
for bipolar disorder among privately insured youth. Prim
Care Companion J Clin Psychiatry 2010; 12: e1–e8.
231. Geller B, Tillman R, Bolhofner K, Zimerman B. Phar-
macological and non-drug treatment of child bipolar I
disorder during prospective eight-year follow-up. Bipolar
Disord 2010; 12: 164–171.
232. Goldstein TR, Ha W, Axelson DA et al. Predictors of
prospectively examined suicide attempts among youth
with bipolar disorder. Arch Gen Psychiatry 2012; 69:
1113–1122.
233. Esposito-Smythers C, Goldstein T, Birmaher B et al.
Clinical and psychosocial correlates of non-suicidal self--
injury within a sample of children and adolescents with
bipolar disorder. J Aﬀect Disord 2010; 125: 89–97.
234. Sala R, Axelson DA, Castro-Fornieles J et al. Comorbid
anxiety in children and adolescents with bipolar spectrum
disorders: prevalence and clinical correlates. J Clin
Psychiatry 2010; 71: 1344–1350.
235. Wozniak J, Faraone SV, Mick E, Monuteaux M, Coville
A, Biederman J. A controlled family study of children
with DSM-IV bipolar-I disorder and psychiatric co-
morbidity. Psychol Med 2010; 40: 1079–1088.
236. Hua LL, Wilens TE, Martelon M, Wong P, Wozniak J,
Biederman J. Psychosocial functioning, familiality, and
psychiatric comorbidity in bipolar youth with and
without psychotic features. J Clin Psychiatry 2011; 72:
397–405.
237. Jerrell JM, McIntyre RS, Tripathi A. A cohort study of
the prevalence and impact of comorbid medical condi-
tions in pediatric bipolar disorder. J Clin Psychiatry 2010;
71: 1518–1525.
238. Goldstein BI, Birmaher B, Axelson DA et al. Preliminary
ﬁndings regarding overweight and obesity in pediatric
bipolar disorder. J Clin Psychiatry 2008; 69: 1953–1959.
239. Goldstein BI, Collinger KA, Lotrich F et al. Preliminary
ﬁndings regarding proinﬂammatory markers and brain-
derived neurotrophic factor among adolescents with
bipolar spectrum disorders. J Child Adolesc Psychophar-
macol 2011; 21: 479–484.
240. Miklowitz DJ, Axelson DA, Birmaher B et al. Family-
focused treatment for adolescents with bipolar disorder:
results of a 2-year randomized trial. Arch Gen Psychiatry
2008; 65: 1053–1061.
241. Miklowitz DJ, Chang KD, Taylor DO et al. Early
psychosocial intervention for youth at risk for bipolar I
or II disorder: a one-year treatment development trial.
Bipolar Disord 2011; 13: 67–75.
242. West AE, Jacobs RH, Westerholm R et al. Child and
family-focused cognitive-behavioral therapy for pediatric
bipolar disorder: pilot study of group treatment format.
J Can Acad Child Adolesc Psychiatry 2009; 18: 239–246.
243. Goldstein TR, Axelson DA, Birmaher B, Brent DA.
Dialectical behavior therapy for adolescents with bipolar
disorder: a 1-year open trial. J Am Acad Child Adolesc
Psychiatry 2007; 46: 820–830.
CANMAT guidelines for bipolar disorder
39
244. Hlastala SA, Kotler JS, McClellan JM, McCauley EA.
Interpersonal and social rhythm therapy for adolescents
with bipolar disorder: treatment development and
results from an open trial. Depress Anxiety 2010; 27:
457–464.
245. American Academy of Child and Adolescent Psychiatry.
Practice parameter on the use of psychotropic medication
in children and adolescents. J Am Acad Child Adolesc
Psychiatry 2009; 48: 961–973.
246. Kuehn BM. FDA panel OKs 3 antipsychotic drugs for
pediatric use, cautions against overuse. JAMA 2009; 302:
833–834.
247. DelBello MP, Chang K, Welge JA et al. A double-blind,
placebo-controlled pilot study of quetiapine for depressed
adolescents with bipolar disorder. Bipolar Disord 2009;
11: 483–493.
248. Duﬀy A, Milin R, Grof P. Maintenance treatment of
adolescent bipolar disorder: open study of the eﬀective-
ness and tolerability of quetiapine. BMC Psychiatry 2009;
9: 4.
249. Scheﬀer RE, Tripathi A, Kirkpatrick FG, Schultz T.
Rapid quetiapine loading in youths with bipolar disorder.
J Child Adolesc Psychopharmacol 2010; 20: 441–445.
250. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W,
Carlson JL, Merida KM, Dittmann RW. The safety of
olanzapine in adolescents with schizophrenia or bipolar I
disorder: a pooled analysis of 4 clinical trials. J Clin
Psychiatry 2009; 70: 247–258.
251. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo
L, Biederman J. Comparison of open-label, 8-week trials
of olanzapine monotherapy and topiramate augmentation
of olanzapine for the treatment of pediatric bipolar
disorder. J Child Adolesc Psychopharmacol 2009; 19:
539–545.
252. Stewart M, DelBello MP, Versavel M, Keller D. Psycho-
social functioning and health-related quality of life in
children and adolescents treated with open-label ziprasi-
done for bipolar mania, schizophrenia, or schizoaﬀective
disorder. J Child Adolesc Psychopharmacol 2009; 19:
635–640.
253. DelBello MP, Versavel M, Ice K, Keller D, Miceli J.
Tolerability of oral ziprasidone in children and adoles-
cents with bipolar mania, schizophrenia, or schizoaﬀec-
tive disorder. J Child Adolesc Psychopharmacol 2008; 18:
491–499.
254. HaasM,DelbelloMP, PandinaGet al.Risperidone for the
treatment of acute mania in children and adolescents with
bipolar disorder: a randomized, double-blind, placebo-
controlled study. Bipolar Disord 2009; 11: 687–700.
255. Pavuluri MN, Henry DB, Findling RL et al. Double-
blind randomized trial of risperidone versus divalproex
in pediatric bipolar disorder. Bipolar Disord 2010; 12:
593–605.
256. Geller B, Luby J, Joshi P et al. A randomized controlled
trial of risperidone, lithium, or divalproex sodium for
initial treatment of bipolar I disorder, manic or mixed
phase, in children and adolescents. Arch Gen Psychiatry
2012; 69: 515–528.
257. MacMillan CM, Withney JE, Korndorfer SR, Tilley CA,
Mrakotsky C, Gonzalez-Heydrich JM. Comparative
clinical responses to risperidone and divalproex in
patients with pediatric bipolar disorder. J Psychiatr Pract
2008; 14: 160–169.
258. Findling RL, Nyilas M, Forbes RA et al. Acute treatment
of pediatric bipolar I disorder, manic or mixed episode,
with aripiprazole: a randomized, double-blind, placebo-
controlled study. J Clin Psychiatry 2009; 70: 1441–1451.
259. Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez
J, Rohde LA. Aripiprazole in children and adolescents
with bipolar disorder comorbid with attention-deﬁ-
cit ⁄hyperactivity disorder: a pilot randomized clinical
trial. J Clin Psychiatry 2009; 70: 756–764.
260. Joshi G, Mick E, Wozniak J et al. Impact of obsessive-
compulsive disorder on the antimanic response to ola-
nzapine therapy in youth with bipolar disorder. Bipolar
Disord 2010; 12: 196–204.
261. Joshi G, Biederman J, Wozniak J et al. Response to
second generation antipsychotics in youth with comorbid
bipolar disorder and autism spectrum disorder. CNS
Neurosci Ther 2012; 18: 28–33.
262. Biederman J, Joshi G, Mick E et al. A prospective open-
label trial of lamotrigine monotherapy in children and
adolescents with bipolar disorder. CNS Neurosci Ther
2010; 16: 91–102.
263. Pavuluri MN, Passarotti AM, Mohammed T, Carbray
JA, Sweeney JA. Enhanced working and verbal memory
after lamotrigine treatment in pediatric bipolar disorder.
Bipolar Disord 2010; 12: 213–220.
264. PavuluriMN,HenryDB,MossM,MohammedT,Carbray
JA, Sweeney JA. Eﬀectiveness of lamotrigine in maintain-
ing symptom control in pediatric bipolar disorder. J Child
Adolesc Psychopharmacol 2009; 19: 75–82.
265. Wagner KD, Redden L, Kowatch RA et al. A double-
blind, randomized, placebo-controlled trial of divalproex
extended-release in the treatment of bipolar disorder in
children and adolescents. J Am Acad Child Adolesc
Psychiatry 2009; 48: 519–532.
266. Redden L, DelBello M, Wagner KD et al. Long-term
safety of divalproex sodium extended-release in children
and adolescents with bipolar I disorder. J Child Adolesc
Psychopharmacol 2009; 19: 83–89.
267. Joshi G, Wozniak J, Mick E et al. A prospective open-
label trial of extended-release carbamazepine monother-
apy in children with bipolar disorder. J Child Adolesc
Psychopharmacol 2010; 20: 7–14.
268. Oostervink F, Boomsma MM, Nolen WA. Bipolar
disorder in the elderly; diﬀerent eﬀects of age and of age
of onset. J Aﬀect Disord 2009; 116: 176–183.
269. Sajatovic M, Jurdi RA, Gildengers A et al. Depres-
sion symptom ratings in geriatric patients with bipolar
mania. Int J Geriatr Psychiatry 2011; 26: 1201–1208.
270. Tsai SY, Kuo CJ, Chung KH, Huang YL, Lee HC, Chen
CC. Cognitive dysfunction and medical morbidity in
elderly outpatients with bipolar disorder. Am J Geriatr
Psychiatry 2009; 17: 1004–1011.
271. Mezuk B, Morden NE, Ganoczy D, Post EP, Kilbourne
AM. Anticonvulsant use, bipolar disorder, and risk of
fracture among older adults in the Veterans Health
Administration. Am J Geriatric Psychiatry 2010; 18:
245–255.
272. Gildengers AG, Mulsant BH, Begley A et al. The
longitudinal course of cognition in older adults with
bipolar disorder. Bipolar Disord 2009; 11: 744–752.
273. Shimizu M, Kubota Y, Mason R, Baba H, Calabrese JR,
Toichi M. Selective deﬁcit of autobiographical incident
memory in subjects with bipolar disorder. Psychopathol-
ogy 2009; 42: 318–324.
274. Delaloye C, Moy G, de Bilbao F et al. Longitudinal
analysis of cognitive performances and structural brain
changes in late-life bipolar disorder. Int J Geriatr Psychi-
atry 2011; 26: 1309–1318.
275. Schouws SN, Comijs HC, Stek ML et al. Cognitive
impairment in early and late bipolar disorder. Am J
Geriatr Psychiatry 2009; 17: 508–515.
Yatham et al.
40
276. Gildengers AG, Mulsant BH, Al Jurdi RK et al. The
relationship of bipolar disorder lifetime duration and
vascular burden to cognition in older adults. Bipolar
Disord 2010; 12: 851–858.
277. Schouws SN, Stek ML, Comijs HC, Beekman AT. Risk
factors for cognitive impairment in elderly bipolar
patients. J Aﬀect Disord 2010; 125: 330–335.
278. Kessing LV, Sondergard L, Forman JL, Andersen PK.
Lithium treatment and risk of dementia. Arch Gen
Psychiatry 2008; 65: 1331–1335.
279. Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the
treatment of bipolar mania in older adults. Bipolar
Disord 2008; 10: 662–671.
280. Sajatovic M, Gildengers A, Al Jurdi RK et al. Multisite,
open-label, prospective trial of lamotrigine for geriatric
bipolar depression: a preliminary report. Bipolar Disord
2011; 13: 294–302.
281. McIntyre R, Schaﬀer A, Beaulieu S. The Canadian
Network for Mood and Anxiety Treatments (CANMAT)
task force recommendations for the management of
patients with mood disorders and comorbid conditions.
Ann Clin Psychiatry 2012; 24: 2–3.
282. Perron BE, Howard MO, Nienhuis JK, Bauer MS,
Woodward AT, Kilbourne AM. Prevalence and burden
of general medical conditions among adults with bipolar I
disorder: results from the National Epidemiologic Survey
on Alcohol and Related Conditions. J Clin Psychiatry
2009; 70: 1407–1415.
283. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL,
Calabrese JR. Medical comorbidity in bipolar disorder:
relationship between illnesses of the endocrine ⁄metabolic
system and treatment outcome. Bipolar Disord 2010; 12:
404–413.
284. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardio-
vascular disease and hypertension among adults with
bipolar I disorder in the United States. Bipolar Disord
2009; 11: 657–662.
285. FiedorowiczJG,SolomonDA,EndicottJet al.Manic ⁄hypo-
manic symptom burden and cardiovascular mortality in
bipolar disorder. PsychosomMed 2009; 71: 598–606.
286. Callaghan RC, Khizar A. The incidence of cardiovascular
morbidity among patients with bipolar disorder: a pop-
ulation-based longitudinal study in Ontario, Canada.
J Aﬀect Disord 2010; 122: 118–123.
287. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar
disorder and metabolic syndrome: an international per-
spective. J Aﬀect Disord 2010; 126: 366–387.
288. McIntyre RS, Woldeyohannes HO, Soczynska JK et al.
The rate of metabolic syndrome in euthymic Canadian
individuals with bipolar I ⁄ II disorder. Adv Ther 2010; 27:
828–836.
289. Calkin C, van de Velde C, Ru˚zˇicˇkova´ M et al. Can body
mass index help predict outcome in patients with bipolar
disorder? Bipolar Disord 2009; 11: 650–656.
290. Bond DJ, Kunz M, Torres IJ, Lam RW, Yatham LN. The
association of weight gain with mood symptoms and
functional outcomes following a ﬁrst manic episode:
prospective 12-month data from the Systematic Treat-
ment Optimization Program for Early Mania (STOP-
EM). Bipolar Disord 2010; 12: 616–626.
291. Goldstein BI, Liu S-M, Zivkovic N, Schaﬀer A, Chien
LC, Blanco C. The burden of obesity among adults with
bipolar disorder in the United States. Bipolar Disord
2011; 13: 387–395.
292. YimCY,SoczynskaJK,KennedySH,WoldeyohannesHO,
Brietzke E, McIntyre RS. The eﬀect of overweight ⁄ obesity
on cognitive function in euthymic individuals with bipolar
disorder. Eur Psychiatry 2011; 27: 223–228.
293. Ortiz A, Cervantes P, Zlotnik G et al. Cross-prevalence of
migraine and bipolar disorder. Bipolar Disord 2010; 12:
397–403.
294. Brietzke E, Moreira CLRL, Bianco-Duarte SV et al.
Impact of migraine comorbidity in the clinical course of
bipolar disorder. Compr Psychiatry 2012; 53: 809–812.
295. Mula M, Schmitz B, Jauch R et al. On the prevalence of
bipolar disorder in epilepsy. Epilepsy Behav 2008; 13:
658–661.
296. Gao K, Kemp DE, Conroy C, Ganocy SJ, Findling RL,
Calabrese JR. Comorbid anxiety and substance use
disorders associated with a lower use of mood stabilisers
in patients with rapid cycling bipolar disorder: a descrip-
tive analysis of the cross-sectional data of 566 patients. Int
J Clin Pract 2010; 64: 336–344.
297. Yoon YH, Chen CM, Yi HY, Moss HB. Eﬀect of
comorbid alcohol and drug use disorders on premature
death among unipolar and bipolar disorder decedents in
the United States, 1999 to 2006. Compr Psychiatry 2011;
52: 453–464.
298. Oquendo MA, Currier D, Liu SM, Hasin DS, Grant BF,
Blanco C. Increased risk for suicidal behavior in
comorbid bipolar disorder and alcohol use disorders:
results from the National Epidemiologic Survey on
Alcohol and Related Conditions (NESARC). J Clin
Psychiatry 2010; 71: 902–909.
299. Agrawal A, Nurnberger JI Jr, Lynskey MT. Cannabis
involvement in individuals with bipolar disorder. Psychi-
atry Res 2011; 185: 459–461.
300. Diaz FJ, James D, Botts S, Maw L, Susce MT, de Leon J.
Tobacco smoking behaviors in bipolar disorder: a com-
parison of the general population, schizophrenia, and
major depression. Bipolar Disord 2009; 11: 154–165.
301. Neves FS, Malloy-Diniz LF, Correa H. Suicidal behavior
in bipolar disorder: what is the inﬂuence of psychiatric
comorbidities? J Clin Psychiatry 2009; 70: 13–18.
302. Ostacher MJ, LeBeau RT, Perlis RH et al. Cigarette
smoking is associated with suicidality in bipolar disorder.
Bipolar Disord 2009; 11: 766–771.
303. Mazza M, Mandelli L, Di Nicola M et al. Clinical
features, response to treatment and functional outcome
of bipolar disorder patients with and without co-occur-
ring substance use disorder: 1-year follow-up. J Aﬀect
Disord 2009; 115: 27–35.
304. Lieberman DZ, Kolodner G, Massey SH, Williams KP.
Antidepressant-induced mania with concomitant mood
stabilizer in patients with comorbid substance abuse and
bipolar disorder. J Addict Dis 2009; 28: 348–355.
305. Goldberg JF. Substance abuse and switch from depres-
sion to mania in bipolar disorder. Am J Psychiatry 2010;
167: 868–869.
306. Zimmerman M, Galione JN, Chelminski I, Young D,
Dalrymple K, Ruggero CJ. Sustained unemployment in
psychiatric outpatients with bipolar disorder: frequency
and association with demographic variables and comor-
bid disorders. Bipolar Disord 2010; 12: 720–726.
307. Toniolo RA, Caetano SC, da Silva PV, Lafer B. Clinical
signiﬁcance of lifetime panic disorder in the course of
bipolar disorder type I. Compr Psychiatry 2009; 50: 9–12.
308. Coryell W, Solomon DA, Fiedorowicz JG, Endicott J,
Schettler PJ, Judd LL. Anxiety and outcome in bipolar
disorder. Am J Psychiatry 2009; 166: 1238–1243.
309. McElroy SL, Frye MA, Hellemann G et al. Preva-
lence and correlates of eating disorders in 875 patients
CANMAT guidelines for bipolar disorder
41
with bipolar disorder. J Aﬀect Disord 2011; 128: 191–
198.
310. John H, Sharma V. Misdiagnosis of bipolar disorder as
borderline personality disorder: clinical and economic
consequences. World J Biol Psychiatry 2009; 10: 612–
615.
311. Ruggero CJ, Zimmerman M, Chelminski I, Young D.
Borderline personality disorder and the misdiagnosis of
bipolar disorder. J Psychiatr Res 2010; 44: 405–408.
312. McIntyre RS, Kennedy SH, Soczynska JK et al. Atten-
tion-deﬁcit ⁄ hyperactivity disorder in adults with bipolar
disorder or major depressive disorder: results from the
international mood disorders collaborative project. Prim
Care Companion J Clin Psychiatry 2010; 12: e1–e7.
313. Ryden E, Thase ME, Straht D, Aberg-Wistedt A, Bejerot
S, Landen M. A history of childhood attention-deﬁcit
hyperactivity disorder (ADHD) impacts clinical outcome
in adult bipolar patients regardless of current ADHD.
Acta Psychiatr Scand 2009; 120: 239–246.
314. Sentissi O, Navarro JC, De Oliveira H et al. Bipolar
disorders and quality of life: the impact of attention
deﬁcit ⁄ hyperactivity disorder and substance abuse in
euthymic patients. Psychiatry Res 2008; 161: 36–42.
315. Kilbourne AM, Biswas K, Pirraglia PA, Sajatovic M,
Williford WO, Bauer MS. Is the collaborative chronic
care model eﬀective for patients with bipolar disorder
and co-occurring conditions? J Aﬀect Disord 2009; 112:
256–261.
316. Kilbourne AM, Post EP, Nossek A, Drill L, Cooley S,
Bauer MS. Improving medical and psychiatric outcomes
among individuals with bipolar disorder: a randomized
controlled trial. Psychiatr Serv 2008; 59: 760–768.
317. Sylvia LG, Nierenberg AA, Stange JP, Peckham AD,
Deckersbach T. Development of an integrated psychoso-
cial treatment to address the medical burden associated
with bipolar disorder. J Psychiatr Pract 2011; 17: 224–232.
318. Wang PW, Hill SJ, Childers ME, Chandler RA, Rasgon
NL, Ketter TA. Open adjunctive ziprasidone associated
with weight loss in obese and overweight bipolar disorder
patients. J Psychiatr Res 2011; 45: 1128–1132.
319. Steinmann WC, Suttmoeller K, Chitima-Matsiga R,
Nagam N, Suttmoeller NR, Halstenson NA. Bariatric
surgery: 1-year weight loss outcomes in patients with
bipolar and other psychiatric disorders. Obes Surg 2011;
21: 1323–1329.
320. Weiss RD, Griﬃn ML, Jaﬀee WB et al. A ‘‘community-
friendly’’ version of integrated group therapy for patients
with bipolar disorder and substance dependence: a
randomized controlled trial. Drug Alcohol Depend
2009; 104: 212–219.
321. Provencher MD, Hawke LD, Thienot E. Psychotherapies
for comorbid anxiety in bipolar spectrum disorders.
J Aﬀect Disord 2011; 133: 371–380.
322. Brown ES, Garza M, Carmody TJ. A randomized,
double-blind, placebo-controlled add-on trial of quetia-
pine in outpatients with bipolar disorder and alcohol use
disorders. J Clin Psychiatry 2008; 69: 701–705.
323. Stedman M, Pettinati HM, Brown ES, Kotz M,
Calabrese JR, Raines S. A double-blind, placebo-
controlled study with quetiapine as adjunct therapy
with lithium or divalproex in bipolar I patients with
coexisting alcohol dependence. Alcohol Clin Exp Res
2010; 34: 1822–1831.
324. Brown ES, Carmody TJ, Schmitz JM et al. A random-
ized, double-blind, placebo-controlled pilot study of
naltrexone in outpatients with bipolar disorder and
alcohol dependence. Alcohol Clin Exp Res 2009; 33:
1863–1869.
325. Nejtek VA, Avila M, Chen LA et al. Do atypical
antipsychotics eﬀectively treat co-occurring bipolar dis-
order and stimulant dependence? A randomized, double-
blind trial. J Clin Psychiatry 2008; 69: 1257–1266.
326. Brown ES, Gorman AR, Hynan LS. A randomized,
placebo-controlled trial of citicoline add-on therapy in
outpatients with bipolar disorder and cocaine depen-
dence. J Clin Psychopharmacol 2007; 27: 498–502.
327. Kemp DE, Gao K, Ganocy SJ et al. Medical and
substance use comorbidity in bipolar disorder. J Aﬀect
Disord 2009; 116: 64–69.
328. Zeni CP, Tramontina S, Ketzer CR, Pheula GF, Rohde
LA. Methylphenidate combined with aripiprazole in
children and adolescents with bipolar disorder and
attention-deﬁcit ⁄ hyperactivity disorder: a randomized
crossover trial. J Child Adolesc Psychopharmacol 2009;
19: 553–561.
329. Sheehan DV, McElroy SL, Harnett-Sheehan K et al.
Randomized, placebo-controlled trial of risperidone for
acute treatment of bipolar anxiety. J Aﬀect Disord 2009;
115: 376–385.
330. Lydiard RB, Culpepper L, Schioler H, Gustafsson U,
Paulsson B. Quetiapine monotherapy as treatment for
anxiety symptoms in patients with bipolar depression: a
pooled analysis of results from 2 double-blind, random-
ized, placebo-controlled studies. Prim Care Companion J
Clin Psychiatry 2009; 11: 215–225.
331. McElroy SL, Martens BE, Winstanley EL, Creech R,
Malhotra S, Keck PE Jr. Placebo-controlled study of
quetiapine monotherapy in ambulatory bipolar spectrum
disorder with moderate-to-severe hypomania or mild
mania. J Aﬀect Disord 2010; 124: 157–163.
332. McElroy SL, Martens BE, Creech RS et al. Randomized,
double-blind, placebo-controlled study of divalproex ex-
tended release loadingmonotherapy in ambulatory bipolar
spectrum disorder patients with moderate-to-severe hypo-
mania or mild mania. J Clin Psychiatry 2010; 71: 557–565.
333. Vieta E, Gasto C, Colom F et al. Role of risperidone in
bipolar II: an open 6-month study. J Aﬀect Disord 2001;
67: 213–219.
334. Swartz HA, Frank E, Frankel DR, Novick D, Houck P.
Psychotherapy as monotherapy for the treatment of
bipolar II depression: a proof of concept study. Bipolar
Disord 2009; 11: 89–94.
335. Young AH, Calabrese JR, Gustafsson U et al. The
eﬃcacy of quetiapine monotherapy in bipolar II depres-
sion: combined data from the BOLDER and EMBOL-
DEN studies. Bipolar Disord 2010; 12 (Suppl. 1): 58.
336. Muzina DJ, Gao K, Kemp DE et al. Acute eﬃcacy of
divalproex sodium versus placebo in mood stabilizer-
naive bipolar I or II depression: a double-blind, random-
ized, placebo-controlled trial. J Clin Psychiatry 2011; 72:
813–819.
337. Sachs G, Collins M, Altshuler L et al. Divalproex Sodium
Versus Placebo in the Treatment of Bipolar Depression
[Abstract]. 40th Ann Mtg Amer Coll Neuropsychophar-
macol. December 8. San Juan, Puerto Rico, 2001.
338. Wang PW, Nowakowska C, Chandler RA et al. Divalp-
roex extended-release in acute bipolar II depression.
J Aﬀect Disord 2010; 124: 170–173.
339. Calabrese JR, Huﬀman RF, White RL et al. Lamotrigine
in the acute treatment of bipolar depression: results of ﬁve
double-blind, placebo-controlled clinical trials. Bipolar
Disord 2008; 10: 323–333.
Yatham et al.
42
340. Amsterdam JD, Shults J. Eﬃcacy and mood conversion
rate of short-term ﬂuoxetine monotherapy of bipolar II
major depressive episode. J Clin Psychopharmacol 2010;
30: 306–311.
341. Amsterdam JD, Wang CH, Shwarz M, Shults J. Venla-
faxine versus lithium monotherapy of rapid and non-
rapid cycling patients with bipolar II major depressive
episode: a randomized, parallel group, open-label trial.
J Aﬀect Disord 2009; 112: 219–230.
342. Amsterdam JD, Wang G, Shults J. Venlafaxine mono-
therapy in bipolar type II depressed patients unresponsive
to prior lithium monotherapy. Acta Psychiatr Scand 2010;
121: 201–208.
343. Medda P, Perugi G, Zanello S, Ciuﬀa M, Cassano GB.
Response to ECT in bipolar I, bipolar II and unipolar
depression. J Aﬀect Disord 2009; 118: 55–59.
344. Magalhaes PV, Dean OM, Bush AI et al. N-acetyl
cysteine add-on treatment for bipolar II disorder: a
subgroup analysis of a randomized placebo-controlled
trial. J Aﬀect Disord 2011; 129: 317–320.
345. Kelly T, Lieberman DZ. The use of triiodothyronine as an
augmentation agent in treatment-resistant bipolar II and
bipolar disorder NOS. J Aﬀect Disord 2009; 116: 222–226.
346. Colom F, Vieta E, Sanchez-Moreno J et al. Psychoedu-
cation for bipolar II disorder: an exploratory, 5-year
outcome subanalysis. J Aﬀect Disord 2009; 112: 30–35.
347. Chang JS, Moon E, Cha B, Ha K. Adjunctive lamotrigine
therapy for patients with bipolar II depression partially
responsive to mood stabilizers. Prog Neuro-psychophar-
macol Biol Psychiatry 2010; 34: 1322–1326.
348. Sharma V, Khan M, Corpse C. Role of lamotrigine in the
management of treatment-resistant bipolar II depression:
a chart review. J Aﬀect Disord 2008; 111: 100–105.
349. Altamura AC, Mundo E, Dellosso B, Tacchini G, Buoli
M, Calabrese JR. Quetiapine and classical mood stabiliz-
ers in the long-term treatment of bipolar disorder: a
4-year follow-up naturalistic study. J Aﬀect Disord 2008;
110: 135–141.
350. Ketter TA, Brooks JO 3rd, Hoblyn JC et al. Long-term
eﬀectiveness of quetiapine in bipolar disorder in a clinical
setting. J Psychiatr Res 2010; 44: 921–929.
351. Amsterdam JD, Shults J. Fluoxetine monotherapy of
bipolar type II and bipolar NOS major depression: a
double-blind, placebo-substitution, continuation study.
Int Clin Psychopharmacol 2005; 20: 257–264.
352. Amsterdam JD, Shults J. Eﬃcacy and safety of long-term
ﬂuoxetine versus lithium monotherapy of bipolar II
disorder: a randomized, double-blind, placebo-substitu-
tion study. Am J Psychiatry 2010; 167: 792–800.
353. Perlis RH, Ostacher MJ, Goldberg JF et al. Transition to
mania during treatment of bipolar depression. Neuropsy-
chopharmacology 2010; 35: 2545–2552.
354. Bond DJ, Noronha MM, Kauer-Santanna M, Lam RW,
Yatham LN. Antidepressant-associated mood elevations
in bipolar II disorder compared with bipolar I disorder
and major depressive disorder: a systematic review and
meta-analysis. J Clin Psychiatry 2008; 69: 1589–1601.
355. Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk
following rapid versus gradual discontinuation of antide-
pressants. Am J Psychiatry 2010; 167: 934–941.
356. Minnai GP, Salis PG, Oppo R, Loche AP, Scano F,
Tondo L. Eﬀectiveness of maintenance electroconvulsive
therapy in rapid-cycling bipolar disorder. J ECT 2011; 27:
123–126.
357. Bora E, Yucel M, Pantelis C, Berk M. Meta-analytic
review of neurocognition in bipolar II disorder. Acta
Psychiatr Scand 2011; 123: 165–174.
358. Kelly T. Is donepezil useful for improving cognitive
dysfunction in bipolar disorder? J Aﬀect Disord 2008;
107: 237–240.
359. Goldberg JF, Perlis RH, Ghaemi SN et al. Adjunctive
antidepressant use and symptomatic recovery among
bipolar depressed patients with concomitant manic symp-
toms: ﬁndings from the STEP-BD. Am J Psychiatry 2007;
164: 1348–1355.
360. Mazzarini L, Colom F, Pacchiarotti I et al. Psychotic
versus non-psychotic bipolar II disorder. J Aﬀect Disord
2010; 126: 55–60.
361. Alloy LB, Urosevic S, Abramson LY et al. Progression
along the bipolar spectrum: a longitudinal study of
predictors of conversion from bipolar spectrum condi-
tions to bipolar I and II disorders. J Abnorm Psychol
2012; 121: 16–27.
362. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and
12-month prevalence of bipolar spectrum disorder in the
National Comorbidity Survey replication. Arch Gen
Psychiatry 2007; 64: 543–552.
363. Angst J, Cui L, Swendsen J et al. Major depressive
disorder with subthreshold bipolarity in the National
Comorbidity Survey Replication. Am J Psychiatry 2010;
167: 1194–1201.
364. Findling RL, Frazier TW, Youngstrom EA et al. Double-
blind, placebo-controlled trial of divalproex monotherapy
in the treatment of symptomatic youth at high risk for
developing bipolar disorder. J Clin Psychiatry 2007; 68:
781–788.
365. Bisol LW, Lara DR. Low-dose quetiapine for patients
with dysregulation of hyperthymic and cyclothymic tem-
peraments. J Psychopharmacol 2010; 24: 421–424.
366. Ng F, Mammen OK, Wilting I et al. The International
Society for Bipolar Disorders (ISBD) consensus guide-
lines for the safety monitoring of bipolar disorder
treatments. Bipolar Disord 2009; 11: 559–595.
367. Edwards SJ, Smith CJ. Tolerability of atypical antipsychot-
ics in the treatment of adults with schizophrenia or bipolar
disorder: a mixed treatment comparison of randomized
controlled trials. Clin Ther 2009; 1: 1345–1359.
368. Bond DJ, Kauer-SantAnna M, Lam RW, Yatham LN.
Weight gain, obesity, and metabolic indices following a
ﬁrst manic episode: prospective 12-month data from the
Systematic Treatment Optimization Program for Early
Mania (STOP-EM). J Aﬀect Disord 2010; 124: 108–117.
369. Citrome L, Holt RI, Walker DJ, Hoﬀmann VP. Weight
gain and changes in metabolic variables following ola-
nzapine treatment in schizophrenia and bipolar disorder.
Clin Drug Investig 2011; 31: 455–482.
370. Bobo WV, Epstein RA Jr, Shelton RC. Eﬀects of orally
disintegrating vs regular olanzapine tablets on body
weight, eating behavior, glycemic and lipid indices, and
gastrointestinal hormones: a randomized, open compar-
ison in outpatients with bipolar depression. Ann Clin
Psychiatry 2011; 23: 193–201.
371. Kemp DE, Karayal ON, Calabrese JR et al. Ziprasidone
with adjunctive mood stabilizer in the maintenance
treatment of bipolar I disorder: long-term changes in
weight and metabolic proﬁles. Eur Neuropsychopharma-
col 2011; 22: 123–131.
372. Kemp DE, Rahman Z, Eudicone JM, Baker RA, Forbes
RA, Carlson BX. Long-term metabolic eﬀects of aripip-
razole adjunctive to lithium, valproate, or lamotrigine.
Bipolar Disord 2011; 13 (Suppl. 1): 60.
373. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane
JM, Malhotra AK. Cardiometabolic risk of second-
generation antipsychotic medications during ﬁrst-time
CANMAT guidelines for bipolar disorder
43
use in children and adolescents. JAMA 2009; 302: 1765–
1773.
374. Gillhoﬀ K, Gaab J, Emini L, Maroni C, Tholuck J, Greil
W. Eﬀects of a multimodal lifestyle intervention on body
mass index in patients with bipolar disorder: a random-
ized controlled trial. Prim Care Companion J Clin
Psychiatry 2010; 12: pii: PCC.09m00906.
375. Chien IC, Chang KC, Lin CH, Chou YJ, Chou P.
Prevalence of diabetes in patients with bipolar disorder in
Taiwan: a population-based national health insurance
study. Gen Hosp Psychiatry 2010; 32: 577–582.
376. Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone
JM, Baker RA. Metabolic syndrome in patients enrolled
in a clinical trial of aripiprazole in the maintenance
treatment of bipolar I disorder: a post hoc analysis of a
randomized, double-blind, placebo-controlled trial. J Clin
Psychiatry 2010; 71: 1138–1144.
377. Chang HH, Yang YK, Gean PW, Huang HC, Chen PS,
Lu RB. The role of valproate in metabolic disturbances in
bipolar disorder patients. J Aﬀect Disord 2010; 124: 319–
323.
378. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI,
Scott RS. Comparison of insulin resistance, metabolic
syndrome and adiponectin in overweight bipolar patients
taking sodium valproate and controls. Aust N Z J
Psychiatry 2009; 43: 53–60.
379. Gau CS, Chang CJ, Tsai FJ, Chao PF, Gau SS.
Association between mood stabilizers and hypothyroid-
ism in patients with bipolar disorders: a nested,
matched case-control study. Bipolar Disord 2010; 12:
253–263.
380. McKnight R, Adida M, Budge K, Stockton S, Goodwin
G, Geddes J. Lithium toxicity proﬁle: a systematic review
and meta-analysis. Lancet 2011; 379: 721–728.
381. Oquendo MA, Galfalvy HC, Currier D et al. Treatment
of suicide attempters with bipolar disorder: a randomized
clinical trial comparing lithium and valproate in the
prevention of suicidal behavior. Am J Psychiatry 2011;
168: 1050–1056.
382. Arts B, Jabben N, Krabbendam L, van Os J. Meta-
analyses of cognitive functioning in euthymic bipolar
patients and their ﬁrst-degree relatives. Psychol Med
2008; 38: 771–785.
383. Kurtz MM, Gerraty RT. A meta-analytic investigation of
neurocognitive deﬁcits in bipolar illness: proﬁle and eﬀects
of clinical state. Neuropsychology 2009; 23: 551–562.
384. Jamrozinski K, Gruber O, Kemmer C, Falkai P, Scherk
H. Neurocognitive functions in euthymic bipolar patients.
Acta Psychiatr Scand 2009; 119: 365–374.
385. Torrent C, Martinez-Aran A, Daban C et al. Eﬀects
of atypical antipsychotics on neurocognition in euthy-
mic bipolar patients. Compr Psychiatry 2011; 52: 613–622.
386. Hill SK, Reilly JL, Harris MS et al. A comparison of
neuropsychological dysfunction in ﬁrst-episode psychosis
patients with unipolar depression, bipolar disorder, and
schizophrenia. Schizophr Res 2009; 113: 167–175.
387. Kozicky JM, Torres IJ, Bond DJ, Lam RW, Yatham LN.
Comparison of neuropsychological eﬀects of adjunctive
risperidone or quetiapine in euthymic patients with bipolar
I disorder. Int Clin Psychopharmacol 2012; 27: 91–99.
388. Burdick K, Braga R, Nnadi C, Shaya Y, Stearns W,
Malhotra A. Cognitive enhancement in euthymic bipolar
patients with pramipexole: a placebo-controlled adjunc-
tive trial. Bipolar Disord 2011; 13 (Suppl. 1): 33.
389. Ghaemi SN, Gilmer WS, Dunn RT et al. A double-blind,
placebo-controlled pilot study of galantamine to improve
cognitive dysfunction in minimally symptomatic bipolar
disorder. J Clin Psychopharmacol 2009; 29: 291–295.
390. Gau SS, Chao PF, Lin YJ, Chang CJ, Gau CS. The
association between carbamazepine and valproate and
adverse cutaneous drug reactions in patients with bipolar
disorder: a nested matched case-control study. J Clin
Psychopharmacol 2008; 28: 509–517.
391. Woo YS, Bahk WM, Jon DI et al. Rash in adult patients
receiving lamotrigine to treat bipolar I disorder in Korea:
a multicenter, prospective, naturalistic, open-label trial.
Prog Neuro-psychopharmacol Biol Psychiatry 2009; 33:
1147–1152.
392. Joe SH, Chang JS, Won S, Rim HD, Ha TH, Ha K.
Feasibility of a slower lamotrigine titration schedule for
bipolar depression: a naturalistic study. Int Clin Psycho-
pharmacol 2009; 24: 105–110.
393. Food and Drug Administration. FDA Drug Safety Com-
munication: Serious Allergic Reactions Reported With the
Use of Saphris (Asenapine Maleate). Silver Spring, MD:
Food and Drug Administration, 2011.
394. Cazorla P, Zhao J, Szegedi A. Incidence, onset, and
duration of treatment emergent somnolence with asena-
pine in patients with schizophrenia or bipolar disorder.
Bipolar Disord 2011; 13 (Suppl. 1): 34.
395. Chen Y, Guo JJ, Steinbuch M, Buckley PF, Patel
NC. Risk of neuroleptic malignant syndrome in
patients with bipolar disorder: a retrospective, popu-
lation-based case-control study. Int J Psychiatry Med
2009; 39: 439–450.
396. Kane JM, Barnes TR, Correll CU et al. Evaluation of
akathisia in patients with schizophrenia, schizoaﬀective
disorder, or bipolar I disorder: a post hoc analysis of
pooled data from short- and long-term aripiprazole trials.
J Psychopharmacol 2010; 24: 1019–1029.
397. Williams LJ, Henry MJ, Berk M et al. Selective serotonin
reuptake inhibitor use and bone mineral density in women
with a history of depression. Int Clin Psychopharmacol
2008; 23: 84–87.
398. Williams LJ, Bjerkeset O, Langhammer A et al. The
association between depressive and anxiety symptoms and
bone mineral density in the general population: the
HUNT study. J Aﬀect Disord 2011; 131: 164–171.
Yatham et al.
44
